<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006788.pub3" GROUP_ID="SYMPT" ID="529005021509503922" MERGED_FROM="246906113017585835" MODIFIED="2017-07-25 09:25:41 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="110" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2017-07-25 09:24:17 +0100" MODIFIED_BY="Anna Erskine">
<TITLE MODIFIED="2010-11-05 16:00:31 +0000" MODIFIED_BY="[Empty name]">Pharmacological treatments for fatigue associated with palliative care</TITLE>
<CONTACT>
<PERSON ID="z1311251608423525204649809803050" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mücke</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>martin.muecke@ukb.uni-bonn.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Bonn</ORGANISATION>
<ADDRESS_1>Sigmund-Freud-Str. 25</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bonn</CITY>
<ZIP>53127</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-07-25 09:23:47 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="z1311251608423525204649809803050" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mücke</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>martin.muecke@ukb.uni-bonn.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Bonn</ORGANISATION>
<ADDRESS_1>Sigmund-Freud-Str. 25</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bonn</CITY>
<ZIP>53127</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1405160957131110616118394243293" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME/>
<MIDDLE_INITIALS/>
<LAST_NAME>Mochamat</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>dr.mochamat@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Bonn</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bonn</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1405160958568988091768240519576" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Henning</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cuhls</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>henning.cuhls@ukb.uni-bonn.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Bonn</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bonn</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="23E89B5282E26AA200CD32E527C3B227" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Vera</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Peuckmann-Post</LAST_NAME>
<SUFFIX/>
<POSITION>Dr. med.</POSITION>
<EMAIL_1>vpeuckmann@ukaachen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Palliative Medicine</DEPARTMENT>
<ORGANISATION>Medical Faculty RWTH Aachen University</ORGANISATION>
<ADDRESS_1>Hauptgebäude, Aufzug B 1, Etage 1, Flur 1, Raum-Nr.5</ADDRESS_1>
<ADDRESS_2>Pauwelsstraße 30</ADDRESS_2>
<CITY>Aachen</CITY>
<ZIP>52074</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 241 80 85721</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="39C4BCB382E26AA201BA4B54B2D0504E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ollie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Minton</LAST_NAME>
<SUFFIX/>
<POSITION>Cancer research UK clinical research fellow &amp; honorary consultant in palliative medicine</POSITION>
<EMAIL_1>ominton@sgul.ac.uk</EMAIL_1>
<EMAIL_2>ominton@sgul.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE>+44 (0) 7977 038541</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Division of Mental Health</DEPARTMENT>
<ORGANISATION>St George's University of London</ORGANISATION>
<ADDRESS_1>Cranmer Terrace</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SW17 0RE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 208 7252620</PHONE_1>
<PHONE_2>+44 208 7250145</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="39CA0E2682E26AA201BA4B54483E1528" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Patrick</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Stone</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Palliative Medicine</POSITION>
<EMAIL_1>p.stone@ucl.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+44 (0) 771 940 4376</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Marie Curie Palliative Care Research Department, UCL Division of Psychiatry</ORGANISATION>
<ADDRESS_1>Room 119, First Floor, Charles Bell House</ADDRESS_1>
<ADDRESS_2>67-73 Riding House Street</ADDRESS_2>
<CITY>London</CITY>
<ZIP>W1W 7EJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 208 725 0145</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0) 208 725 2161</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="99E2B40082E26AA2009B3E5E3CEFF35A" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Lukas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Radbruch</LAST_NAME>
<SUFFIX/>
<POSITION>Chair of Palliative Medicine, University of Bonn</POSITION>
<EMAIL_1>Lukas.Radbruch@malteser.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Bonn</ORGANISATION>
<ADDRESS_1>Sigmund Freud Str. 25</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bonn</CITY>
<ZIP>53127</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>++49 241 80 80 880</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-06-11 14:35:52 +0100" MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="28" MONTH="4" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="4" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="11" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2017-07-25 09:24:17 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-07-25 09:24:17 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="25" MONTH="7" YEAR="2017"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-07-25 09:24:07 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2017-07-25 09:24:07 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="16" MONTH="6" YEAR="2016"/>
<DESCRIPTION>
<P>See <LINK TAG="FEEDBACK" TYPE="SECTION">Feedback</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-06-16 13:41:42 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="27" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Contact details amended.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-05-27 16:18:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>This review updates the original review, 'Pharmacological treatments for fatigue associated with palliative care' (<LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>), and also incorporates 'Drug therapy for the management of cancer-related fatigue' (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>). The updated search strategy identified 20 additional studies suitable for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-27 16:18:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>We used an updated search strategy and included 'Risk of bias' tables in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-06 12:43:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Minor amendment to title - text was italicised on publication and update of contact details.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Further RevMan 5 conversion changes.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-07 21:28:26 +0000" MODIFIED_BY="Jessica R Thomas">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-03-19 16:54:48 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-05-14 11:12:17 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-05-14 11:11:23 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department of Palliative Medicine, University Hospital of Bonn, Bonn</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-05-14 11:12:17 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department of General Medicine and Family Medicine, University Hospital of Bonn, Bonn</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-03-19 16:54:48 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-03-19 16:54:48 +0000" MODIFIED_BY="[Empty name]">
<NAME>Department of Anesthesiology and Intensive Care, University of Diponegoro/Kariadi Hospital Semarang</NAME>
<COUNTRY CODE="ID">Indonesia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-07-25 09:24:47 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY MODIFIED="2016-06-16 13:43:54 +0100" MODIFIED_BY="Anna Erskine">
<TITLE MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<I>Pharmacological treatments for fatigue associated with advanced disease</I>
</TITLE>
<SUMMARY_BODY MODIFIED="2016-06-16 13:43:54 +0100" MODIFIED_BY="Anna Erskine">
<P>In an advanced disease such as cancer, fatigue can be described as tiredness, weakness or lack of energy. Fatigue can affect daily activity and quality of life, and it is frequently reported by palliative care patients. The underlying causes of fatigue are not very well understood and fatigue is difficult to treat.</P>
<P>We searched the literature in April 2014 and found 45 randomised controlled trials for this update of the review. We analysed data from 4696 participants who received treatment for their fatigue. The trials dealt with neurological diseases (such as multiple sclerosis (753 participants), post-polio syndrome (58) and Parkinson's disease (19)), different types of cancer (3223), HIV/AIDS (514), end-stage renal disease (56), multi-type advanced disease in hospice patients (30), amyotrophic lateral sclerosis (28) and end-stage chronic lung disease (15).</P>
<P>There was weak evidence for the efficacy of amantadine, pemoline and modafinil in reducing fatigue in patients with multiple sclerosis. There was also weak evidence for the efficacy of carnitine and donepezil for cancer-related fatigue. One small trial showed that people with HIV/AIDS and fatigue seemed to benefit from treatment with methylphenidate or pemoline. There was some low-quality evidence from small trials that methylphenidate, a stimulant drug that improves concentration, is effective for the management of cancer-related fatigue. There was no information about dexamphetamine, paroxetine or testosterone.</P>
<P>Previous studies have shown that erythropoietin and darbepoetin, drugs that improve anaemia (a shortage of red cells or haemoglobin in the blood), are also effective for cancer-related fatigue. However, due to safety concerns and side effects shown by more recent studies, erythropoietin and darbepoetin should no longer be used. Therefore, we excluded these drugs from this review update.</P>
<P>Overall, most side effects of the investigated drugs seemed to be mild.</P>
<P>Based on limited evidence from small studies, the evidence does not support the use of a specific drug for the treatment of fatigue in palliative care. Future trials should measure fatigue in advanced disease using comparable and standardised measures.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-05-17 15:28:58 +0100" MODIFIED_BY="[Empty name]">
<P>This review updates the original review, 'Pharmacological treatments for fatigue associated with palliative care' and also incorporates the review 'Drug therapy for the management of cancer-related fatigue'.</P>
<P>In healthy individuals, fatigue is a protective response to physical or mental stress, often relieved by rest. By contrast, in palliative care patients' fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life. Fatigue frequently occurs in patients with advanced disease (e.g. cancer-related fatigue) and modalities used to treat cancer can often contribute. Further complicating issues are the multidimensionality, subjective nature and lack of a consensus definition of fatigue. The pathophysiology is not fully understood and evidence-based treatment approaches are needed.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PsycINFO and EMBASE, and a selection of cancer journals up to 28 April 2014. We searched the references of identified articles and contacted authors to obtain unreported data. To validate the search strategy we selected sentinel references.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-05-23 14:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>We considered randomised controlled trials (RCTs) concerning adult palliative care with a focus on pharmacological treatment of fatigue compared to placebo, application of two drugs, usual care or a non-pharmacological intervention. The primary outcome had to be non-specific fatigue (or related terms such as asthenia). We did not include studies on fatigue related to antineoplastic treatment (e.g. chemotherapy, radiotherapy, surgical intervention). We also included secondary outcomes that were assessed in fatigue-related studies (e.g. exhaustion, tiredness).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-05-23 14:49:37 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (MM and MC) independently assessed trial quality and extracted data. We screened the search results and included studies if they met the selection criteria. If we identified two or more studies that investigated a specific drug with the same dose in a population with the same disease and using the same assessment instrument or scale, we conducted meta-analysis. In addition, we compared the type of drug investigated in specific populations, as well as the frequent adverse effects of fatigue treatment, by creating overview tables.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we screened 1645 publications of which 45 met the inclusion criteria (20 additional studies to the previous reviews). In total, we analysed data from 18 drugs and 4696 participants. There was a very high degree of statistical and clinical heterogeneity in the trials and we discuss the reasons for this in the review. There were some sources of potential bias in the included studies, including a lack of description of the methods of blinding and allocation concealment, and the small size of the study populations. We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis. Treatment results pointed to weak and inconclusive evidence for the efficacy of amantadine, pemoline and modafinil in multiple sclerosis and for carnitine and donepezil in cancer-related fatigue. Methylphenidate and pemoline seem to be effective in patients with HIV, but this is based only on one study per intervention, with only a moderate number of participants in each study. Meta-analysis shows an estimated superior effect for methylphenidate in cancer-related fatigue (standardised mean difference (SMD) 0.49, 95% confidence interval (CI) 0.15 to 0.83). Therapeutic effects could not be described for dexamphetamine, paroxetine or testosterone. There were a variety of results for the secondary outcomes in some studies. Most studies had low participant numbers and were heterogeneous. In general, adverse reactions were mild and had little or no impact.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Based on limited evidence, we cannot recommend a specific drug for the treatment of fatigue in palliative care patients. Fatigue research in palliative care seems to focus on modafinil and methylphenidate, which may be beneficial for the treatment of fatigue associated with palliative care although further research about their efficacy is needed. Dexamethasone, methylprednisolone, acetylsalicylic acid, armodafinil, amantadine and L-carnitine should be further examined. Consensus is needed regarding fatigue outcome parameters for clinical trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>This review is not only an update of a previously published review in the Cochrane Database of Systematic Reviews (<LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>). We have also conducted it with a new search strategy to incorporate another review on drug therapy for the management of cancer-related fatigue (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>), in order to increase its scope.</P>
<P>In healthy individuals, fatigue serves as a protective response to physical or mental stress. By contrast, in patients with chronic disease, fatigue can be severely debilitating and thereby have an impact on quality of life and daily activities (<LINK REF="REF-Morrow-2005" TYPE="REFERENCE">Morrow 2005</LINK>). Fatigue is a common symptom in palliative care patients and virtually every intervention used to treat cancer, as well as the primary disease itself, may cause or contribute to fatigue. In a study of 1000 patients in an American palliative care programme, fatigue, weakness and lack of energy were three of the five most frequently reported symptoms with a prevalence of 84%, 66% and 61%, respectively (<LINK REF="REF-Walsh-2000" TYPE="REFERENCE">Walsh 2000</LINK>). Fatigue is also commonly reported in non-cancer patients with progressive life-threatening diseases, such as multiple sclerosis and amyotrophic lateral sclerosis (progressive degeneration of motor neurons leading to cumulative paralysis), as well as chronic heart, kidney or lung diseases (<LINK REF="REF-Jhamb-2013" TYPE="REFERENCE">Jhamb 2013</LINK>; <LINK REF="REF-Tang-2010" TYPE="REFERENCE">Tang 2010</LINK>). More than half of patients with multiple sclerosis describe fatigue as one of their most troubling symptoms (<LINK REF="REF-Bakshi-2003" TYPE="REFERENCE">Bakshi 2003</LINK>; <LINK REF="REF-Krupp-2003" TYPE="REFERENCE">Krupp 2003</LINK>; <LINK REF="REF-NMSS-2002" TYPE="REFERENCE">NMSS 2002</LINK>). Fatigue has also been reported by the majority of patients with chronic obstructive pulmonary disease (COPD) (<LINK REF="REF-Elkington-2005" TYPE="REFERENCE">Elkington 2005</LINK>; <LINK REF="REF-Stridsman-2014" TYPE="REFERENCE">Stridsman 2014</LINK>; <LINK REF="REF-Trendall-2001" TYPE="REFERENCE">Trendall 2001</LINK>) and heart failure (<LINK REF="REF-Goodlin-2005" TYPE="REFERENCE">Goodlin 2005</LINK>). Approximately half of HIV patients suffer from fatigue (<LINK REF="REF-Breitbart-1998" TYPE="REFERENCE">Breitbart 1998</LINK>; <LINK REF="REF-Norval-2004" TYPE="REFERENCE">Norval 2004</LINK>). High levels of tumour necrosis factor (TNF) and interleukin-1 from HIV infections may cause fatigue (<LINK REF="REF-Darko-1995" TYPE="REFERENCE">Darko 1995</LINK>). Cancer-related fatigue is one of the most common symptoms experienced by cancer patients (<LINK REF="REF-Cuhls-2014" TYPE="REFERENCE">Cuhls 2014</LINK>; <LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>). It can be problematic at the time of diagnosis, during and after treatment and in patients with advanced disease (<LINK REF="REF-Cuhls-2014" TYPE="REFERENCE">Cuhls 2014</LINK>; <LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>). Most studies have reported prevalence figures in excess of 60% (<LINK REF="REF-Stone-2002" TYPE="REFERENCE">Stone 2002</LINK>). The subjective sensations attributed to cancer-related fatigue are characterised by a pervasive and persistent sense of tiredness, which is not relieved by sleep or rest. Several drugs, such as the new anti-neoplastic therapies, may be associated with novel causes of secondary fatigue. Drugs regularly used in palliative care have sedative properties, for example opioid analgesics, benzodiazepines, antidepressants or anticonvulsants can cause fatigue load (<LINK REF="REF-EAPC-2008" TYPE="REFERENCE">EAPC 2008</LINK>).<BR/>
</P>
<CONDITION MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>The pathophysiology of fatigue in palliative care patients is not fully understood. 'Primary fatigue' has been said to be related to the high cytokine load (release of high amounts of cytokines from the tumour or antineoplastic therapy). Associated disease-related symptoms, such as sleep disturbances, infections, malnutrition, hypothyroidism and anaemia, may also account for fatigue and may be termed 'secondary fatigue'. Synonyms for fatigue are asthenia, neuromuscular weakness and tiredness. There seems to be a considerable overlap between fatigue and depression. Weakness and tiredness are among the predominant symptoms of depression and feeling depressed is often part of the affective dimension of fatigue. However, there are some symptoms that are associated with depression (such as sustained feelings of worthlessness, recurrent thoughts of death) and some symptoms that are considered specific to fatigue (such as post-exertional malaise).</P>
<P>Different definitions have been proposed for fatigue. In partnership with the American Cancer Society, the National Comprehensive Cancer Network (NCCN) defines cancer-related fatigue as "a distressing persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning" (<LINK REF="REF-NCCN-2014" TYPE="REFERENCE">NCCN 2014</LINK>). A similar definition has been used for multiple sclerosis: "a subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities" (<LINK REF="REF-NMSS-2002" TYPE="REFERENCE">NMSS 2002</LINK>). The Fatigue Coalition has suggested the use of the International Classification of Diseases &#8211; 10 (ICD-10) criteria for the definition of cancer-related fatigue, which is "significant fatigue, diminished energy or an increased need to rest, disproportionate to any recent change in activity level" and has to be present every day or nearly every day for two consecutive weeks out of the last month (<LINK REF="REF-Cella-2001" TYPE="REFERENCE">Cella 2001</LINK>). Five out of 10 additional symptoms, such as generalised weakness, diminished concentration or unrestorative sleep, are required for the diagnosis. However, the symptom thresholds and time span have been chosen arbitrarily (<LINK REF="REF-Cella-1998" TYPE="REFERENCE">Cella 1998</LINK>), and this has been criticised. Considering the lack of an internationally acknowledged definition, we identified and chose the following working definition for this review: "Fatigue is a subjective feeling of tiredness, weakness, or lack of energy"; this definition has been suggested by an expert working group of the European Association of Palliative Care (<LINK REF="REF-EAPC-2008" TYPE="REFERENCE">EAPC 2008</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of fatigue will depend on subjective self evaluation by the patient, substituted by caregiver or medical staff estimations only where self assessment is not possible. Single-item scales (e.g. 'do you get tired for no reason?') have been proposed and a multitude of checklists and questionnaires with multiple dimensions (such as physical, affective and cognitive) have been validated (<LINK REF="REF-Dittner-2004" TYPE="REFERENCE">Dittner 2004</LINK>).</P>
<P>Lack of consensus on the definition of fatigue and its subjective and multidimensional nature, as well as culture and language differences, have challenged research approaches to fatigue. Further, standard research studies, such as double-blinded randomised controlled trials (RCTs), can often not be performed in this debilitated patient population due to fluctuating symptom intensity, declining performance status, rapid disease trajectories and short prognosis, resulting in weak evidence for treatment strategies. Several instruments exist to evaluate fatigue, but no consensus on significant cut-off levels has yet been achieved to establish a model of clinically meaningful improvement of fatigue. Only a few scales and instruments have been evaluated for different languages (<LINK REF="REF-Cantarero_x002d_Villanueva-2014" TYPE="REFERENCE">Cantarero-Villanueva 2014</LINK>; <LINK REF="REF-Kummer-2011" TYPE="REFERENCE">Kummer 2011</LINK>). A structured approach with assessment and treatment steps is lacking. As a result, fatigue continues to be underestimated and undertreated. Consequently, a structured approach, including treatment options, is needed.</P>
<P>Treatment options for fatigue should address the causal mechanism if possible. However, the underlying mechanism of action is often not known and may be complex. Most patients will require symptomatic treatment of fatigue with pharmacological and non-pharmacological therapies. Non-pharmacological treatment options include patient education with provision of information on fatigue and its treatment, keeping a diary, energy expenditure planning and physical exercise (review in <LINK REF="REF-Mock-2004" TYPE="REFERENCE">Mock 2004</LINK>; <LINK REF="REF-NCCN-2014" TYPE="REFERENCE">NCCN 2014</LINK>; <LINK REF="REF-Schmitz-2005" TYPE="REFERENCE">Schmitz 2005</LINK>). Recent studies support the use of resistance training or 'anabolic' exercise (<LINK REF="REF-Galvao-2005" TYPE="REFERENCE">Galvao 2005</LINK>). Most patients will try to counteract exhaustion and fatigue with prolonged periods of rest (<LINK REF="REF-Richardson-1997" TYPE="REFERENCE">Richardson 1997</LINK>). However, rest will often not restore energy and persistent reduction of physical activity may even promote fatigue (<LINK REF="REF-Evans-2007" TYPE="REFERENCE">Evans 2007</LINK>).</P>
<P>Pharmacological treatment of fatigue may work through interaction with cytokine load and the patient's host reaction to the underlying disease, restoring peripheral energy depletion, or by treating metabolic disorders and supplementing other apparent physiological deficiencies such as decreased haemoglobin concentration (<LINK REF="REF-Morrow-2005" TYPE="REFERENCE">Morrow 2005</LINK>). There is a growing body of evidence that gives examples of effective pharmacological treatments for fatigue (<LINK REF="STD-Barak-2014" TYPE="STUDY">Barak 2014</LINK>; <LINK REF="REF-Lawrence-2004" TYPE="REFERENCE">Lawrence 2004</LINK>; <LINK REF="REF-Morrow-2005" TYPE="REFERENCE">Morrow 2005</LINK>; <LINK REF="REF-Patrick-2004" TYPE="REFERENCE">Patrick 2004</LINK>; <LINK REF="REF-Rao-2004" TYPE="REFERENCE">Rao 2004</LINK>; <LINK REF="REF-Rosenberg-2005" TYPE="REFERENCE">Rosenberg 2005</LINK>; <LINK REF="REF-Wagner-2004" TYPE="REFERENCE">Wagner 2004</LINK>; <LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>; <LINK REF="REF-Zifko-2004" TYPE="REFERENCE">Zifko 2004</LINK>). Drug treatment for non-specific fatigue will be required by many patients in addition to specific measures against deficiencies or comorbid conditions. Concerning drug-induced fatigue, for example with opioid treatment, symptomatic pharmacological treatment of fatigue may functionally counteract this adverse effect, probably by enhancing excitatory mechanisms as observed following treatment with amphetamines (<LINK REF="REF-Sood-2006" TYPE="REFERENCE">Sood 2006</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>The latest systematic review about pharmacological treatments for fatigue associated with palliative care was published several years ago (<LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>). Other systematic reviews have covered the use of particular drugs for fatigue in multiple sclerosis, such as amantadine (<LINK REF="REF-Pucci-2007" TYPE="REFERENCE">Pucci 2007</LINK>), and carnitine (<LINK REF="REF-Tejani-2012" TYPE="REFERENCE">Tejani 2012</LINK>). Treatment of fatigue in cancer patients, including erythropoietic agents, was the subject of another Cochrane review with meta-analysis (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>). In contrast to this meta-analysis our review aims to cover a broader scope of palliative care patients with cancer and non-cancer diseases, but it is restricted to advanced-stage diseases. We have incorporated the main topic of <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> into this review, so that cancer-related fatigue will be reflected.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-04-09 13:20:12 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We only included randomised controlled trials (RCTs). We considered full reports concerning fatigue in palliative care with a focus on pharmacological treatment. The primary outcome of these studies had to be fatigue (or related terms such as asthenia). We searched for diseases requiring palliative care or diseases at an advanced, life-threatening stage.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Age 18 years or more.</LI>
<LI>Participants of both sexes.</LI>
<LI>Palliative care patients with fatigue, i.e. patients with an incurable disease (terminal illness) such as advanced cancer, HIV/AIDS, multiple sclerosis, amyotrophic lateral sclerosis, or cardiac, lung or kidney failure. Participants could receive anticancer treatment. We considered terminal illness to be when the estimated life expectancy is six months or less, under the assumption that the disease will run its normal course.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Identified studies had to evaluate and report the effect of pharmacological treatment on fatigue with the following drugs: psychostimulants (amphetamines, modafinil, armodafinil, methylphenidate, pemoline), amantadine, corticosteroids (dexamethasone, prednisone, methylprednisolone), donepezil, antidepressants such as selective serotonin reuptake inhibitors (SSRIs; paroxetine), acetylsalicylic acid, megestrol acetate, alfacalcidol and acetyl-L-carnitine.</LI>
<LI>If we identified further agents used for the treatment of unspecific fatigue, we added these studies.</LI>
<LI>Studies should compare fatigue with drug treatment versus no drug treatment or versus alternative drug treatment, or both.</LI>
<LI>We did not include studies on the pharmacological treatment of fatigue with a primary target of clinical conditions such as depression or anxiety.</LI>
<LI>We included antidepressants only if used for the treatment of fatigue as the primary outcome.</LI>
<LI>We did not focus on physiological deficiencies such as lack of haemoglobin (erythropoietic agents, blood transfusion), nor did we focus on drugs targeting specific cytokines, e.g. for reduction of tumour necrosis factor alpha, as these treatments target specific aetiologies of fatigue. Erythropoietic agents have been covered in the review by Minton et al (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>).</LI>
<LI>We did not include studies comparing different types of cancer-modifying treatment and the effect on prognosis and quality of life. We also excluded those studies which did not focus on pharmacological treatment.</LI>
<LI>We did not include studies on fatigue related to antineoplastic treatment (e.g. chemotherapy, radiotherapy, surgical intervention).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Patient-reported fatigue (self reported measures or validated self assessment tools, or both), substituted by caregiver or medical staff estimations only where self assessment was not possible, and measurement using reliable and valid assessment instruments (single-item scales or questionnaire instruments).</LI>
<LI>Improvement of fatigue. Since no gold standard for the treatment or improvement of fatigue exists, we suggested an improvement of fatigue intensity by 33% related to the range of the assessment instrument to be clinically significant. This is congruent with the improvement of pain intensity, where a 33% reduction has been described as significant from the patient's point of view (<LINK REF="REF-Farrar-2003" TYPE="REFERENCE">Farrar 2003</LINK>).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Asthenia (lack of strength) assessed with quality of life instruments such as SF-36.</LI>
<LI>Weakness assessed with scales, e.g. visual analogue scale - fatigue (VAS-F).</LI>
<LI>Tiredness, sedation assessed with scales such as the Chalder Fatigue Scale (CFS) or Center for Epidemiologic Studies Depression (CESD) scale.</LI>
<LI>Exhaustion, assessed with e.g. the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30).</LI>
<LI>Treatment&#8211;related burden: adverse events (including cardiac arrhythmia and thromboembolic events), morbidity or mortality measured as percentages of participants, adverse events also measured as a percentage of participants with moderate/severe intensity, probability of a causal relationship between adverse events and treatment.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we have re-engineered the search strategy (filter) of the previous review (<LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>) to facilitate the combination with another review (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>). To identify studies for inclusion in this updated review, we developed a detailed search strategy for each electronic database and other resources. To validate the search strategy, we selected sentinel references. There were no language or date restrictions.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 3); search strategy as detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>;</LI>
<LI>MEDLINE (OVID) from inception to 28 April 2014; search strategy as detailed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>;</LI>
<LI>EMBASE (OVID) from inception to 28 April 2014; search strategy as detailed in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>;</LI>
<LI>PsycINFO (OVID) from inception to 28 April 2014; search strategy as detailed in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We screened the reference lists of identified articles for additional studies. </P>
<P>We handsearched standard textbooks on palliative medicine (<I>Oxford Textbook of Palliative Medicine</I>, Oxford; <I>Textbook of Nursing</I>, <I>Textbook of Palliative Medicine</I>). </P>
<P>We also obtained unpublished literature through searches of conference proceedings, such as all meetings of the American Society of Clinical Oncology (ASCO) from 2000 to 2013, the 2013 meeting of the European Cancer Congress (ECCO) and the European Association of Palliative Care (EAPC) databases of all abstracts registered online from 2003 to 2014.</P>
<P>We contacted experts in the field of fatigue in palliative care in order to identify research awaiting publication.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-04-09 13:20:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We retrieved in full all studies in which the abstract refers to drug intervention aimed at treating fatigue in palliative care. Eligible studies had to define fatigue as a primary outcome and at least one treatment arm had to be a drug intervention.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-04-09 13:20:12 +0100" MODIFIED_BY="[Empty name]">
<P>We organised data using the software Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). Two review authors extracted data (MM and MC) using a standard data extraction form. Two authors (MM and MC) reviewed the data from the included studies and two other authors (LR and HC) cross-checked a sub-sample. We resolved disagreement by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (MM and MC) independently assessed risk of bias for each study, using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion or by involving other review authors (LR, HC). We assessed the following for each study:</P>
<P>
<B>Random sequence generation </B>(checking for possible selection bias)</P>
<P>We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We carefully considered studies using a non-random process.</P>
<P>
<B>Allocation concealment </B>(checking for possible selection bias)</P>
<P>The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list).</P>
<P>
<B>Blinding of outcome assessment </B>(checking for possible detection bias)</P>
<P>We assessed the methods used to blind study participants and outcome assessors from the knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding, e.g. identical tablets, matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how this was achieved). We excluded studies that were not double-blind.</P>
<P>
<B>Incomplete outcome data</B> (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</P>
<P>We assessed the methods used to deal with incomplete data as: low risk (less than 10% of participants did not complete the study and/or used 'baseline observation carried forward' analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis).</P>
<P>
<B>Size of study</B> (checking for possible biases confounded by small size)</P>
<P>We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We intended to evaluate the methodological quality of each study, as well as the evidence for drug interventions to treat fatigue, using the GRADE system (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>). We aimed to further evaluate studies by setting 'clinically relevant improvement' equal to improvement by one-third compared to baseline fatigue intensity and to calculate a number needed to treat to benefit (NNTB) accordingly (NNTB to achieve at least a 33% improvement of fatigue intensity compared to the baseline fatigue level). We aimed to calculate numbers needed to treat to harm (NNTH) for adverse events with moderate or severe intensity.</P>
<P>If calculation of the NNTB was not possible, 'clinically relevant improvement' would be defined as a change of 5% or more of the primary outcome instrument used in the study. This would be in accordance with the study of Cella et al, identifying changes between 3.7% and 5.8% of the aggregated summary scores as 'clinically important' (<LINK REF="REF-Cella-2002" TYPE="REFERENCE">Cella 2002</LINK>).</P>
<P>In addition, for each identified study, we aimed to extract:</P>
<UL>
<LI>number of participants in each arm;</LI>
<LI>type of control group;</LI>
<LI>quality of the study (randomisation, blinding, per protocol analysis, intention-to-treat (ITT) analysis, number of withdrawals described);</LI>
<LI>demographic characteristics, including age and sex;</LI>
<LI>type of primary disease;</LI>
<LI>type and stage of treatment, if applicable;</LI>
<LI>type of drug used for the pharmacological intervention;</LI>
<LI>duration and pharmacological regimen of drug treatment with the drug of interest;</LI>
<LI>outcome measures employed, including means and standard deviations.</LI>
</UL>
<P>We documented outcomes of fatigue in different ways. If we identified two or more studies that investigated a specific drug with the same dose in a population with the same disease and same assessment instrument or scale, we conducted a meta-analysis. We aimed to calculate the standardised mean difference (SMD) in fatigue intensity, stating whether it had reached a potentially significant cut-off level and we aimed to compare these data to other interventions and control groups, wherever available. Wherever appropriate, we calculated standard deviations (SD) for standardisation of the mean difference (MD) as the square root of the average of the variances before and after the intervention. Similarly, if only 95% confidence intervals (CI) were described, we converted these values to SDs by dividing the difference of the CI and mean by a factor of 1.96.</P>
<P>A NNTB of 50% reduction has been suggested as significant for an exercise intervention in cancer-related fatigue (<LINK REF="REF-Cramp-2012" TYPE="REFERENCE">Cramp 2012</LINK>). Since only limited information on the cut-off level for clinically significant fatigue has been identified to date, we suggested a 33% improvement as a basis for NNTB calculation, since palliative care patients are more debilitated than the population that was examined in the <LINK REF="REF-Cramp-2012" TYPE="REFERENCE">Cramp 2012</LINK> review. A 33% reduction of pain intensity has been described as significant from the patients' point of view in studies on breakthrough pain management (<LINK REF="REF-Farrar-2003" TYPE="REFERENCE">Farrar 2003</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-09-08 13:32:47 +0100" MODIFIED_BY="Martin Mücke">
<P>The unit of randomisation was the individual patient.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the original investigators to request missing data. We used intention-to-treat (ITT) analysis where possible. The ITT population consisted of participants who were randomised, took the assigned study medication and provided at least one post-baseline assessment. We assigned missing participants zero improvement (baseline observation carried forward (BOCF), where this could be done. We were aware that imputation methods might be problematic and examined trial reports for information about them.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We explored the homogeneity of the results of the various endpoints of interest using I² statistic values. We regarded heterogeneity in the results as a result of many potential factors (postulated a priori), and we made efforts to identify subgroups for sensitivity analysis. We undertook meta-analysis. As a result of high statistical heterogeneity, we used a random-effects model for analysis. If possible, and where applicable, we conducted subgroup analyses to explore possible sources of heterogeneity due to participants, interventions or methods.</P>
<P>Potential sources of heterogeneity:</P>
<UL>
<LI>disease entities;</LI>
<LI>performance status;</LI>
<LI>quality of studies;</LI>
<LI>medication dose and frequency;</LI>
<LI>duration of treatment;</LI>
<LI>duration of follow-up;</LI>
<LI>rate of attrition;</LI>
<LI>outcome measures used;</LI>
<LI>case mix/stage of disease accessed.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-04-09 13:01:52 +0100" MODIFIED_BY="[Empty name]">
<P>To decrease the influence of potential publication bias, we conducted manual and electronic searches of multiple databases, without imposing any language restriction, to check for published or registered study protocols and to verify whether results from these studies have been published subsequently. We contacted the trial authors by email if there was insufficient information to assess reporting bias. We also contacted the authors to clarify information, if there were mismatches between study protocols and reports.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>For data synthesis, we used Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), as provided by The Cochrane Collaboration. We grouped meta-analyses of the data from all included studies using the I² statistic. If the I² value was greater than or equal to 50% (substantial or considerable heterogeneity), we used a random-effects model. If the I² value was less than 50%, we used a fixed-effect model. We reported the results from both models.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We intended to conduct a subgroup analysis where data were available. We performed separate analysis for different kinds of primary diseases (such as cancer or multiple sclerosis). If it was not possible to carry out a quantitative analysis, then we considered a qualitative review and a synthesis of the study results.</P>
<P>In this review, we performed subgroup analyses for the following:</P>
<UL>
<LI>different types of drug treatment;</LI>
<LI>different types of disease;</LI>
<LI>different types of assessment tools.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out sensitivity analysis for the primary outcome measurements in order to explore effect size differences and the robustness of our conclusions. We planned sensitivity analysis determined a priori based on:</P>
<UL>
<LI>studies without study limitations with regard to a) allocation concealment; b) blinding of participants and investigators; c) recruitment bias; d) baseline imbalance between groups; e) loss to follow-up of clusters; f) adequate analysis;</LI>
<LI>method of analysis: results of a) studies using number of patients analysed; b) studies using number of patients randomised.</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>This review updates and combines two existing reviews: <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> and <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>. The previous review, <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>, found 31 studies involving 7140 participants and the review <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK> identified 22 eligible studies with a total of 1632 participants. We used a new search strategy for this update, providing 1645 results that we screened. Most of these articles did not focus on fatigue as a primary outcome but on the drug treatment of underlying disease. The updated search strategy identified 20 additional studies suitable for inclusion. Only seven of the studies included in the <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> review, but all 22 of the previously included studies in <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>, matched our results. The small number of matched study results between this updated review and the <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> review is due to the fact that we did not include haemopoietic growth factors in our search strategy. Safety concerns have been raised regarding the erythropoiesis-stimulating agents (erythropoietin and darbepoetin) since the last publication of the original review, therefore the use of these drugs is no longer recommended in practice (<LINK REF="REF-Bennet-2008" TYPE="REFERENCE">Bennet 2008</LINK>; <LINK REF="REF-Bohlius-2009" TYPE="REFERENCE">Bohlius 2009</LINK>; <LINK REF="REF-EAPC-2008" TYPE="REFERENCE">EAPC 2008</LINK>; <LINK REF="REF-Glaspy-2009" TYPE="REFERENCE">Glaspy 2009</LINK>; <LINK REF="REF-Glaspy-2010" TYPE="REFERENCE">Glaspy 2010</LINK>; <LINK REF="REF-Tonelli-2009" TYPE="REFERENCE">Tonelli 2009</LINK>). We found and removed 186 duplicate studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We checked the retrieved articles against the inclusion criteria and included 45 studies. We identified no additional unpublished data by contacting experts in palliative care and we retrieved no additional studies from the handsearched reference lists or abstract databases on the Internet.</P>
<P>Meta-analysis of data was possible for modafinil in multiple sclerosis (two studies, n = 136 participants), pemoline in multiple sclerosis (two studies, n = 103 participants) and methylphenidate in cancer patients (two studies, n = 146 participants).</P>
<P>See also <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We screened 1645 publications, of which 45 met the inclusion criteria and we included them for further analysis. In total, we analysed data from 18 drugs and 4696 participants. We used studies investigating pemoline and modafinil in participants with multiple sclerosis-associated fatigue and methylphenidate in participants suffering from cancer and fatigue for meta-analysis.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>The 45 studies retrieved for the review yielded a broad spectrum of diseases associated with fatigue as well as different drugs (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Fatigue was typically examined in association with diseases as follows: multiple sclerosis (13 studies), HIV/AIDS (including HIV and hypogonadism) (seven studies), cancer (including advanced cancer, cancer of different origins and brain tumours) (18 studies), post-polio (two studies), Parkinson's disease (one study), end-stage renal disease (ESRD) (one study), amyotrophic lateral sclerosis (one study), multi-type advanced disease (hospice patients) (one study) and end-stage COPD (one study).</P>
<P>Drug studied were as follows: amantadine (nine studies), pemoline (three studies), megestrol acetate (one study), methylphenidate (seven studies), dexamphetamine (two studies), paroxetine (two studies), acetyl-L-carnitine (four studies), testosterone (three studies), donepezil (one study), modafinil (eight studies), dexamethasone (one study), fluoxetine (two studies), alfacalcidol (one study), armodafinil (one study), mistletoe extract PS76A2 (one study), methylprednisolone (one study), medroxyprogesterone acetate (one study) and acetylsalicylic acid (two studies).</P>
<P>In contrast, <LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK> examined fatigue related to both cancer and treatment. <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK> and <LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK> examined fatigue in patients with depression, where it may be difficult to differentiate whether fatigue was primary or secondary to depression.</P>
<P>Most studies reported data from a relatively small number of participants: for the 45 studies included, only 17 reported a participant number greater than 100. Participant numbers, including controls, varied from six (<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>) to 544 (<LINK REF="STD-Jean_x002d_Pierre-2010" TYPE="STUDY">Jean-Pierre 2010</LINK>). The total number of participants who completed the studies included in our analysis was 4696. Issues associated with inconclusive findings were as follows: differences in data reporting, heterogenous populations, inconsistent symptom assessment (the use of instrument differed greatly) and lack of a consistent definition for a clinically significant reduction in fatigue. Therefore it was not possible to calculate the NNTB or NNTH, nor could we calculate a 5% reduction of fatigue as consistently as intended and described above.</P>
<P>Some trials in this review only used single-item fatigue assessment. However, it is now considered by European palliative care experts that a single-item tool could be as good as a comprehensive assessment. Single-item assessments of fatigue may have drawbacks, but more complex assessment methods may also be problematic in patients with advanced disease as they require some cognitive capacity, which is often lacking in a fatigue patient group. Excluding these studies would cause a new bias, as would excluding studies in end-of-life care and focused on patients in oncological care. Hence, we included and analysed these trials in our review.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-04-20 14:28:08 +0100" MODIFIED_BY="[Empty name]">
<P>The previous review, <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>, excluded 23 studies and the review by <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> excluded 14 studies. For this update, we had to exclude 49 studies in the final selection process after reading the manuscript. Reasons for exclusion were typically a lack of inclusion criteria match (e.g. fatigue defined as a secondary outcome; case series; not a RCT), investigation of fatigue attributed to narcotic-induced sedation, data were a subset of another study which had been already included in the analysis, or data were not from patients with advanced disease. We listed these studies with the reason for exclusion in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Some studies specifically described the randomisation and blinding procedure and we therefore considered them to have a minimal risk of bias concerning allocation concealment (e.g. <LINK REF="STD-Cruciani-2012" TYPE="STUDY">Cruciani 2012</LINK>; <LINK REF="STD-Roth-2010" TYPE="STUDY">Roth 2010</LINK>). However, some studies did not specify these procedures, but used the terminology "double-blind, randomised controlled trial", allowing the assumption of a low risk of bias (e.g. <LINK REF="STD-Barak-2014" TYPE="STUDY">Barak 2014</LINK>; <LINK REF="STD-Lange-2009" TYPE="STUDY">Lange 2009</LINK>).</P>
<P>Considering the relatively small number of participants in most of the included studies, as well as the variety of instruments used, the results have to be interpreted with caution. The small numbers of participants may be a reason for a lack of stratification (for example, for relevant health conditions such as depression or sociodemographic data such as age or sex), which may alter the outcome as demonstrated by some investigators (<LINK REF="REF-Eriksen-2003" TYPE="REFERENCE">Eriksen 2003</LINK>; <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>).</P>
<P>We assessed each study using the Cochrane 'Risk of bias' tool. The findings are presented in the 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), which reviews the authors' judgements about each risk of bias item shown as percentages across all included studies, and the 'Risk of bias' summary (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), which reviews the authors' judgements about each risk of bias item for each included study.</P>
<ALLOCATION MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>All studies reported randomisation, but no more than 23 included a proper description of the methods used (<LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>; <LINK REF="STD-Bruera-2006" TYPE="STUDY">Bruera 2006</LINK>; <LINK REF="STD-Bruera-2007" TYPE="STUDY">Bruera 2007</LINK>; <LINK REF="STD-Cruciani-2009" TYPE="STUDY">Cruciani 2009</LINK>; <LINK REF="STD-Cruciani-2012" TYPE="STUDY">Cruciani 2012</LINK>; <LINK REF="STD-Fisch-2003" TYPE="STUDY">Fisch 2003</LINK>; <LINK REF="STD-Jean_x002d_Pierre-2010" TYPE="STUDY">Jean-Pierre 2010</LINK>; <LINK REF="STD-Kerr-2012" TYPE="STUDY">Kerr 2012</LINK>; <LINK REF="STD-Knapp-2008" TYPE="STUDY">Knapp 2008</LINK>; <LINK REF="STD-Moraska-2010" TYPE="STUDY">Moraska 2010</LINK>; <LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>; <LINK REF="STD-Rabkin-2000" TYPE="STUDY">Rabkin 2000</LINK>; <LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>; <LINK REF="STD-Rabkin-2009" TYPE="STUDY">Rabkin 2009</LINK>; <LINK REF="STD-Rabkin-2010" TYPE="STUDY">Rabkin 2010</LINK>; <LINK REF="STD-Rabkin-2011" TYPE="STUDY">Rabkin 2011</LINK>; <LINK REF="STD-Semiglazov-2006" TYPE="STUDY">Semiglazov 2006</LINK>; <LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>; <LINK REF="STD-Simons-1996" TYPE="STUDY">Simons 1996</LINK>; <LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>; <LINK REF="STD-Vasconcelos-2007" TYPE="STUDY">Vasconcelos 2007</LINK>; <LINK REF="STD-Westman-1999" TYPE="STUDY">Westman 1999</LINK>; <LINK REF="STD-Wingerchuk-2005" TYPE="STUDY">Wingerchuk 2005</LINK>). Only nine described the method used to conceal the allocation appropriately (<LINK REF="STD-Bruera-2006" TYPE="STUDY">Bruera 2006</LINK>; <LINK REF="STD-Bruera-2007" TYPE="STUDY">Bruera 2007</LINK>; <LINK REF="STD-Lacasse-2004" TYPE="STUDY">Lacasse 2004</LINK>; <LINK REF="STD-Moraska-2010" TYPE="STUDY">Moraska 2010</LINK>; <LINK REF="STD-Rabkin-2009" TYPE="STUDY">Rabkin 2009</LINK>; <LINK REF="STD-Semiglazov-2006" TYPE="STUDY">Semiglazov 2006</LINK>; <LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>; <LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>; <LINK REF="STD-Vasconcelos-2007" TYPE="STUDY">Vasconcelos 2007</LINK>; <LINK REF="STD-Wingerchuk-2005" TYPE="STUDY">Wingerchuk 2005</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty studies were double-blind (<LINK REF="STD-Ashtari-2009" TYPE="STUDY">Ashtari 2009</LINK>; <LINK REF="STD-Auret-2009" TYPE="STUDY">Auret 2009</LINK>; <LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>; <LINK REF="STD-Butler-2007" TYPE="STUDY">Butler 2007</LINK>; <LINK REF="STD-Cruciani-2009" TYPE="STUDY">Cruciani 2009</LINK>; <LINK REF="STD-Cruciani-2012" TYPE="STUDY">Cruciani 2012</LINK>; <LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>; <LINK REF="STD-Lou-2009" TYPE="STUDY">Lou 2009</LINK>; <LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>; <LINK REF="STD-Rabkin-2000" TYPE="STUDY">Rabkin 2000</LINK>; <LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>; <LINK REF="STD-Rabkin-2009" TYPE="STUDY">Rabkin 2009</LINK>; <LINK REF="STD-Rabkin-2010" TYPE="STUDY">Rabkin 2010</LINK>; <LINK REF="STD-Rabkin-2011" TYPE="STUDY">Rabkin 2011</LINK>; <LINK REF="STD-Roth-2010" TYPE="STUDY">Roth 2010</LINK>; <LINK REF="STD-Semiglazov-2006" TYPE="STUDY">Semiglazov 2006</LINK>; <LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>; <LINK REF="STD-Vasconcelos-2007" TYPE="STUDY">Vasconcelos 2007</LINK>; <LINK REF="STD-Westman-1999" TYPE="STUDY">Westman 1999</LINK>; <LINK REF="STD-Wingerchuk-2005" TYPE="STUDY">Wingerchuk 2005</LINK>). The remainder did not provide sufficient information to assess risk of bias (unclear risk).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>There were only four studies lacking sufficient information to assess risk (unclear risk of bias) (<LINK REF="STD-Butler-2007" TYPE="STUDY">Butler 2007</LINK>; <LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>; <LINK REF="STD-Weinshenker-1992" TYPE="STUDY">Weinshenker 1992</LINK>; <LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>). We judged the remaining 41 studies to meet the criteria for low risk of bias.</P>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment group size was an issue. Small studies are thought to be at increased risk of bias, probably because the conduct of small studies is more likely to be less rigorous, allowing critical criteria to be compromised. Only two of the treatment groups in this review were large enough to give a low risk of bias (<LINK REF="STD-Jean_x002d_Pierre-2010" TYPE="STUDY">Jean-Pierre 2010</LINK>; <LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>). We judged 14 studies to have an unclear risk (<LINK REF="STD-Barak-2014" TYPE="STUDY">Barak 2014</LINK>; <LINK REF="STD-Bruera-2006" TYPE="STUDY">Bruera 2006</LINK>; <LINK REF="STD-Bruera-2007" TYPE="STUDY">Bruera 2007</LINK>; <LINK REF="STD-Canadian-MSRG-1987" TYPE="STUDY">Canadian MSRG 1987</LINK>; <LINK REF="STD-Cruciani-2012" TYPE="STUDY">Cruciani 2012</LINK>; <LINK REF="STD-Della-Cuna-1989" TYPE="STUDY">Della Cuna 1989</LINK>; <LINK REF="STD-Fisch-2003" TYPE="STUDY">Fisch 2003</LINK>; <LINK REF="STD-Moraska-2010" TYPE="STUDY">Moraska 2010</LINK>; <LINK REF="STD-Rabkin-2010" TYPE="STUDY">Rabkin 2010</LINK>; <LINK REF="STD-Semiglazov-2006" TYPE="STUDY">Semiglazov 2006</LINK>; <LINK REF="STD-Simons-1996" TYPE="STUDY">Simons 1996</LINK>; <LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>; <LINK REF="STD-Stankoff-2005" TYPE="STUDY">Stankoff 2005</LINK>; <LINK REF="STD-Westman-1999" TYPE="STUDY">Westman 1999</LINK>). We judged the remainder to have a high risk of bias due to size.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>Most studies reported some benefit of the active treatment. However, there was often a substantial and very similar placebo effect. Further, reviewing only fatigue-specific instruments (e.g. the Chalder Fatigue Scale (CFS), Fatigue Severity Scale (FSS), visual analogue scale (VAS) for fatigue), these benefits could not be confirmed in many cases. See also: <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>. In general, adverse reactions were mild and had little or no impact (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>)<B>.</B>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Acetyl-L-carnitine versus placebo</HEADING>
<P>Acetyl-L-carnitine was compared with placebo in a study of 29 participants with cancer-related fatigue, with no significant effect (<LINK REF="STD-Cruciani-2009" TYPE="STUDY">Cruciani 2009</LINK>). FACT-fatigue mean scores were 15.7 (SD 10.6) at baseline and 22.2 (10.4) at week two (P value = 0.97). A recent study of 209 participants did not show statistically significant improvement in fatigue compared to placebo (<LINK REF="STD-Cruciani-2012" TYPE="STUDY">Cruciani 2012</LINK>). The primary outcome, fatigue, measured using the Brief Fatigue Inventory (BFI), improved in both arms in comparison to baseline (L-carnitine: -0.96, 95% confidence interval (CI) -1.32 to -0.60; placebo: -1.11, 95% CI -1.44 to -0.78). There were no statistically significant differences between the arms (P value <I>= </I>0.57), while the secondary outcomes, including fatigue measured on the Functional Assessment for Chronic Illness Therapy - Fatigue (FACIT-F) scale, did not show a significant difference between arms, with a change in mean of 31.4 (standard deviation (SD) 9.21; L-carnitine) versus 23.67 (SD 11.24; placebo) (P value= 0.61).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Acetyl-L-carnitine versus amantadine</HEADING>
<P>In another study of 36 participants, acetyl-L-carnitine was compared with amantadine in patients with multiple sclerosis (<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>). Improvement assessed with the FSS was superior with L-carnitine compared with amantadine. In addition, L-carnitine was better tolerated than amantadine. However, differences in the absolute changes in the FSS did not reach statistical significance and the number of responders was similar for both drugs. There was no significant change for the secondary outcome of clinical scale scores (Fatigue Impact Scale, Beck Depression Inventory and Social Experience Checklist). The fatigue domain of the Kidney Disease Questionnaire (KDQ) also significantly improved after 12 weeks and 24 weeks of carnitine therapy compared with placebo in 56 patients with end-stage renal disease, but did not significantly affect the total score (<LINK REF="STD-Brass-2001" TYPE="STUDY">Brass 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Acetylsalicylic acid versus placebo</HEADING>
<P>
<LINK REF="STD-Wingerchuk-2005" TYPE="STUDY">Wingerchuk 2005</LINK> was able to show significantly better relief of fatigue with 1300 mg/day of acetylsalicylic acid compared to placebo in 26 patients with multiple sclerosis. Wingerchuk et al used the Modified Fatigue Impact Scale (MFIS) and Kurtzke Expanded Disability Status Scale (KEDSS) as instruments. In another study of 52 patients with multiple sclerosis (<LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>), 500 mg/day showed a significant decrease in FSS scores. We did not perform meta-analysis due to the different doses and assessment instruments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Alfacalcidol versus placebo</HEADING>
<P>A recent study using alfacalcidol 1 µg/day compared with placebo was conducted to treat fatigue in 158 multiple sclerosis patients. The Fatigue Impact Scale (FIS) total score decreased significantly. 'RAYS' quality of life assessments also improved significantly in the psychological and social subscale (<LINK REF="STD-Barak-2014" TYPE="STUDY">Barak 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amantadine versus placebo</HEADING>
<P>Amantadine was used in seven studies of 370 participants with multiple sclerosis with heterogenous outcomes, showing a tendency towards improved outcomes with amantadine with different fatigue instruments and scales (<LINK REF="STD-Ashtari-2009" TYPE="STUDY">Ashtari 2009</LINK>; <LINK REF="STD-Canadian-MSRG-1987" TYPE="STUDY">Canadian MSRG 1987</LINK>; <LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>; <LINK REF="STD-Murray-1985" TYPE="STUDY">Murray 1985</LINK>; <LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>; <LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>; <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>). Amantadine was significantly better than placebo on the MS-Fatigue scale. One study of 25 participants used amantadine post-polio using the Fatigue Severity Scale (FSS) without proving efficacy (<LINK REF="STD-Stein-1995" TYPE="STUDY">Stein 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amantadine versus other drugs</HEADING>
<P>
<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK> tested amantadine against pemoline (93 participants). No difference between amantadine and pemoline was seen on the FSS. On the other hand, <LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK> performed a comparison of amantadine against acetyl-L-carnitine (ALCAR). ALCAR showed superior effect to amantadine. <LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK> tested amantadine against acetylsalicylic acid. Both groups showed a significant decrease in the FSS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Armodafinil versus placebo</HEADING>
<P>Armodafinil was tested in 70 patients with HIV to evaluate its efficacy and safety for fatigue and depressive symptoms. In intention-to-treat analyses, the fatigue response rate to armodafinil was 75% and to placebo 26% (<LINK REF="STD-Rabkin-2011" TYPE="STUDY">Rabkin 2011</LINK>). Armodafinil appeared to be effective in alleviating fatigue and was well tolerated. For the secondary endpoint depression, measured with the Hamilton Depression Rating Scale (HDRS) and Beck Depression Inventory (BDI), a significant effect was not shown. However, further multicentre studies with larger samples are needed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dexamethasone versus placebo</HEADING>
<P>Dexamethasone 4 mg was compared with placebo in a recent study to treat fatigue in 84 participants with advanced cancer. The study showed that dexamethasone was significantly superior to placebo (<LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>). However, there was no significant difference in the improvement of individual symptoms on the Edmonton Symptom Assessment Scale (ESAS), psychological distress, anxiety scores on the Hospital Anxiety and Depression Scale (HADS) or HADS depression scores in the dexamethasone group compared with placebo. Further dexamethasone studies are needed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dextroamphetamine versus placebo</HEADING>
<P>Dextroamphetamine was compared with placebo to treat fatigue in a study of 39 cancer patients (<LINK REF="STD-Auret-2009" TYPE="STUDY">Auret 2009</LINK>) and in 22 patients with HIV (<LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>). Neither study showed significant effects. The secondary outcome quality of life, which was measured using the McGill Quality of Life Questionnaire (MQOL), also showed no significant effect (<LINK REF="STD-Auret-2009" TYPE="STUDY">Auret 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Donepezil versus placebo</HEADING>
<P>In a large study with 142 participants with cancer, donepezil significantly relieved fatigue intensity in both the intervention and control arms, with no significant difference as measured by the FACIT-F scale. Edmonton Symptom Assessment Scale (ESAS) and sleep pattern assessment were also used as supplemental scales. Neither showed significant effects. Thus, donepezil did not appear to be superior to placebo (<LINK REF="STD-Bruera-2007" TYPE="STUDY">Bruera 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fluoxetine versus placebo</HEADING>
<P>Another study of 129 patients with multiple sclerosis showed that 20 mg of fluoxetine over 12 weeks appeared to be superior to placebo as measured by the change in Functional Assessment of Cancer Therapy - General (FACT-G) scores. The fluoxetine group also showed significant improvement on the depression scale (P value = 0 .0005) compared with placebo, which was measured using the Brief Zung Self-Rating Depression Scale (BZSDS) (<LINK REF="STD-Fisch-2003" TYPE="STUDY">Fisch 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fluoxetine versus testosterone</HEADING>
<P>Fluoxetine was inferior to testosterone in 90 patients with HIV and fatigue, while the difference in the effect on depression, as measured with the HDRS, was non-significant (P value = 0.38) (<LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Medroxyprogesterone versus placebo</HEADING>
<P>Medroxyprogesterone was tested in only one study of 134 participants using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) (<LINK REF="STD-Simons-1996" TYPE="STUDY">Simons 1996</LINK>). The use of 500 mg twice a day over 12 weeks showed no significant effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Megestrol acetate versus placebo</HEADING>
<P>Megestrol acetate was tested in 255 patients with cancer. The administration of 320 mg/day for 12 weeks was performed to investigate the effect of megestrol acetate on quality of life, appetite, weight and survival. However, megestrol acetate does not appear to improve global quality of life as measured by the EORTC QLQ-C30 (<LINK REF="STD-Westman-1999" TYPE="STUDY">Westman 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methylphenidate versus placebo</HEADING>
<P>Five studies tested methylphenidate in 318 cancer patients (<LINK REF="STD-Bruera-2006" TYPE="STUDY">Bruera 2006</LINK>; <LINK REF="STD-Butler-2007" TYPE="STUDY">Butler 2007</LINK>; <LINK REF="STD-Escalante-2014" TYPE="STUDY">Escalante 2014</LINK>; <LINK REF="STD-Moraska-2010" TYPE="STUDY">Moraska 2010</LINK>; <LINK REF="STD-Roth-2010" TYPE="STUDY">Roth 2010</LINK>). Meta-analysis was possible only for two studies (<LINK REF="STD-Bruera-2006" TYPE="STUDY">Bruera 2006</LINK>; <LINK REF="STD-Butler-2007" TYPE="STUDY">Butler 2007</LINK>), which used FACIT-F as the assessment tool in fatigue, comparing methylphenidate with placebo. The studies showed a slightly superior effect of methylphenidate compared to placebo (standardised mean difference (SMD) 0.49, 95% confidence interval (CI) 0.15 to 0.83; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). <LINK REF="STD-Moraska-2010" TYPE="STUDY">Moraska 2010</LINK> used the Brief Fatigue Inventory (BFI) instrument, and could not show significant effects of methylphenidate (18 mg to 54 mg) compared with placebo. <LINK REF="STD-Escalante-2014" TYPE="STUDY">Escalante 2014</LINK> used a stable dose (18 mg) for two weeks. They reported that methylphenidate improved cancer-related fatigue according to the BFI scores. The smallest dose was used by <LINK REF="STD-Roth-2010" TYPE="STUDY">Roth 2010</LINK> (5 mg to 30 mg). In this study, clinically significant improvement was seen on the BFI.</P>
<P>The other study of 30 participants using methylphenidate concerned the treatment of fatigue in multi-type advanced disease (hospice) patients (<LINK REF="STD-Kerr-2012" TYPE="STUDY">Kerr 2012</LINK>). The study showed that methylphenidate was superior to placebo, although the improvement of the fatigue score was dose-dependent, as measured by Piper Fatigue Scale, Visual Analogue Scale for Fatigue and ESAS. However, secondary outcomes of depressive symptoms, measured with the revised Beck Depression Inventory-II (BDI-II), the ESAS depression score and the Center for Epidemiologic Studies Depression Scale (CESD), showed no statistically significant differences.</P>
<P>Methylphenidate was also investigated in 209 HIV patients and compared with pemoline and placebo (<LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>). This study demonstrated a significantly higher number of responders using methylphenidate compared with placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methylprednisolone versus placebo</HEADING>
<P>Methylprednisolone (125 mg/day for eight weeks) was used with significant effect in only one study of 403 participants with cancer-related fatigue (<LINK REF="STD-Della-Cuna-1989" TYPE="STUDY">Della Cuna 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Mistletoe extract PS76A2 versus placebo</HEADING>
<P>Mistletoe extract was tested in 337 patients with breast cancer (<LINK REF="STD-Semiglazov-2006" TYPE="STUDY">Semiglazov 2006</LINK>). It showed a significant positive effect using the FACT-G.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Modafinil versus placebo</HEADING>
<P>Modafinil has been explored for the treatment of fatigue in two studies of 704 patients with cancer (<LINK REF="STD-Jean_x002d_Pierre-2010" TYPE="STUDY">Jean-Pierre 2010</LINK>; <LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>). The <LINK REF="STD-Jean_x002d_Pierre-2010" TYPE="STUDY">Jean-Pierre 2010</LINK> study showed a significant interaction between treatment condition (modafinil 200 mg/day) and baseline fatigue, where patients with severe baseline fatigue benefited from modafinil and patients with mild or moderate fatigue did not. A recent study demonstrated that both modafinil (100 to 200 mg/day) and placebo led to a clinically significant improvement in FACIT-F scores (<LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>). However, there was no significant difference between placebo and modafinil.</P>
<P>Though modafinil has been tested in several studies in multiple sclerosis, we found only two controlled trials (<LINK REF="STD-Lange-2009" TYPE="STUDY">Lange 2009</LINK>; <LINK REF="STD-Stankoff-2005" TYPE="STUDY">Stankoff 2005</LINK>). The <LINK REF="STD-Stankoff-2005" TYPE="STUDY">Stankoff 2005</LINK> study included a larger number of participants (n = 115), but failed to demonstrate the superiority of modafinil versus placebo. <LINK REF="STD-Lange-2009" TYPE="STUDY">Lange 2009</LINK> included only 21 participants and stated that they used a subpopulation of a larger trial. Thus, although there was a clear beneficial effect of modafinil, this result must be interpreted with caution due to the small participant numbers. Meta-analysis of these two studies also failed to demonstrate a significant effect, with a SMD of -0.14 (95% CI -0.48 to 0.21; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>Modafinil was also tested for the treatment of fatigue in 33 participants with post-polio syndrome (<LINK REF="STD-Vasconcelos-2007" TYPE="STUDY">Vasconcelos 2007</LINK>). However, in this study modafinil failed to demonstrate superiority over placebo.</P>
<P>There was also a trial using modafinil for fatigue in 105 HIV/AIDS patients (<LINK REF="STD-Rabkin-2010" TYPE="STUDY">Rabkin 2010</LINK>). In the intention-to-treat analyses, the fatigue response rate to modafinil was 73% and to placebo 28%; the attrition rate was 9%. Secondary endpoints (depression), including the Hamilton Depression Rating Scale (HDRS) and Beck Depression Inventory (BDI), did not show a significant effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Paroxetine versus placebo</HEADING>
<P>Paroxetine was tested in a study of 479 patients with cancer (<LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>), and a study of 15 patients with end-stage chronic obstructive pulmonary disease (COPD; <LINK REF="STD-Lacasse-2004" TYPE="STUDY">Lacasse 2004</LINK>). Neither study showed significant effects. However, the Center for Epidemiological Studies Depression (CESD) score, controlling baseline depression scores, confirmed that the dose of paroxetine provided was more effective than placebo in reducing depression (P value = 0 .001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pemoline versus placebo</HEADING>
<P>Pemoline was used for the treatment of fatigue in 41 participants with multiple sclerosis. However, in this study pemoline failed to demonstrate superiority over placebo (<LINK REF="STD-Weinshenker-1992" TYPE="STUDY">Weinshenker 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pemoline versus other drugs</HEADING>
<P>Pemoline was tested in 93 patients with multiple sclerosis and severe fatigue (<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>). The drug did not appear to be superior to placebo. One study with HIV patients compared pemoline to methylphenidate and to a placebo (<LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>). The <LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK> study demonstrated a significantly higher number of responders with pemoline and methylphenidate compared with placebo.</P>
<P>Meta-analysis was possible for two studies in multiple sclerosis patients as they all included a control group with placebo and reported continuous outcome indicators (<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>; <LINK REF="STD-Weinshenker-1992" TYPE="STUDY">Weinshenker 1992</LINK>). There was no superior effect of pemoline (SMD -0.02; 95% CI -0.12 to 0.08; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>However, the US Food and Drug Administration (FDA) has decided to withdraw pemoline products (marketed as Cylert) due to the risk of liver toxicity, which outweighs the benefits of the drug. All manufacturers have agreed to stop the sale and marketing of pemoline (<LINK REF="REF-FDA-2005" TYPE="REFERENCE">FDA 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Testosterone versus placebo</HEADING>
<P>Testosterone cypionate was investigated in 208 patients with HIV in three studies by the same workgroup (<LINK REF="STD-Knapp-2008" TYPE="STUDY">Knapp 2008</LINK>; <LINK REF="STD-Rabkin-2000" TYPE="STUDY">Rabkin 2000</LINK>; <LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>). The older study included HIV patients with symptoms of hypogonadism and found that testosterone relieved these symptoms in patients with fatigue at baseline (<LINK REF="STD-Rabkin-2000" TYPE="STUDY">Rabkin 2000</LINK>). However, fatigue intensity on the CFS merely showed a positive trend, but no significant difference from placebo. The newer study did not show any significant benefit of testosterone compared to fluoxetine or placebo (<LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>). Only <LINK REF="STD-Knapp-2008" TYPE="STUDY">Knapp 2008</LINK> showed superiority of testosterone over placebo.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>This review updates the original review 'Pharmacological treatments for fatigue associated with palliative care' (<LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>) and also incorporates 'Drug therapy for the management of cancer-related fatigue' (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>). <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK> and <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> included 22 and 31 studies, respectively. This updated review includes seven studies from <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> and 22 studies from <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review update identified 45 studies for inclusion, with a wide range of underlying diseases and drug interventions. Treatment results pointed to weak and inconclusive evidence for the efficacy of amantadine, pemoline and modafinil in multiple sclerosis and for carnitine and donepezil in cancer-related fatigue. Methylphenidate and pemoline seem to be effective in patients with HIV, but this is based only on one study per intervention, with only a moderate number of participants in each study. Meta-analysis shows an estimated superior effect for methylphenidate in cancer-related fatigue, but not for pemoline and modafinil in multiple sclerosis. Therapeutic effects could not be described for dexamphetamine, paroxetine or testosterone.</P>
<P>Acetylsalicylic acid demonstrated surprising efficacy in patients with multiple sclerosis (<LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>; <LINK REF="STD-Wingerchuk-2005" TYPE="STUDY">Wingerchuk 2005</LINK>). However, this result was not supported by other studies. For clinical recommendation, further research confirming this positive effect is needed.</P>
<P>Some studies used other drugs, for example mistletoe extract, megestrol acetate and medroxyprogesterone acetate (<LINK REF="STD-Semiglazov-2006" TYPE="STUDY">Semiglazov 2006</LINK>; <LINK REF="STD-Simons-1996" TYPE="STUDY">Simons 1996</LINK>; <LINK REF="STD-Westman-1999" TYPE="STUDY">Westman 1999</LINK>), but these studies lacked strong evidence and the clinical use of these drugs is rather rare. Further studies need to demonstrate their clinical efficacy.</P>
<P>The available evidence from randomised controlled trials (RCTs) is scarce, even though there is a surplus of case reports and uncontrolled trials. It has to be kept in mind that many of the included studies involved only a small number of participants (<LINK REF="STD-Lacasse-2004" TYPE="STUDY">Lacasse 2004</LINK>; <LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>), and did not follow a consistent research methodology. In some cases the investigated population was very heterogenous and any outcome may have been associated with depression (<LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>; <LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>), making it difficult to distinguish from primary fatigue. Fatigue often occurs in clusters, and fatigue and emotional distress are often concurrent factors. The National Comprehensive Cancer Network (NCCN) guidelines discuss studies, some of which show fatigue as an independent factor of depression, while others report moderate correlation. The 2014 NCCN guidelines recommended that the psychostimulant methylphenidate may be considered with caution for the pharmacological treatment of fatigue in selected patients. However, corticosteroids are recommended for short-term but not long-term therapy, due to their toxicity (<LINK REF="REF-NCCN-2014" TYPE="REFERENCE">NCCN 2014</LINK>).</P>
<P>Treatment of secondary fatigue should be initiated with the treatment of the underlying cause. Some causes of secondary fatigue, such as anaemia, depression, infection, dehydration, malnutrition, hypercalcaemia, hypomagnesaemia, other metabolic disorders or the side effects of treatment with opioids and other sedative drugs, should also be treated, though little evidence from randomised trials is available on the efficacy of these treatments (<LINK REF="REF-EAPC-2008" TYPE="REFERENCE">EAPC 2008</LINK>).</P>
<P>This review only included studies specifically focusing on palliative care in patients with advanced disease with the aim of relieving fatigue. Studies investigating curative treatment (e.g. treatment of early breast cancer) and fatigue directly related to treatment were not included in this review.</P>
<P>In addition, the results of the literature search indicate that recent research interest focuses on modafinil (eight studies) and its use in fatigue management for palliative care patients. This may be an interesting future perspective.</P>
</SUMMARY_OF_RESULTS>
<POTENTIAL_BIASES MODIFIED="2015-05-21 13:34:50 +0100" MODIFIED_BY="[Empty name]">
<P>None of the authors of this review were involved in any of the excluded or included studies. In addition, none of the authors has any conflict of interest. Our search strategy was as comprehensive as possible. All studies were independently assessed for inclusion by two review authors so we are confident that we have included all relevant studies and attempted to reduce bias in the review process.</P>
<P>Due to difficulties in conducting these types of trials for any of these drugs, trials may not have been published at all. Therefore, there is the potential for publication bias in this review. However, by contacting experts in this field we have attempted to reduce this bias as much as possible.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>There have been two previous Cochrane Reviews (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>; <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK>), which are merged in this systematic review using a new search strategy to increase its coverage. <LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK> concluded in their last published version that there is increasing evidence that psychostimulant trials improve cancer-related fatigue at a clinically meaningful level. This review described the need for a large-scale RCT of methylphenidate to confirm the preliminary results from their review. They recommended haemopoietic growth factors for the treatment of cancer-related fatigue. However, with new safety data indicating increased adverse outcomes, these drugs can no longer be recommended in the treatment of cancer-related fatigue (<LINK REF="REF-Bennet-2008" TYPE="REFERENCE">Bennet 2008</LINK>; <LINK REF="REF-Bohlius-2009" TYPE="REFERENCE">Bohlius 2009</LINK>; <LINK REF="REF-EAPC-2008" TYPE="REFERENCE">EAPC 2008</LINK>; <LINK REF="REF-Glaspy-2009" TYPE="REFERENCE">Glaspy 2009</LINK>; <LINK REF="REF-Tonelli-2009" TYPE="REFERENCE">Tonelli 2009</LINK>). <LINK REF="REF-Peuckmann_x002d_Post-2011" TYPE="REFERENCE">Peuckmann-Post 2011</LINK> concluded that, based on limited evidence, they could not recommend a specific drug for the treatment of fatigue in palliative care patients. The review pointed out that until 2009, corticosteroids had not been the focus of research on fatigue treatment, although these drugs were frequently used in clinical practice. This review also stated that fatigue research seems to focus on modafinil, which may be beneficial, although there is no evidence.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>This review update found no evidence to support the use of a specific drug to treat fatigue in palliative care patients. Amantadine seems to be promising in patients with multiple sclerosis and fatigue, while methylphenidate is advantageous in patients with cancer-related fatigue. However, since the number of studies examining the effect of these drugs on fatigue, as well as the participant numbers, were relatively low, the evidence remains weak. Whether amantadine also relieves fatigue in cancer patients and whether methylphenidate relieves fatigue in multiple sclerosis patients has not been shown but should be investigated. Further studies are needed in patients with advanced disease and fatigue to show whether dexamethasone, methylprednisolone, donepezil, carnitine or modafinil may be beneficial, since the available evidence currently does not support these interventions.</P>
<P>Overall, most adverse effects of the investigated drugs seemed to be fairly moderate. Patients with HIV/AIDS and fatigue should be offered treatment with methylphenidate or pemoline. Similarly, other drugs may be tested, if the above-mentioned drugs are not available.</P>
<P>Clinical practice includes corticosteroids as a short-term therapeutic option for relief of fatigue in palliative care (<LINK REF="REF-Radbruch-2008" TYPE="REFERENCE">Radbruch 2008</LINK>; <LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>). However, only one randomised controlled trial (RCT) from our literature search matched the inclusion criteria (<LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>). There are still not enough studies to show the therapeutic benefits of corticosteroids for this indication.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Patient group</B>
</P>
<P>Trials with a higher participant numbers may be able to detect small differences between groups. Palliative care studies in patients with advanced diseases, with the aim of relieving primary or secondary fatigue, should remain a focus of research. Further trials investigating subpopulations with different diseases in the end stage may be helpful. Stratification according to sociodemographic variables should be performed since, for example, younger age and male sex have been shown to predict worse fatigue (<LINK REF="STD-Auret-2009" TYPE="STUDY">Auret 2009</LINK>; <LINK REF="STD-Butler-2007" TYPE="STUDY">Butler 2007</LINK>).</P>
<P>
<B>Interventions</B>
</P>
<P>Amantadine, methylphenidate, carnitine, acetylsalicylic acid, dexamethasone, alfacalcidol, armodafinil and modafinil have been used in a few studies in this review with positive results. These drugs should be investigated in more detail to confirm their efficacy and should be examined for potentially similar efficacy in populations with different diseases and related fatigue. For instance, amantadine has been studied exclusively in multiple sclerosis patients and in post-polio studies. Therefore, it may be relevant to examine the effect of amantadine in other populations, such as cancer patients. Also, investigation of corticosteroids in RCTs would be highly relevant.</P>
<P>
<B>Comparisons</B>
</P>
<P>Future trials should compare one anti-fatigue drug to another anti-fatigue drug, combined with placebo-controlled comparisons.</P>
<P>
<B>Outcomes</B>
</P>
<P>There is no consensus on threshold values for relief of fatigue or on criteria for the responder. Patient-reported fatigue and variance in the outcome instruments could be used to measure the improvement of fatigue. Outcomes should also clearly define both the response and adverse effects from the treatment. It would be helpful to agree on the use of particular measurement instruments in order to perform better comparisons and analysis (<LINK REF="REF-Minton-2009" TYPE="REFERENCE">Minton 2009</LINK>).</P>
<P>
<B>Trial design</B>
</P>
<P>Further research is needed to identify effective and safe treatment for fatigue in palliative care. Multi-centre RCTs are recommended to assess the value of pharmacological treatments for fatigue. Additional data are required to confirm the results of this review and to provide a more significant estimate of efficacy.</P>
<P>Overall, this review demonstrates a lack of evidence rather than a lack of efficacy of the interventions. With regard to future research, studies with larger participant numbers are needed. However, the difficulties of low recruitment and high attrition rates have been described repeatedly in research in palliative care, as patients with advanced and life-threatening diseases are involved. It would also be helpful to limit the diversity of scales and scores used. Since no standardised recommendations for assessment of fatigue yet exist, it is difficult to determine whether the outcome measures were appropriate. Minton and Stone have suggested using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) fatigue subscale or the Functional Assessment of Cancer Therapy fatigue scale (<LINK REF="REF-Minton-2009" TYPE="REFERENCE">Minton 2009</LINK>).</P>
<P>Interestingly, there were no more than two studies with a focus on corticosteroids and fatigue as the primary outcome (<LINK REF="STD-Della-Cuna-1989" TYPE="STUDY">Della Cuna 1989</LINK>; <LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>), although corticosteroids have been recommended (<LINK REF="REF-EAPC-2008" TYPE="REFERENCE">EAPC 2008</LINK>) and are frequently used for this indication by clinicians since clinical experience shows a beneficial effect on many of the symptoms experienced by palliative care patients. The impact of corticosteroids should be investigated in future studies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Frank Elsner, Norbert Krumm and Peter Trottenburg for their preparatory work. We would like to acknowledge the authors of the previous review: Ollie Minton, Alison Richardson, Michael Sharpe, Matthew Hotopf and Patrick Stone. We thank Anna Mücke, Putri Nastiti, Birgit Jaspers, Johannes Kögler, Grace and Anna Hobson for their helpful support during all stages of the report and their never-ending patience with all delays that occurred, and Roman Rolke who gave valuable feedback for the drafting of the review.</P>
<P>CRG Funding Acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-10-22 13:48:45 +0100" MODIFIED_BY="Anna Hobson">
<P>Martin Mücke has no relevant conflicts of interest to declare.</P>
<P>Mochamat has no relevant conflicts of interest to declare.</P>
<P>Henning Cuhls has no relevant conflicts of interest to declare.</P>
<P>Vera Peuckmann-Post has no relevant conflicts of interest to declare.</P>
<P>Ollie Minton has no relevant conflicts of interest to declare.</P>
<P>Patrick Stone has no relevant conflicts of interest to declare.</P>
<P>Lukas Radbruch has no relevant conflicts of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>MM, MC, LR: guarantors of the review, conceived the review, designed the search strategy, responsible for write up of the protocol and review. </P>
<P>MM and MC: responsible for the update of the review.</P>
<P>MM, MC: extracted data from papers and entered data into RevMan.</P>
<P>MM, MC, HC, LR: organised retrieval of papers, undertook searches and screened retrieved papers against inclusion criteria.</P>
<P>OM, PS: were involved in the original development of the search strategy (first published in Issue 3, 2007) and the appraisal of papers relating to pharmacological management of cancer-related fatigue, and approved the final manuscript.</P>
<P>LR, VP: were involved in the original development of the search strategy (first published in Issue 4, 2007) and the appraisal of papers relating to pharmacological treatments for fatigue associated with palliative care, and approved the final manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>We modified the search strategy to match the inclusion criteria better and to prevent technical error. NNTB and NNTH calculations were not possible, as the information required to calculate these indicators was not included in the papers.</P>
<P>This updated review also incorporates another Cochrane review, 'Drug therapy for the management of cancer-related fatigue' (<LINK REF="REF-Minton-2010" TYPE="REFERENCE">Minton 2010</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2017-07-25 09:24:47 +0100" MODIFIED_BY="Anna Erskine">
<P>A restricted search in 2017 did not identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. If appropriate, we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-07-25 09:25:41 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ashtari-2009" MODIFIED="2015-03-19 16:14:18 +0000" MODIFIED_BY="[Empty name]" NAME="Ashtari 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-03-19 16:14:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ashtari F, Fatehi F, Shaygannejad V, Chitsaz A</AU>
<TI>Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>2009</YR>
<VL>43</VL>
<NO>5</NO>
<PG>428-32</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:16:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904452"/><IDENTIFIER MODIFIED="2014-05-16 09:16:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11176767"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-13 15:25:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904451"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auret-2009" MODIFIED="2009-12-16 12:04:21 +0000" MODIFIED_BY="[Empty name]" NAME="Auret 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-30 19:27:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auret KA, Schug SA, Bremner AP, Bulsara M</AU>
<TI>A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>4</NO>
<PG>613-21</PG>
<IDENTIFIERS MODIFIED="2009-09-29 14:26:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904454"/><IDENTIFIER TYPE="PUBMED" VALUE="18790598"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904453"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barak-2014" MODIFIED="2015-03-19 16:14:59 +0000" MODIFIED_BY="[Empty name]" NAME="Barak 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-03-19 16:14:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barak Y, Magalashvili D, Dolgopiat MD, Ladkani D, Nitzani D, Mazor Z, et al</AU>
<TI>Effect of alfacalcidol on fatigue in ms patients: a randomized, double-blind study</TI>
<SO>Neurology</SO>
<YR>2014</YR>
<VL>82</VL>
<NO>10 Suppl</NO>
<PG>S23.004</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904456"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-13 15:29:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904455"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brass-2001" MODIFIED="2015-03-19 16:15:20 +0000" MODIFIED_BY="[Empty name]" NAME="Brass 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-03-19 16:15:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A, et al</AU>
<TI>Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>5</NO>
<PG>1018-28</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:28:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904458"/><IDENTIFIER MODIFIED="2014-05-16 09:28:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11325685"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breitbart-2001" MODIFIED="2009-11-30 19:27:39 +0000" MODIFIED_BY="[Empty name]" NAME="Breitbart 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-30 19:27:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J</AU>
<TI>A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2001</YR>
<VL>161</VL>
<NO>3</NO>
<PG>411-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904460"/><IDENTIFIER TYPE="PUBMED" VALUE="11176767"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904459"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-2006" MODIFIED="2015-03-19 16:15:38 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-19 16:15:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, et al</AU>
<TI>Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>13</NO>
<PG>2073-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904462"/><IDENTIFIER TYPE="PUBMED" VALUE="16648508"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904461"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-2007" MODIFIED="2015-03-19 16:15:47 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-03-19 16:15:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, El Osta B, Valero V, Driver LC, Pei BL, Shen L, et al</AU>
<TI>Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>23</NO>
<PG>3475-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904464"/><IDENTIFIER TYPE="PUBMED" VALUE="17687152"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904463"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Butler-2007" MODIFIED="2009-12-04 15:20:29 +0000" MODIFIED_BY="[Empty name]" NAME="Butler 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-12-04 15:20:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, et al</AU>
<TI>A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>5</NO>
<PG>1496-501</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904466"/><IDENTIFIER TYPE="PUBMED" VALUE="17869448"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904465"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canadian-MSRG-1987" MODIFIED="2015-03-19 16:16:26 +0000" MODIFIED_BY="[Empty name]" NAME="Canadian MSRG 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-03-19 16:16:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canadian MS Research Group</AU>
<TI>A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1987</YR>
<VL>14</VL>
<NO>3</NO>
<PG>273-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904468"/><IDENTIFIER TYPE="PUBMED" VALUE="2889518"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1989" MODIFIED="2009-11-30 19:29:35 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-11-30 19:29:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen RA, Fisher M</AU>
<TI>Amantadine treatment of fatigue associated with multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>6</NO>
<PG>676-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904470"/><IDENTIFIER TYPE="PUBMED" VALUE="2730380"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904469"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruciani-2009" MODIFIED="2009-11-30 19:29:54 +0000" MODIFIED_BY="[Empty name]" NAME="Cruciani 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-30 19:29:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J, et al</AU>
<TI>L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>4</NO>
<PG>622-31</PG>
<IDENTIFIERS MODIFIED="2009-09-29 14:28:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904472"/><IDENTIFIER TYPE="PUBMED" VALUE="18809275"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904471"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruciani-2012" MODIFIED="2015-03-19 16:17:18 +0000" MODIFIED_BY="[Empty name]" NAME="Cruciani 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-19 16:17:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruciani RA, Zhang JJ, Manola J, Cella D, Ansari B, Fisch MJ</AU>
<TI>L-carnitine supplementation for the management of fatigue in patients with cancer: an Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>31</NO>
<PG>3864-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:35:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904474"/><IDENTIFIER MODIFIED="2014-05-16 09:35:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22987089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904473"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Della-Cuna-1989" MODIFIED="2015-03-19 16:17:37 +0000" MODIFIED_BY="[Empty name]" NAME="Della Cuna 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-03-19 16:17:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Della Cuna GR, Pellegrini A, Piazzi M</AU>
<TI>Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group</TI>
<SO>European Journal of Cancer and Clinical Oncology</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>12</NO>
<PG>1817-21</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:41:28 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904476"/><IDENTIFIER MODIFIED="2014-05-16 09:41:28 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2698804"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escalante-2014" MODIFIED="2015-03-19 16:18:21 +0000" MODIFIED_BY="[Empty name]" NAME="Escalante 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-03-19 16:18:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, et al</AU>
<TI>A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients</TI>
<SO>Cancer Journal (Sudbury, Mass.)</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>1</NO>
<PG>8-14</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:45:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904478"/><IDENTIFIER MODIFIED="2014-05-16 09:45:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24445757"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisch-2003" MODIFIED="2015-03-19 16:18:47 +0000" MODIFIED_BY="[Empty name]" NAME="Fisch 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-03-19 16:18:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, et al</AU>
<TI>Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1937-43</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:49:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904480"/><IDENTIFIER MODIFIED="2014-05-16 09:49:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12743146"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jean_x002d_Pierre-2010" MODIFIED="2014-05-16 09:51:15 +0100" MODIFIED_BY="[Empty name]" NAME="Jean-Pierre 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-05-16 09:51:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, et al</AU>
<TI>A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study</TI>
<SO>Cancer</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>14</NO>
<PG>3513-20</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:51:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904482"/><IDENTIFIER MODIFIED="2014-05-16 09:51:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20564068"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904481"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerr-2012" MODIFIED="2015-03-19 16:19:10 +0000" MODIFIED_BY="[Empty name]" NAME="Kerr 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-19 16:19:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerr CW, Drake J, Milch RA, Brazeau DA, Skretny JA, Brazeau GA, et al</AU>
<TI>Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2012</YR>
<VL>43</VL>
<NO>1</NO>
<PG>68-77</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:54:16 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904484"/><IDENTIFIER MODIFIED="2014-05-16 09:54:16 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20564068"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904483"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knapp-2008" MODIFIED="2015-03-19 16:20:24 +0000" MODIFIED_BY="[Empty name]" NAME="Knapp 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-03-19 16:20:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knapp PE, Storer TW, Herbst KL, Singh AB, Dzekov C, Dzekov J, et al</AU>
<TI>Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss</TI>
<SO>American Journal of Physiology. Endocrinology and Metabolism</SO>
<YR>2008</YR>
<VL>294</VL>
<NO>6</NO>
<PG>E1135-43</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:56:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904486"/><IDENTIFIER MODIFIED="2014-05-16 09:56:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 18430965"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904485"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krupp-1995" MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]" NAME="Krupp 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB</AU>
<TI>The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>2</NO>
<PG>185-8</PG>
<IDENTIFIERS MODIFIED="2015-04-16 11:53:17 +0100" MODIFIED_BY="mochamat "><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904488"/><IDENTIFIER MODIFIED="2015-04-16 11:53:17 +0100" MODIFIED_BY="mochamat " TYPE="PUBMED" VALUE="8639070"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-17 11:49:11 +0100" MODIFIED_BY="mochamat " PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al</AU>
<TI>Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>11</NO>
<PG>1956-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904489"/><IDENTIFIER TYPE="PUBMED" VALUE="7501140"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904487"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacasse-2004" MODIFIED="2015-03-19 16:20:45 +0000" MODIFIED_BY="[Empty name]" NAME="Lacasse 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-03-19 16:20:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacasse Y, Beaudoin L, Rousseau L, Maltais F</AU>
<TI>Randomized trial of paroxetine in end-stage COPD</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>3</NO>
<PG>140-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904491"/><IDENTIFIER TYPE="PUBMED" VALUE="15679006"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904490"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange-2009" MODIFIED="2009-12-16 12:05:03 +0000" MODIFIED_BY="[Empty name]" NAME="Lange 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-12-16 12:05:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange R, Volkmer M, Heesen C, Liepert J</AU>
<TI>Modafinil effects in multiple sclerosis patients with fatigue</TI>
<SO>Journal of Neurology</SO>
<YR>2009</YR>
<VL>256</VL>
<NO>4</NO>
<PG>645-50</PG>
<IDENTIFIERS MODIFIED="2009-12-01 21:01:09 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904493"/><IDENTIFIER TYPE="PUBMED" VALUE="19367356"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904492"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lou-2009" MODIFIED="2015-03-19 16:21:00 +0000" MODIFIED_BY="[Empty name]" NAME="Lou 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-03-19 16:21:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lou JS, Dimitrova DM, Park BS, Johnson SC, Eaton R, Arnold G, et al</AU>
<TI>Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>6</NO>
<PG>305-10</PG>
<IDENTIFIERS MODIFIED="2014-05-16 09:59:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904495"/><IDENTIFIER MODIFIED="2014-05-16 09:59:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 19620846 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moraska-2010" MODIFIED="2015-03-19 16:21:21 +0000" MODIFIED_BY="[Empty name]" NAME="Moraska 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-03-19 16:21:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, et al</AU>
<TI>Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>23</NO>
<PG>3673-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:01:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904497"/><IDENTIFIER MODIFIED="2014-05-16 10:01:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20625123"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904496"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrow-2003" MODIFIED="2015-03-19 16:21:30 +0000" MODIFIED_BY="[Empty name]" NAME="Morrow 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-03-19 16:21:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PL, Flynn PJ, et al</AU>
<TI>Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>24</NO>
<PG>4635-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904499"/><IDENTIFIER TYPE="PUBMED" VALUE="14673053"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904498"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murray-1985" MODIFIED="2015-03-19 16:21:45 +0000" MODIFIED_BY="[Empty name]" NAME="Murray 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-03-19 16:21:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murray TJ</AU>
<TI>Amantadine therapy for fatigue in multiple sclerosis</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1985</YR>
<VL>12</VL>
<NO>3</NO>
<PG>251-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904501"/><IDENTIFIER TYPE="PUBMED" VALUE="3902184"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904500"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2000" MODIFIED="2009-11-30 19:31:26 +0000" MODIFIED_BY="[Empty name]" NAME="Rabkin 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-30 19:31:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, Wagner GJ, Rabkin R</AU>
<TI>A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>2</NO>
<PG>141-7; discussion 155-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904503"/><IDENTIFIER TYPE="PUBMED" VALUE="10665616"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904502"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2004" MODIFIED="2009-11-30 19:31:37 +0000" MODIFIED_BY="[Empty name]" NAME="Rabkin 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-30 19:31:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH</AU>
<TI>Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>4</NO>
<PG>379-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904505"/><IDENTIFIER TYPE="PUBMED" VALUE="15232328"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904504"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2009" MODIFIED="2015-03-19 16:22:08 +0000" MODIFIED_BY="[Empty name]" NAME="Rabkin 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-03-19 16:22:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H</AU>
<TI>Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study</TI>
<SO>Muscle and Nerve</SO>
<YR>2009</YR>
<VL>39</VL>
<NO>3</NO>
<PG>297-303</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:12:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904507"/><IDENTIFIER MODIFIED="2014-05-16 10:12:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 19208404"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904506"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2010" MODIFIED="2015-03-19 16:22:18 +0000" MODIFIED_BY="[Empty name]" NAME="Rabkin 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-03-19 16:22:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, McElhiney MC, Rabkin R, McGrath P</AU>
<TI>Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2010</YR>
<VL>71</VL>
<NO>6</NO>
<PG>707-15</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:15:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904509"/><IDENTIFIER MODIFIED="2014-05-16 10:15:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20492840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904508"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2011" MODIFIED="2015-03-19 16:22:37 +0000" MODIFIED_BY="[Empty name]" NAME="Rabkin 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-19 16:22:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, McElhiney MC, Rabkin R</AU>
<TI>Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial</TI>
<SO>Psychosomatics</SO>
<YR>2011</YR>
<VL>52</VL>
<NO>4</NO>
<PG>328-36</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:10:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904511"/><IDENTIFIER MODIFIED="2014-05-16 10:10:21 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 21777715"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904510"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenberg-1988" MODIFIED="2014-05-16 10:17:32 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenberg 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-05-16 10:17:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg GA, Appenzeller O</AU>
<TI>Amantadine, fatigue, and multiple sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>1104-6</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:17:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904513"/><IDENTIFIER MODIFIED="2014-05-16 10:17:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2972270"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904512"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roth-2010" MODIFIED="2015-03-19 16:22:55 +0000" MODIFIED_BY="[Empty name]" NAME="Roth 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-03-19 16:22:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roth AJ, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M, et al</AU>
<TI>Methylphenidate for fatigue in ambulatory men with prostate cancer</TI>
<SO>Cancer</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>21</NO>
<PG>5102-10</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:19:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904515"/><IDENTIFIER MODIFIED="2014-05-16 10:19:45 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20665492"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904514"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semiglazov-2006" MODIFIED="2015-03-19 16:23:04 +0000" MODIFIED_BY="[Empty name]" NAME="Semiglazov 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-19 16:23:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U</AU>
<TI>Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial</TI>
<SO>Anticancer research</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>2B</NO>
<PG>1519-29</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:21:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904517"/><IDENTIFIER MODIFIED="2014-05-16 10:21:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16619567"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904516"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaygannejad-2012" MODIFIED="2015-03-19 16:23:25 +0000" MODIFIED_BY="[Empty name]" NAME="Shaygannejad 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-19 16:23:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H</AU>
<TI>Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study</TI>
<SO>Neurological Research</SO>
<YR>2012</YR>
<VL>34</VL>
<NO>9</NO>
<PG>854-8</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:22:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904519"/><IDENTIFIER MODIFIED="2014-05-16 10:22:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22979982"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904518"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simons-1996" MODIFIED="2015-03-19 16:23:44 +0000" MODIFIED_BY="[Empty name]" NAME="Simons 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-03-19 16:23:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simons JP, Aaronson NK, Vansteenkiste JF, ten Velde GP, Muller MJ, Drenth BM, et al</AU>
<TI>Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>4</NO>
<PG>1077-84</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:23:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904521"/><IDENTIFIER MODIFIED="2014-05-16 10:23:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8648360"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904520"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spathis-2014" MODIFIED="2015-03-19 16:23:58 +0000" MODIFIED_BY="[Empty name]" NAME="Spathis 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-03-19 16:23:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R, et al</AU>
<TI>Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2014</YR>
<VL>32</VL>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:25:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904523"/><IDENTIFIER MODIFIED="2014-05-16 10:25:54 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24778393"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904522"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stankoff-2005" MODIFIED="2009-10-30 00:32:31 +0000" MODIFIED_BY="[Empty name]" NAME="Stankoff 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-24 20:09:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, et al</AU>
<TI>Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>7</NO>
<PG>1139-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904525"/><IDENTIFIER TYPE="PUBMED" VALUE="15824337"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904524"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1995" MODIFIED="2009-10-30 00:29:08 +0000" MODIFIED_BY="[Empty name]" NAME="Stein 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-10-29 23:07:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein DP, Dambrosia JM, Dalakas MC</AU>
<TI>A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1995</YR>
<VL>753</VL>
<PG>296-302</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904527"/><IDENTIFIER TYPE="PUBMED" VALUE="7611638"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904526"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomassini-2004" MODIFIED="2009-11-17 15:22:19 +0000" MODIFIED_BY="[Empty name]" NAME="Tomassini 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-17 15:22:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al</AU>
<TI>Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2004</YR>
<VL>218</VL>
<NO>1-2</NO>
<PG>103-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904529"/><IDENTIFIER TYPE="PUBMED" VALUE="14759641"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904528"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasconcelos-2007" MODIFIED="2015-03-20 10:08:48 +0000" MODIFIED_BY="[Empty name]" NAME="Vasconcelos 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-05-16 10:27:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vasconcelos OM, Prokhorenko OA, Salajegheh MK, Kelley KF, Livornese K, Olsen CH, et al</AU>
<TI>Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>20</NO>
<PG>1680-6</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:27:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904531"/><IDENTIFIER MODIFIED="2014-05-16 10:27:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 17502549"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904530"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-2000" MODIFIED="2015-03-19 16:24:37 +0000" MODIFIED_BY="[Empty name]" NAME="Wagner 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-03-19 16:24:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagner GJ, Rabkin R</AU>
<TI>Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>6</NO>
<PG>436-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904533"/><IDENTIFIER TYPE="PUBMED" VALUE="10901342"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904532"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinshenker-1992" MODIFIED="2009-10-30 00:33:04 +0000" MODIFIED_BY="[Empty name]" NAME="Weinshenker 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-07-24 20:10:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP</AU>
<TI>A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1468-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904535"/><IDENTIFIER TYPE="PUBMED" VALUE="1641137"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904534"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Westman-1999" MODIFIED="2015-03-19 16:24:54 +0000" MODIFIED_BY="[Empty name]" NAME="Westman 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-03-19 16:24:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Westman G, Bergman B, Albertsson M, Kadar L, Gustavsson G, Thaning L, et al</AU>
<TI>Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>4</NO>
<PG>586-95</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:29:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904537"/><IDENTIFIER MODIFIED="2014-05-16 10:29:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10492632 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904536"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wingerchuk-2005" MODIFIED="2009-07-24 21:07:26 +0100" MODIFIED_BY="[Empty name]" NAME="Wingerchuk 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-24 21:07:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, et al</AU>
<TI>A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>7</NO>
<PG>1267-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904539"/><IDENTIFIER TYPE="PUBMED" VALUE="15824361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904538"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yennurajalingam-2013" MODIFIED="2015-03-19 16:25:18 +0000" MODIFIED_BY="[Empty name]" NAME="Yennurajalingam 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-03-19 16:25:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al</AU>
<TI>Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>25</NO>
<PG>3076-82</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:31:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904541"/><IDENTIFIER MODIFIED="2014-05-16 10:31:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23897970"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904540"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-04-17 11:45:30 +0100" MODIFIED_BY="mochamat ">
<STUDY DATA_SOURCE="PUB" ID="STD-Agteresch-2000" MODIFIED="2014-05-16 10:38:01 +0100" MODIFIED_BY="[Empty name]" NAME="Agteresch 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-05-16 10:38:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH</AU>
<TI>Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>4</NO>
<PG>321-8</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:38:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904543"/><IDENTIFIER MODIFIED="2014-05-16 10:38:01 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10675381"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904542"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-1987" MODIFIED="2009-11-30 19:32:39 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-11-30 19:32:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald RN</AU>
<TI>Methylphenidate associated with narcotics for the treatment of cancer pain</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1987</YR>
<VL>71</VL>
<NO>1</NO>
<PG>67-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904545"/><IDENTIFIER TYPE="PUBMED" VALUE="3791269"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904544"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-1998" MODIFIED="2015-03-19 16:25:53 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-03-19 16:25:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J, et al</AU>
<TI>Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study</TI>
<SO>Cancer Prevention and Control</SO>
<YR>1998</YR>
<VL>2</VL>
<NO>2</NO>
<PG>74-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904547"/><IDENTIFIER TYPE="PUBMED" VALUE="9765767"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904546"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruera-2003" MODIFIED="2009-11-30 19:32:59 +0000" MODIFIED_BY="[Empty name]" NAME="Bruera 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-30 19:32:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruera E, Strasser F, Shen L, Palmer JL, Willey J, Driver LC, et al</AU>
<TI>The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>5</NO>
<PG>1049-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904549"/><IDENTIFIER TYPE="PUBMED" VALUE="14585555"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904548"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capuron-2002" MODIFIED="2015-03-19 16:26:30 +0000" MODIFIED_BY="[Empty name]" NAME="Capuron 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-03-19 16:26:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al</AU>
<TI>Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>5</NO>
<PG>643-52</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:39:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904551"/><IDENTIFIER MODIFIED="2014-05-16 10:39:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11927189"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904550"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2005" MODIFIED="2015-03-19 16:26:49 +0000" MODIFIED_BY="[Empty name]" NAME="Carter 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-03-19 16:26:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter GT, Weiss MD, Lou JS, Jensen MP, Abresch RT, Martin TK, et al</AU>
<TI>Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study</TI>
<SO>American Journal of Hospice and Palliative Care</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>1</NO>
<PG>55-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904553"/><IDENTIFIER TYPE="PUBMED" VALUE="15736608"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904552"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerchietti-2004" MODIFIED="2009-11-30 19:33:35 +0000" MODIFIED_BY="[Empty name]" NAME="Cerchietti 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-30 19:33:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, et al</AU>
<TI>Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>1</NO>
<PG>85-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904555"/><IDENTIFIER TYPE="PUBMED" VALUE="14711473"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904554"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruciani-2004" MODIFIED="2014-05-16 10:41:35 +0100" MODIFIED_BY="[Empty name]" NAME="Cruciani 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-05-16 10:41:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al</AU>
<TI>L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2004</YR>
<VL>1033</VL>
<PG>168-76</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:41:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904557"/><IDENTIFIER MODIFIED="2014-05-16 10:41:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15591014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904556"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruciani-2006" MODIFIED="2015-03-19 16:27:22 +0000" MODIFIED_BY="[Empty name]" NAME="Cruciani 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-19 16:27:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruciani RA, Dvorkin E, Homel P, Malamud S, Culliney B, Lapin J, et al</AU>
<TI>Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>6</NO>
<PG>551-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:43:08 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904559"/><IDENTIFIER MODIFIED="2014-05-16 10:43:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 17157757"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904558"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cueva-2012" MODIFIED="2015-03-19 16:27:37 +0000" MODIFIED_BY="[Empty name]" NAME="Cueva 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-19 16:27:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cueva JF, Calvo M, Anido U, León L, Gallardo E, Areses C, et al</AU>
<TI>Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study</TI>
<SO>Investigational New Drugs</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>2</NO>
<PG>688-94</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:44:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904561"/><IDENTIFIER MODIFIED="2014-05-16 10:44:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 20844926"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904560"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cullum-2004" MODIFIED="2009-11-30 19:33:54 +0000" MODIFIED_BY="[Empty name]" NAME="Cullum 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-30 19:33:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS</AU>
<TI>Bupropion sustained release treatment reduces fatigue in cancer patients</TI>
<SO>Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie</SO>
<YR>2004</YR>
<VL>49</VL>
<NO>2</NO>
<PG>139-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904563"/><IDENTIFIER TYPE="PUBMED" VALUE="15065748"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904562"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Conno-1998" MODIFIED="2015-03-19 16:28:28 +0000" MODIFIED_BY="[Empty name]" NAME="De Conno 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-03-19 16:28:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Conno F, Martini C, Zecca E, Balzarini A, Venturino P, Groff L, et al</AU>
<TI>Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial</TI>
<SO>European Journal of Cancer</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>11</NO>
<PG>1705-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:46:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904565"/><IDENTIFIER MODIFIED="2014-05-16 10:46:26 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9893656 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904564"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diel-2004" MODIFIED="2015-03-19 16:28:48 +0000" MODIFIED_BY="[Empty name]" NAME="Diel 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-03-19 16:28:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al</AU>
<TI>Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>11</NO>
<PG>1704-12</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:48:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904567"/><IDENTIFIER MODIFIED="2014-05-16 10:48:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15251160"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904566"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Downer-1993" MODIFIED="2015-03-19 16:29:00 +0000" MODIFIED_BY="[Empty name]" NAME="Downer 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-03-19 16:29:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Downer S, Joel S, Allbright A, Plant H, Stubbs L, Talbot D, et al</AU>
<TI>A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia</TI>
<SO>British Journal of Cancer</SO>
<YR>1993</YR>
<VL>67</VL>
<NO>5</NO>
<PG>1102-5</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:50:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904569"/><IDENTIFIER MODIFIED="2014-05-16 10:50:02 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 8494706"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904568"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunlop-2007" MODIFIED="2015-03-19 16:29:18 +0000" MODIFIED_BY="[Empty name]" NAME="Dunlop 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-03-19 16:29:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, et al</AU>
<TI>Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>6</NO>
<PG>614-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:52:46 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904571"/><IDENTIFIER MODIFIED="2014-05-16 10:52:46 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18004129"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904570"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gehring-2012" MODIFIED="2015-03-19 16:32:31 +0000" MODIFIED_BY="[Empty name]" NAME="Gehring 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-19 16:32:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, et al</AU>
<TI>A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor</TI>
<SO>Journal of Neuro-oncology</SO>
<YR>2012</YR>
<VL>107</VL>
<NO>1</NO>
<PG>165-74</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:53:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904573"/><IDENTIFIER MODIFIED="2014-05-16 10:53:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21964738"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904572"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graziano-2002" MODIFIED="2015-03-19 16:33:00 +0000" MODIFIED_BY="[Empty name]" NAME="Graziano 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-03-19 16:33:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, et al</AU>
<TI>Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>12</NO>
<PG>1854-7</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:54:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904575"/><IDENTIFIER MODIFIED="2014-05-16 10:54:59 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12085175"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904574"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hannestad-2011" MODIFIED="2015-03-19 16:33:19 +0000" MODIFIED_BY="[Empty name]" NAME="Hannestad 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-19 16:33:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hannestad J, Della Gioia N, Ortiz N, Pittman B, Bhagwagar Z</AU>
<TI>Citalopram reduces endotoxin-induced fatigue</TI>
<SO>Brain, Behavior, and Immunity</SO>
<YR>2011</YR>
<VL>25</VL>
<NO>2</NO>
<PG>256-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:56:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904577"/><IDENTIFIER MODIFIED="2014-05-16 10:56:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20955776"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904576"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hovey-2014" MODIFIED="2015-03-19 16:33:33 +0000" MODIFIED_BY="[Empty name]" NAME="Hovey 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-03-19 16:33:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hovey E, de Souza P, Marx G, Parente P, Rapke T, Hill A, et al</AU>
<TI>Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2014</YR>
<VL>22</VL>
<NO>5</NO>
<PG>1233-42</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:58:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904579"/><IDENTIFIER MODIFIED="2014-05-16 10:58:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24337761"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904578"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inoue-2003" MODIFIED="2015-03-19 16:33:45 +0000" MODIFIED_BY="[Empty name]" NAME="Inoue 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-03-19 16:33:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inoue A, Yamada Y, Matsumura Y, Shimada Y, Muro K, Gotoh M, et al</AU>
<TI>Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>8</NO>
<PG>528-32</PG>
<IDENTIFIERS MODIFIED="2014-05-16 10:59:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904581"/><IDENTIFIER MODIFIED="2014-05-16 10:59:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12844250"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904580"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lauretti--2013" MODIFIED="2014-05-16 11:01:59 +0100" MODIFIED_BY="[Empty name]" NAME="Lauretti  2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-16 11:01:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lauretti GR, Rizzo CC, Mattos AL, Rodrigues SW</AU>
<TI>Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone</TI>
<SO>British Journal of Cancer</SO>
<YR>2013</YR>
<VL>108</VL>
<NO>2</NO>
<PG>259-64</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:01:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904583"/><IDENTIFIER MODIFIED="2014-05-16 11:01:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23322191"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904582"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laval-2008" MODIFIED="2015-03-19 16:33:56 +0000" MODIFIED_BY="[Empty name]" NAME="Laval 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-03-19 16:33:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laval G, Paris A</AU>
<TI>Methylphenidate in palliative care in cancer patient: a double-blind randomised trial versus placebo</TI>
<TO>Methylphenidate et asthenie en soins palliatifs chez le patient cancereux: essai multicentrique randomise versus placebo en double aveugle</TO>
<SO>Bulletin du Cancer</SO>
<YR>2008</YR>
<VL>95</VL>
<NO>2</NO>
<PG>241-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904585"/><IDENTIFIER TYPE="PUBMED" VALUE="18304907"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904584"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lower-2009" MODIFIED="2015-03-19 16:34:09 +0000" MODIFIED_BY="[Empty name]" NAME="Lower 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-03-19 16:34:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, et al</AU>
<TI>Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>5</NO>
<PG>650-62</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:03:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904587"/><IDENTIFIER MODIFIED="2014-05-16 11:03:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19896571"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904586"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mar-Fan-2008" MODIFIED="2015-03-19 16:34:48 +0000" MODIFIED_BY="[Empty name]" NAME="Mar Fan 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-03-19 16:34:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, et al</AU>
<TI>A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>6</NO>
<PG>577-83</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:04:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904589"/><IDENTIFIER MODIFIED="2014-05-16 11:04:57 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17972110"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904588"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McElhiney-2010" MODIFIED="2015-03-19 16:35:23 +0000" MODIFIED_BY="[Empty name]" NAME="McElhiney 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-03-19 16:35:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McElhiney M, Rabkin J, Van Gorp W, Rabkin R</AU>
<TI>Modafinil effects on cognitive function in HIV+ patients treated for fatigue: a placebo controlled study</TI>
<SO>Journal of Clinical and Experimental Neuropsychology</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>5</NO>
<PG>474-80</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:07:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904591"/><IDENTIFIER MODIFIED="2014-05-16 11:07:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19937504"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904590"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McElhiney-2013" MODIFIED="2015-03-19 16:35:33 +0000" MODIFIED_BY="[Empty name]" NAME="McElhiney 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-03-19 16:35:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McElhiney M, Rabkin J, Van Gorp W, Rabkin R</AU>
<TI>Effect of armodafinil on cognition in patients with HIV/AIDS and fatigue</TI>
<SO>Journal of Clinical and Experimental Neuropsychology</SO>
<YR>2013</YR>
<VL>35</VL>
<NO>7</NO>
<PG>718-27</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:09:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904593"/><IDENTIFIER MODIFIED="2014-05-16 11:09:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23944194"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904592"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercadante-2001" MODIFIED="2015-03-19 16:35:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mercadante 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-03-19 16:35:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercadante S, Fulfaro F, Casuccio A</AU>
<TI>The use of corticosteroids in home palliative care</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>5</NO>
<PG>386-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:11:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904595"/><IDENTIFIER MODIFIED="2014-05-16 11:11:19 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11497394"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904594"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metz-2004" MODIFIED="2009-11-30 19:34:39 +0000" MODIFIED_BY="[Empty name]" NAME="Metz 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-30 19:34:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, et al</AU>
<TI>The effect of immunomodulatory treatment on multiple sclerosis fatigue</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>7</NO>
<PG>1045-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904597"/><IDENTIFIER TYPE="PUBMED" VALUE="15201369"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904596"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moertel-1974" MODIFIED="2014-05-16 11:12:54 +0100" MODIFIED_BY="[Empty name]" NAME="Moertel 1974" YEAR="1974">
<REFERENCE MODIFIED="2014-05-16 11:12:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG</AU>
<TI>Corticosteroid therapy of preterminal gastrointestinal cancer</TI>
<SO>Cancer</SO>
<YR>1974</YR>
<VL>33</VL>
<NO>6</NO>
<PG>1607-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:12:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904599"/><IDENTIFIER MODIFIED="2014-05-16 11:12:54 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="4135151"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904598"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohr-2003" MODIFIED="2015-03-19 16:36:15 +0000" MODIFIED_BY="[Empty name]" NAME="Mohr 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-03-19 16:36:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohr DC, Hart SL, Goldberg A</AU>
<TI>Effects of treatment for depression on fatigue in multiple sclerosis</TI>
<SO>Psychosomatic Medicine</SO>
<YR>2003</YR>
<VL>65</VL>
<NO>4</NO>
<PG>542-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904601"/><IDENTIFIER TYPE="PUBMED" VALUE="12883103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904600"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monk-2006" MODIFIED="2015-03-19 16:36:30 +0000" MODIFIED_BY="[Empty name]" NAME="Monk 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-19 16:36:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, et al</AU>
<TI>Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>12</NO>
<PG>1852-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:14:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904603"/><IDENTIFIER MODIFIED="2014-05-16 11:14:15 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16622259"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904602"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moss-2006" MODIFIED="2009-11-30 19:34:51 +0000" MODIFIED_BY="[Empty name]" NAME="Moss 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-30 19:34:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moss EL, Simpson JS, Pelletier G, Forsyth P</AU>
<TI>An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners</TI>
<SO>Psycho-Oncology</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>3</NO>
<PG>259-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904605"/><IDENTIFIER TYPE="PUBMED" VALUE="16041840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904604"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Popiela-1989" MODIFIED="2015-03-19 16:36:54 +0000" MODIFIED_BY="[Empty name]" NAME="Popiela 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-03-19 16:36:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Popiela T, Lucchi R, Giongo F</AU>
<TI>Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group</TI>
<SO>European Journal of Cancer and Clinical Oncology</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>12</NO>
<PG>1823-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:15:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904607"/><IDENTIFIER MODIFIED="2014-05-16 11:15:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2483687"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904606"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2000a" MODIFIED="2009-10-28 18:23:47 +0000" MODIFIED_BY="[Empty name]" NAME="Rabkin 2000a" YEAR="2000">
<REFERENCE MODIFIED="2009-10-28 18:23:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R</AU>
<TI>DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>1</NO>
<PG>53-68</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904609"/><IDENTIFIER TYPE="PUBMED" VALUE="10633535"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904608"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2011a" MODIFIED="2015-03-19 16:37:17 +0000" MODIFIED_BY="[Empty name]" NAME="Rabkin 2011a" YEAR="2011">
<REFERENCE MODIFIED="2015-03-19 16:37:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, McElhiney MC, Rabkin R</AU>
<TI>Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C</TI>
<SO>International Journal of STD &amp; AIDS</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>2</NO>
<PG>95-101</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:17:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904611"/><IDENTIFIER MODIFIED="2014-05-16 11:17:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21427431"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904610"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rammohan-2002" MODIFIED="2009-11-30 19:35:06 +0000" MODIFIED_BY="[Empty name]" NAME="Rammohan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-30 19:35:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN</AU>
<TI>Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2002</YR>
<VL>72</VL>
<NO>2</NO>
<PG>179-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904613"/><IDENTIFIER TYPE="PUBMED" VALUE="11796766"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904612"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romani-2004" MODIFIED="2009-11-30 19:35:18 +0000" MODIFIED_BY="[Empty name]" NAME="Romani 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-30 19:35:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romani A, Bergamaschi R, Candeloro E, Alfonsi E, Callieco R, Cosi V</AU>
<TI>Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment</TI>
<SO>Multiple Sclerosis (Houndmills, Basingstoke, England)</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>462-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904615"/><IDENTIFIER TYPE="PUBMED" VALUE="15327047"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904614"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roscoe-2005" MODIFIED="2009-11-30 19:35:32 +0000" MODIFIED_BY="[Empty name]" NAME="Roscoe 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-30 19:35:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, et al</AU>
<TI>Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>2005</YR>
<VL>89</VL>
<NO>3</NO>
<PG>243-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904617"/><IDENTIFIER TYPE="PUBMED" VALUE="15754122"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904616"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sailer-2000" MODIFIED="2009-10-30 01:15:58 +0000" MODIFIED_BY="[Empty name]" NAME="Sailer 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-10-27 19:12:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sailer M, Heinze HJ, Schoenfeld MA, Hauser U, Smid HG</AU>
<TI>Amantadine influences cognitive processing in patients with multiple sclerosis</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2000</YR>
<VL>33</VL>
<NO>1</NO>
<PG>28-37</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904619"/><IDENTIFIER TYPE="PUBMED" VALUE="10721881"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904618"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-2006" MODIFIED="2015-03-19 16:38:21 +0000" MODIFIED_BY="[Empty name]" NAME="Shaw 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-03-19 16:38:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, et al</AU>
<TI>Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>9</NO>
<PG>1415-20</PG>
<IDENTIFIERS MODIFIED="2014-05-16 11:19:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904621"/><IDENTIFIER MODIFIED="2014-05-16 11:19:31 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16549835"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904620"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-2013" MODIFIED="2015-03-19 16:38:53 +0000" MODIFIED_BY="[Empty name]" NAME="Shaw 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-03-19 16:38:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw EG, Case D, Bryant D, Grisell D, Lesser G, Monitto DC, et al</AU>
<TI>Phase II double-blind placebo-controlled study of armodafinil for brain radiation induced fatigue</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>Suppl</NO>
<PG>Abstr 9505</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904623"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904622"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spathis-2009" MODIFIED="2009-11-30 19:35:43 +0000" MODIFIED_BY="[Empty name]" NAME="Spathis 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-30 19:35:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K</AU>
<TI>Modafinil for the treatment of fatigue in lung cancer: a pilot study</TI>
<SO>Palliative Medicine</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>4</NO>
<PG>325-31</PG>
<IDENTIFIERS MODIFIED="2009-11-10 22:37:18 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904625"/><IDENTIFIER TYPE="PUBMED" VALUE="19270033"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904624"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stockler-2007" MODIFIED="2015-03-19 16:39:08 +0000" MODIFIED_BY="[Empty name]" NAME="Stockler 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-03-19 16:39:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, et al</AU>
<TI>Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial</TI>
<SO>Lancet Oncology</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>7</NO>
<PG>603-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904627"/><IDENTIFIER TYPE="PUBMED" VALUE="17548243"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-30 01:16:17 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904626"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torta-2007" MODIFIED="2015-03-19 16:39:22 +0000" MODIFIED_BY="[Empty name]" NAME="Torta 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-03-19 16:39:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torta R, Berra C, Binaschi L, Borio R</AU>
<TI>Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>5</NO>
<PG>539-46</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:13:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904629"/><IDENTIFIER MODIFIED="2014-05-16 17:13:30 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17406919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904628"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wade-2002" MODIFIED="2009-11-30 19:35:58 +0000" MODIFIED_BY="[Empty name]" NAME="Wade 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-30 19:35:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wade DT, Young CA, Chaudhuri KR, Davidson DL</AU>
<TI>A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2002</YR>
<VL>73</VL>
<NO>3</NO>
<PG>246-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904631"/><IDENTIFIER TYPE="PUBMED" VALUE="12185153"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904630"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-1997" MODIFIED="2009-11-30 19:36:10 +0000" MODIFIED_BY="[Empty name]" NAME="Wagner 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-11-30 19:36:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagner GJ, Rabkin JG, Rabkin R</AU>
<TI>Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>4</NO>
<PG>407-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904633"/><IDENTIFIER TYPE="PUBMED" VALUE="9160280"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904632"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weitzner-2002" MODIFIED="2015-03-19 16:39:46 +0000" MODIFIED_BY="[Empty name]" NAME="Weitzner 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-03-19 16:39:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weitzner MA, Moncello J, Jacobsen PB, Minton S</AU>
<TI>A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>4</NO>
<PG>337-45</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:16:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904635"/><IDENTIFIER MODIFIED="2014-05-16 17:16:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11997203"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904634"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wilwerding-1995" MODIFIED="2015-03-19 16:39:58 +0000" MODIFIED_BY="[Empty name]" NAME="Wilwerding 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-03-19 16:39:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilwerding MB, Loprinzi CL, Mailliard JA, O'Fallon JR, Miser AW, van Haelst C, et al</AU>
<TI>A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1995</YR>
<VL>3</VL>
<NO>2</NO>
<PG>135-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904637"/><IDENTIFIER TYPE="PUBMED" VALUE="7539701"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904636"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zifko-2002" MODIFIED="2015-03-19 16:40:06 +0000" MODIFIED_BY="[Empty name]" NAME="Zifko 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-03-19 16:40:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM</AU>
<TI>Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study</TI>
<SO>Journal of Neurology</SO>
<YR>2002</YR>
<VL>249</VL>
<NO>8</NO>
<PG>983-7</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:18:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2904639"/><IDENTIFIER MODIFIED="2014-05-16 17:18:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12195441"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2904638"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-05-14 09:53:22 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-03-19 17:08:11 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-03-19 17:08:11 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2014-05-16 17:40:27 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bakshi-2003" MODIFIED="2014-05-16 17:41:20 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Bakshi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bakshi R</AU>
<TI>Fatigue associated with multiple sclerosis: diagnosis, impact and management</TI>
<SO>Multiple Sclerosis</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>3</NO>
<PG>219-27</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:41:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:41:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12814166"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennet-2008" MODIFIED="2015-03-19 16:40:43 +0000" MODIFIED_BY="[Empty name]" NAME="Bennet 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al</AU>
<TI>Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>299</VL>
<NO>8</NO>
<PG>914-24</PG>
<IDENTIFIERS MODIFIED="2015-01-15 08:46:27 +0000" MODIFIED_BY="mochamat "><IDENTIFIER MODIFIED="2015-01-15 08:46:10 +0000" MODIFIED_BY="mochamat " TYPE="DOI" VALUE="10.1001/jama.299.8.914"/><IDENTIFIER MODIFIED="2015-01-15 08:46:27 +0000" MODIFIED_BY="mochamat " TYPE="PUBMED" VALUE="18314434"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bohlius-2009" MODIFIED="2015-03-19 16:41:04 +0000" MODIFIED_BY="[Empty name]" NAME="Bohlius 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al</AU>
<TI>Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>373</VL>
<NO>9674</NO>
<PG>1532-42</PG>
<IDENTIFIERS MODIFIED="2015-01-15 08:17:45 +0000" MODIFIED_BY="mochamat "><IDENTIFIER MODIFIED="2015-01-15 08:17:45 +0000" MODIFIED_BY="mochamat " TYPE="DOI" VALUE="10.1016/S0140-6736(09)60502-X"/><IDENTIFIER MODIFIED="2015-01-15 08:17:19 +0000" MODIFIED_BY="mochamat " TYPE="PUBMED" VALUE="19410717"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Breitbart-1998" MODIFIED="2014-05-16 17:46:11 +0100" MODIFIED_BY="[Empty name]" NAME="Breitbart 1998" TYPE="JOURNAL_ARTICLE">
<AU>Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S</AU>
<TI>Fatigue in ambulatory AIDS patients</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>3</NO>
<PG>159-67</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:46:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:46:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9564117"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cantarero_x002d_Villanueva-2014" MODIFIED="2015-03-19 16:41:27 +0000" MODIFIED_BY="[Empty name]" NAME="Cantarero-Villanueva 2014" TYPE="JOURNAL_ARTICLE">
<AU>Cantarero-Villanueva I, Fernández-Lao C, Díaz-Rodríguez L, Cuesta-Vargas AI, Fernández-de-las-Peñas C, Piper BF, et al</AU>
<TI>The Piper Fatigue Scale-Revised: translation and psychometric evaluation in Spanish-speaking breast cancer survivors</TI>
<SO>Quality of Life Research</SO>
<YR>2014</YR>
<VL>23</VL>
<NO>1</NO>
<PG>271-6</PG>
<IDENTIFIERS MODIFIED="2014-05-22 15:39:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-22 15:39:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23695719"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cella-1998" MODIFIED="2015-03-19 16:42:04 +0000" MODIFIED_BY="[Empty name]" NAME="Cella 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W</AU>
<TI>Progress towards guidelines for the management of fatigue</TI>
<SO>Oncology (Williston Park)</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>11A</NO>
<PG>369-77</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:47:07 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:47:07 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10028520 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cella-2001" MODIFIED="2014-05-16 17:48:03 +0100" MODIFIED_BY="[Empty name]" NAME="Cella 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cella D, Davis K, Breitbart W, Curt G</AU>
<TI>Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>14</NO>
<PG>3385-91</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:48:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:48:03 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11454886"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cella-2002" MODIFIED="2014-05-16 17:48:59 +0100" MODIFIED_BY="[Empty name]" NAME="Cella 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cella D, Eton DT, Lai J, Peterman SA, Merkel DE</AU>
<TI>Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2002</YR>
<VL>24</VL>
<PG>547-61</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:48:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:48:59 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12551804"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cramp-2012" MODIFIED="2014-06-06 12:17:50 +0100" MODIFIED_BY="[Empty name]" NAME="Cramp 2012" TYPE="COCHRANE_REVIEW">
<AU>Cramp F, Byron-Daniel J</AU>
<TI>Exercise for the management of cancer-related fatigue in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-06-06 11:58:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-06-06 11:58:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006145.pub3"/><IDENTIFIER MODIFIED="2014-05-16 17:52:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23152233"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cuhls-2014" MODIFIED="2015-03-19 16:43:39 +0000" MODIFIED_BY="[Empty name]" NAME="Cuhls 2014" TYPE="JOURNAL_ARTICLE">
<AU>Cuhls H, Mücke M, Mochamat M, Radbruch L</AU>
<TI>Underestimated symptom: frequent and burdensome than pain</TI>
<TO>Unterschätztes Symptom: Häufiger und belastender als Schmerzen</TO>
<SO>Im Focus Onkologie</SO>
<YR>2014</YR>
<VL>17</VL>
<NO>9</NO>
<PG>60-7</PG>
<IDENTIFIERS MODIFIED="2015-01-16 08:33:42 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-01-16 08:33:42 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s15015-014-0007-7"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Darko-1995" MODIFIED="2015-03-19 16:44:12 +0000" MODIFIED_BY="[Empty name]" NAME="Darko 1995" TYPE="JOURNAL_ARTICLE">
<AU>Darko DF, Mitler MM, Henriksen SJ</AU>
<TI>Lentiviral infection, immune response peptides and sleep</TI>
<SO>Advances in Neuroimmunology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>57-77</PG>
<IDENTIFIERS MODIFIED="2015-01-15 15:10:49 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-01-15 15:10:49 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7795894"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dittner-2004" MODIFIED="2014-05-16 17:53:55 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Dittner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dittner AJ, Wessely SC, Brown RG</AU>
<TI>The assessment of fatigue: a practical guide for clinicians and researchers</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2004</YR>
<VL>56</VL>
<NO>2</NO>
<PG>157-70</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:53:55 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:53:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15016573"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EAPC-2008" MODIFIED="2015-03-19 16:44:27 +0000" MODIFIED_BY="[Empty name]" NAME="EAPC 2008" TYPE="JOURNAL_ARTICLE">
<AU>Radbruch L, Strasser F, Elsner F, Gonçalves JF, Løge J, Kaasa S, et al; Research Steering Committee of the European Association for Palliative Care (EAPC)</AU>
<TI>Fatigue in palliative care patients -- an EAPC approach</TI>
<SO>Palliative Medicine</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>13-32</PG>
<IDENTIFIERS MODIFIED="2015-01-15 13:12:29 +0000" MODIFIED_BY="mochamat "><IDENTIFIER MODIFIED="2015-01-15 13:12:02 +0000" MODIFIED_BY="mochamat " TYPE="DOI" VALUE="10.1177/0269216307085183"/><IDENTIFIER MODIFIED="2015-01-15 13:12:29 +0000" MODIFIED_BY="mochamat " TYPE="PUBMED" VALUE=" 18216074"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elkington-2005" MODIFIED="2014-05-16 17:55:13 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Elkington 2005" TYPE="JOURNAL_ARTICLE">
<AU>Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P</AU>
<TI>The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life</TI>
<SO>Palliative Medicine</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>6</NO>
<PG>485-91</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:55:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:55:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16218161"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eriksen-2003" MODIFIED="2009-11-03 01:30:12 +0000" MODIFIED_BY="[Empty name]" NAME="Eriksen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Eriksen J, Jensen MK, Sjogren P, Ekholm O, Rasmussen NK</AU>
<TI>Epidemiology of chronic non-malignant pain in Denmark</TI>
<SO>Pain</SO>
<YR>2003</YR>
<VL>106</VL>
<NO>3</NO>
<PG>221-8</PG>
<IDENTIFIERS MODIFIED="2009-11-03 01:30:10 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="14659505"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Evans-2007" MODIFIED="2014-05-16 17:56:04 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Evans 2007" TYPE="JOURNAL_ARTICLE">
<AU>Evans WJ, Lambert CP</AU>
<TI>Physiological basis of fatigue</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>2007</YR>
<VL>86</VL>
<PG>S29-46</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:56:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:56:04 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17370370"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Farrar-2003" MODIFIED="2014-05-16 17:56:51 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Farrar 2003" TYPE="JOURNAL_ARTICLE">
<AU>Farrar JT, Berlin JA, Strom BL</AU>
<TI>Clinically important changes in acute pain outcome measures: a validation study</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>5</NO>
<PG>406-11</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:56:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:56:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12727037"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2005" MODIFIED="2015-03-19 16:45:17 +0000" MODIFIED_BY="[Empty name]" NAME="FDA 2005" TYPE="OTHER">
<AU>U.S. Food and Drug Administration</AU>
<TI>Information for Healthcare Professionals: Pemoline Tablets and Chewable Tablets (marketed as Cylert)</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126461.htm</SO>
<YR>2005 (accessed 3 September 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galvao-2005" MODIFIED="2014-05-16 17:57:44 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Galvao 2005" TYPE="JOURNAL_ARTICLE">
<AU>Galvao DA, Newton RU</AU>
<TI>Review of exercise intervention studies in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>4</NO>
<PG>899-909</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:57:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:57:44 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15681536"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glaspy-2009" MODIFIED="2015-01-15 08:34:56 +0000" MODIFIED_BY="mochamat " NAME="Glaspy 2009" TYPE="JOURNAL_ARTICLE">
<AU>Glaspy JA</AU>
<TI>Erythropoietin in cancer patients</TI>
<SO>Annual Review of Medicine</SO>
<YR>2009</YR>
<VL>60</VL>
<PG>181-92</PG>
<IDENTIFIERS MODIFIED="2015-01-15 08:34:56 +0000" MODIFIED_BY="mochamat "><IDENTIFIER MODIFIED="2015-01-15 08:34:30 +0000" MODIFIED_BY="mochamat " TYPE="DOI" VALUE="10.1146/annurev.med.60.050307.110718"/><IDENTIFIER MODIFIED="2015-01-15 08:34:56 +0000" MODIFIED_BY="mochamat " TYPE="PUBMED" VALUE="18980468"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glaspy-2010" MODIFIED="2015-03-19 16:45:32 +0000" MODIFIED_BY="[Empty name]" NAME="Glaspy 2010" TYPE="JOURNAL_ARTICLE">
<AU>Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al</AU>
<TI>Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes</TI>
<SO>British Journal of Cancer</SO>
<YR>2010</YR>
<VL>102</VL>
<PG>301-15</PG>
<IDENTIFIERS MODIFIED="2015-01-15 08:28:58 +0000" MODIFIED_BY="mochamat "><IDENTIFIER MODIFIED="2015-01-15 08:28:25 +0000" MODIFIED_BY="mochamat " TYPE="DOI" VALUE="10.1038/sj.bjc.6605498"/><IDENTIFIER MODIFIED="2015-01-15 08:28:58 +0000" MODIFIED_BY="mochamat " TYPE="PUBMED" VALUE="20051958"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goodlin-2005" MODIFIED="2014-05-16 17:58:25 +0100" MODIFIED_BY="[Empty name]" NAME="Goodlin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Goodlin SJ</AU>
<TI>Palliative care for end-stage heart failure</TI>
<SO>Current Heart Failure Reports</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>3</NO>
<PG>155-60</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:58:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:58:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16138952"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-03-19 16:46:13 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane&#8211;handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jhamb-2013" MODIFIED="2015-03-19 16:46:39 +0000" MODIFIED_BY="[Empty name]" NAME="Jhamb 2013" TYPE="JOURNAL_ARTICLE">
<AU>Jhamb M, Liang K, Yabes J, Steel JL, Dew MA, Shah N, et al</AU>
<TI>Prevalence and correlates of fatigue in chronic kidney disease and end-stage renal disease: are sleep disorders a key to understanding fatigue?</TI>
<SO>American Journal of Nephrology</SO>
<YR>2013</YR>
<VL>38</VL>
<NO>6</NO>
<PG>489-95</PG>
<IDENTIFIERS MODIFIED="2014-05-22 14:25:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-22 14:25:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24335380"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krupp-2003" MODIFIED="2014-05-16 17:59:00 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Krupp 2003" TYPE="JOURNAL_ARTICLE">
<AU>Krupp LB</AU>
<TI>Fatigue in multiple sclerosis: definition, pathophysiology and treatment</TI>
<SO>CNS Drugs</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>4</NO>
<PG>225-34</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:59:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:59:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12665396"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kummer-2011" MODIFIED="2015-03-19 16:46:54 +0000" MODIFIED_BY="[Empty name]" NAME="Kummer 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kummer A, Scalzo P, Cardoso F, Teixeira AL</AU>
<TI>Evaluation of fatigue in Parkinson's disease using the Brazilian version of Parkinson's Fatigue Scale</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2011</YR>
<VL>123</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS MODIFIED="2014-05-22 15:42:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-22 15:42:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1600-0404.2010.01364.x"/><IDENTIFIER MODIFIED="2014-05-22 15:42:28 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20456242"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lawrence-2004" MODIFIED="2014-05-16 17:59:51 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Lawrence 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J</AU>
<TI>Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients</TI>
<SO>Journal of the National Cancer Institute. Monographs</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>40-50</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:59:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:59:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15263040"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Minton-2009" MODIFIED="2015-03-19 16:47:14 +0000" MODIFIED_BY="[Empty name]" NAME="Minton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Minton O, Stone P</AU>
<TI>A systematic review of the scales used for the measurement of cancer-related fatigue (CRF)</TI>
<SO>Annals of Oncology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>1</NO>
<PG>17-25</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="18678767"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Minton-2010" MODIFIED="2014-05-16 18:00:52 +0100" MODIFIED_BY="[Empty name]" NAME="Minton 2010" TYPE="COCHRANE_REVIEW">
<AU>Minton O, Richardson A, Sharpe M, Hotopf M, Stone P</AU>
<TI>Drug therapy for the management of cancer-related fatigue</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>7</NO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-05-16 18:00:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-10-06 14:17:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006704.pub3"/><IDENTIFIER MODIFIED="2014-05-16 18:00:52 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="20614448 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mock-2004" MODIFIED="2014-05-16 18:01:48 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Mock 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mock V</AU>
<TI>Evidence-based treatment for cancer-related fatigue</TI>
<SO>Journal of the National Cancer Institute. Monographs</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>112-8</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:01:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:01:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15263051"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morrow-2005" MODIFIED="2014-05-16 18:02:52 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Morrow 2005" TYPE="JOURNAL_ARTICLE">
<AU>Morrow GR, Shelke AR, Roscoe JA, Hickok JT, Mustian K</AU>
<TI>Management of cancer-related fatigue</TI>
<SO>Cancer Investigations</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>3</NO>
<PG>229-39</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:02:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:02:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15945509"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NCCN-2014" MODIFIED="2015-03-19 16:48:27 +0000" MODIFIED_BY="[Empty name]" NAME="NCCN 2014" TYPE="OTHER">
<AU>National Comprehensive Cancer Network</AU>
<TI>Cancer related fatigue</TI>
<SO>www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf</SO>
<YR>(accessed 30 October 2014)</YR>
<IDENTIFIERS MODIFIED="2010-10-06 13:26:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-NMSS-2002" MODIFIED="2015-03-19 16:48:38 +0000" MODIFIED_BY="[Empty name]" NAME="NMSS 2002" TYPE="OTHER">
<AU>National Multiple Sclerosis Society</AU>
<TI>Management of MS-related fatigue</TI>
<SO>www.nationalmssociety.org/PRC.asp</SO>
<YR>2002 (accessed 17 November 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norval-2004" MODIFIED="2014-05-16 18:03:57 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Norval 2004" TYPE="JOURNAL_ARTICLE">
<AU>Norval DA</AU>
<TI>Symptoms and sites of pain experienced by AIDS patients</TI>
<SO>South African Medical Journal</SO>
<YR>2004</YR>
<VL>94</VL>
<NO>6</NO>
<PG>450-4</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:03:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:03:57 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15250459"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patrick-2004" MODIFIED="2014-05-16 18:05:02 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Patrick 2004" TYPE="JOURNAL_ARTICLE">
<AU>Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, et al</AU>
<TI>National Institutes of Health state-of-the-science conference statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002</TI>
<SO>Journal of the National Cancer Institute. Monographs</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>9-16</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:05:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:05:02 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15263035"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pucci-2007" MODIFIED="2014-06-06 12:39:54 +0100" MODIFIED_BY="[Empty name]" NAME="Pucci 2007" TYPE="COCHRANE_REVIEW">
<AU>Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C, et al</AU>
<TI>Amantadine for fatigue in multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-06-06 12:39:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-06-06 12:39:30 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002818.pub2"/><IDENTIFIER MODIFIED="2014-06-06 12:39:54 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17253480"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Radbruch-2008" MODIFIED="2010-10-06 13:28:50 +0100" MODIFIED_BY="[Empty name]" NAME="Radbruch 2008" TYPE="JOURNAL_ARTICLE">
<AU>Radbruch L, Strasser F, Elsner F, Goncalves JF, Loge J, Kaasa S, et al</AU>
<TI>Fatigue in palliative care patients -- an EAPC approach</TI>
<SO>Palliative Medicine</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>1</NO>
<PG>13-32</PG>
<IDENTIFIERS MODIFIED="2009-11-02 15:50:02 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="18216074"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rao-2004" MODIFIED="2014-05-16 18:06:50 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Rao 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rao A, Cohen HJ</AU>
<TI>Symptom management in the elderly cancer patient: fatigue, pain, and depression</TI>
<SO>Journal of the National Cancer Institute. Monographs</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>150-7</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:06:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:06:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15263059"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-01-23 12:52:12 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richardson-1997" MODIFIED="2014-05-16 18:07:36 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Richardson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Richardson A, Ream EK</AU>
<TI>Self-care behaviours initiated by chemotherapy patients in response to fatigue</TI>
<SO>International Journal of Nursing Studies</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>1</NO>
<PG>35-43</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:07:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:07:36 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9055119"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rosenberg-2005" MODIFIED="2014-05-16 18:08:21 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Rosenberg 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg JH, Shafor R</AU>
<TI>Fatigue in multiple sclerosis: a rational approach to evaluation and treatment</TI>
<SO>Current Neurology and Neuroscience Reports</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>2</NO>
<PG>140-6</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:08:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:08:21 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15743552"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schmitz-2005" MODIFIED="2014-05-16 18:09:13 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Schmitz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz KH, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R</AU>
<TI>Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis</TI>
<SO>Cancer Epidemiology, Biomarkers and Prevention</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>7</NO>
<PG>1588-95</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:09:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:09:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16030088"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sood-2006" MODIFIED="2014-05-16 18:09:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sood 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sood A, Barton DL, Loprinzi CL</AU>
<TI>Use of methylphenidate in patients with cancer</TI>
<SO>American Journal of Hospice and Palliative Medicine</SO>
<YR>2006</YR>
<VL>23</VL>
<PG>35-40</PG>
<IDENTIFIERS MODIFIED="2014-05-16 18:09:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 18:09:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16450661"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stone-2002" MODIFIED="2015-03-19 16:49:44 +0000" MODIFIED_BY="[Empty name]" NAME="Stone 2002" TYPE="JOURNAL_ARTICLE">
<AU>Stone P</AU>
<TI>The measurement, causes and effective management of cancer-related fatigue</TI>
<SO>International Journal of Palliative Nursing</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>120-8</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:32:16 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:32:16 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11923740"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stridsman-2014" MODIFIED="2015-03-19 16:50:01 +0000" MODIFIED_BY="[Empty name]" NAME="Stridsman 2014" TYPE="JOURNAL_ARTICLE">
<AU>Stridsman C, Lindberg A, Skär L</AU>
<TI>Fatigue in chronic obstructive pulmonary disease: a qualitative study of people's experiences</TI>
<SO>Scandinavian Journal of Caring Sciences</SO>
<YR>2014</YR>
<VL>28</VL>
<NO>1</NO>
<PG>130-8</PG>
<IDENTIFIERS MODIFIED="2014-05-22 14:32:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-22 14:31:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/scs.12033"/><IDENTIFIER MODIFIED="2014-05-22 14:32:09 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23517049"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tang-2010" MODIFIED="2014-05-22 14:29:32 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2010" TYPE="JOURNAL_ARTICLE">
<AU>Tang WR, Yu CY, Yeh SJ</AU>
<TI>Fatigue and its related factors in patients with chronic heart failure</TI>
<SO>Journal of Clinical Nursing</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>1-2</NO>
<PG>69-78</PG>
<IDENTIFIERS MODIFIED="2014-05-22 14:29:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-22 14:29:32 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20500245"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tejani-2012" MODIFIED="2015-03-19 17:08:11 +0000" MODIFIED_BY="[Empty name]" NAME="Tejani 2012" TYPE="COCHRANE_REVIEW">
<AU>Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S</AU>
<TI>Carnitine for fatigue in multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2015-03-19 17:08:11 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-03-19 17:08:11 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007280.pub3"/><IDENTIFIER MODIFIED="2014-05-16 17:34:46 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22592719"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tonelli-2009" MODIFIED="2015-03-19 16:51:12 +0000" MODIFIED_BY="[Empty name]" NAME="Tonelli 2009" TYPE="JOURNAL_ARTICLE">
<AU>Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al</AU>
<TI>Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2009</YR>
<VL>180</VL>
<NO>11</NO>
<PG>62-71</PG>
<IDENTIFIERS MODIFIED="2015-01-15 08:40:15 +0000" MODIFIED_BY="mochamat "><IDENTIFIER MODIFIED="2015-01-15 08:39:56 +0000" MODIFIED_BY="mochamat " TYPE="DOI" VALUE="10.1503/cmaj.090470"/><IDENTIFIER MODIFIED="2015-01-15 08:40:15 +0000" MODIFIED_BY="mochamat " TYPE="PUBMED" VALUE="19407261"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Trendall-2001" MODIFIED="2015-03-19 16:51:26 +0000" MODIFIED_BY="[Empty name]" NAME="Trendall 2001" TYPE="JOURNAL_ARTICLE">
<AU>Trendall J</AU>
<TI>Assessing fatigue in patients with COPD</TI>
<SO>Professional Nurse</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>7</NO>
<PG>1217-20</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:35:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:35:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12026780"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wagner-2004" MODIFIED="2014-05-16 17:37:25 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Wagner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wagner LI, Cella D</AU>
<TI>Fatigue and cancer: causes, prevalence and treatment approaches</TI>
<SO>British Journal of Cancer</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>5</NO>
<PG>822-8</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:37:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:37:25 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15238987"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walsh-2000" MODIFIED="2014-05-16 17:38:38 +0100" MODIFIED_BY="[Empty name]" NAME="Walsh 2000" TYPE="JOURNAL_ARTICLE">
<AU>Walsh D, Donnelly S, Rybicki L</AU>
<TI>The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>3</NO>
<PG>175-9</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:38:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:38:38 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10789956"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zifko-2004" MODIFIED="2014-05-16 17:39:59 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Zifko 2004" TYPE="JOURNAL_ARTICLE">
<AU>Zifko UA</AU>
<TI>Management of fatigue in patients with multiple sclerosis</TI>
<SO>Drugs</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1295-304</PG>
<IDENTIFIERS MODIFIED="2014-05-16 17:39:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-05-16 17:39:59 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15200345"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-03-19 09:15:27 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Peuckmann_x002d_Post-2011" MODIFIED="2015-03-19 09:15:27 +0000" MODIFIED_BY="[Empty name]" NAME="Peuckmann-Post 2011" TYPE="COCHRANE_REVIEW">
<AU>Peuckmann-Post V, Elsner F, Krumm N, Trottenberg P, Radbruch L</AU>
<TI>Pharmacological treatments for fatigue associated with palliative care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2015-03-19 09:15:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-03-19 09:15:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006788.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-12-01 15:01:20 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-04-20 15:22:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ashtari-2009">
<CHAR_METHODS MODIFIED="2015-04-20 15:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:28:34 +0000" MODIFIED_BY="[Empty name]">
<P>N = 42 patients with multiple sclerosis who were divided randomly into 2 groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:28:34 +0000" MODIFIED_BY="[Empty name]">
<P>Amantadine 200 mg/day</P>
<P>Duration: 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:22:26 +0100" MODIFIED_BY="[Empty name]">
<P>FSS scores at baseline and 2 months later were compared in the 2 groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:28:34 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-21 13:41:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Auret-2009">
<CHAR_METHODS MODIFIED="2015-04-20 15:22:34 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:28:40 +0000" MODIFIED_BY="[Empty name]">
<P>N = 70 pts with advanced cancer and cancer considered, 50 included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:28:40 +0000" MODIFIED_BY="[Empty name]">
<P>Dexamphetamine 10 mg/twice a day or placebo</P>
<P>Duration: 8 days</P>
<P>ITT basis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-21 13:41:41 +0100" MODIFIED_BY="[Empty name]">
<P>BFI, McGill Quality of Life Questionnaire, ECOG; side effects monitored. Pts were included if they reported fatigue as at least 4 of 10 on a 0 to 10 NRS. Reduction by 2 points on a 10-point scale (BFI) was considered a minimum important clinical difference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:28:40 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:22:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barak-2014">
<CHAR_METHODS MODIFIED="2015-04-20 15:22:39 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:28:50 +0000" MODIFIED_BY="[Empty name]">
<P>N = 158 pts with multiple sclerosis</P>
<P>(mean age 41.1 + 9.2 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:28:50 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to receive alfacalcidol (1 µg) or placebo once daily for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:22:38 +0100" MODIFIED_BY="[Empty name]">
<P>FIS and QOL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:28:50 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:22:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brass-2001">
<CHAR_METHODS MODIFIED="2015-04-20 15:22:42 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-13 16:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>N = 60 pts with end-stage renal disease (ESRD)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:28:57 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised and divided into 2 groups 1:1; placebo and treatment</P>
<P>Study A: treatment with L-carnitine 20 mg/kg IV for 24 weeks</P>
<P>Study B: treatment with L-carnitine dose-ranging 10 to 20 to 40 mg/kg for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>KDQ</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:28:58 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:22:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breitbart-2001">
<CHAR_METHODS MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:29:06 +0000" MODIFIED_BY="[Empty name]">
<P>HIV pts with fatigue receiving ambulatory care</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:29:06 +0000" MODIFIED_BY="[Empty name]">
<P>Titration up to max. 60 mg methylphenidate or 150 mg pemoline, or 8 capsules placebo daily</P>
<P>Duration 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:22:47 +0100" MODIFIED_BY="[Empty name]">
<P>PFS, VAS-F; side effects monitored</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:29:06 +0000" MODIFIED_BY="[Empty name]">
<P>The authors concluded that pts responded favourably to both treatments. However, while the PFS total score showed a significant difference, the VAS total fatigue scale (in which the energy score was significant only) did not. Therefore, the authors' conclusion seems to be too positive</P>
<P>A confounding factor may have been improvement in fatigue due to an antidepressant effect, according to the authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:22:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-2006">
<CHAR_METHODS MODIFIED="2015-04-20 15:22:50 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, patient-controlled, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>N = 112 cancer pts with a fatigue score of at least 4 on a scale of 0 to 10 were included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>Pts were randomised to methylphenidate 5 mg PO or placebo every 2 hours prn (max 4 times/day) for 1 week, followed by a 4-week open-label trial of methylphenidate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:22:51 +0100" MODIFIED_BY="[Empty name]">
<P>FACIT-F, ESAS, daily diary. The authors proposed to detect a decrease in fatigue in the methylphenidate group over and above the placebo group, of half the SD, or a score of approximately 7 on the FACIT-F scale. They therefore adjusted the sample size to declare this difference statistically significant, assuming a one-sided significance level of 0.05 and 80% power</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>The authors stated that a longer study duration of more than 1 week was justified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:22:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-2007">
<CHAR_METHODS MODIFIED="2015-04-20 15:22:56 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:29:47 +0000" MODIFIED_BY="[Empty name]">
<P>Pts with fatigue score of at least 4 on a scale of 0 to 10 were included; 112 of 142 pts with cancer fatigue were assigned to treatment (71 each)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:30:02 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to donepezil 5 mg PO or placebo every morning for 1 week. Second week: open-label</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:22:55 +0100" MODIFIED_BY="[Empty name]">
<P>FACIT-F, ESAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:30:20 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-21 13:43:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Butler-2007">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT, phase III trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>N = 68 pts with primary or metastatic brain tumour scheduled to receive radiotherapy; 34 pts included in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>D-threo-methylphenidate HCl 5 mg/twice a day, titrated to max. 15 mg/twice a day, duration 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-21 13:43:45 +0100" MODIFIED_BY="[Empty name]">
<P>Cognitive function, FACIT-F, Center for Epidemiologic Studies scale, MMSE, KPS</P>
<P>Assessed at baseline, end of RT and 4, 8 and 12 weeks after brain RT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>This study examines prophylactic treatment (before and after RT). The population was quite heterogenous, since approximately half of the pts had metastatic disease and 75% received radiotherapy without chemotherapy. The age range was 28 to 83 years (median 52 for verum and 60 years for placebo group)</P>
<P>There was a 71% drop-out from baseline (n = 33 methylphenidate group, n = 29 placebo group) until weeks 5 to 12 (n = 9 each group). Further, the post-treatment effect of radiotherapy during a 12-week course may vary concerning fatigue and pain, for example, which in part may be caused or relieved by the treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-21 13:44:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canadian-MSRG-1987">
<CHAR_METHODS MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT, cross-over; multicentre trial (11 MS centres)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-21 13:44:23 +0100" MODIFIED_BY="[Empty name]">
<P>N = 115 of 159 were randomised to treatment</P>
<P>Eligible participants had at least a 6-month history of "definite multiple sclerosis" and a 3-month history of chronic, persistent, moderate to severe daily fatigue</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-21 13:44:30 +0100" MODIFIED_BY="[Empty name]">
<P>Amantadine 100 mg/twice a day or placebo</P>
<P>10 weeks duration</P>
<P>2 x 3-week treatment periods</P>
<P>Each treatment period was preceded by a single-blind, 2-week placebo period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:05 +0100" MODIFIED_BY="[Empty name]">
<P>KEDSS; BDI; VAS-F</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:31:32 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-1989">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>DB, RCT, cross-over, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:32:54 +0000" MODIFIED_BY="[Empty name]">
<P>N = 29 eligible participants had "satisfied criteria for a definite/probable diagnosis of multiple sclerosis" at least 6 months before diagnosed; all had daily symptomatic fatigue for at least 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 16:58:55 +0000" MODIFIED_BY="[Empty name]">
<P>Random assignment to 100 mg amantadine Hcl twice a day or placebo for 4 weeks, followed by a 2-week wash-out, then cross-over to an alternate treatment (verum/placebo) for another 4-week-period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:09 +0100" MODIFIED_BY="[Empty name]">
<P>Kurtzke rating; mBDI, "Stroop Interference Test" (attentional measure of freedom from distracting information). "Overall fatigue" was averaged across mean diary ratings for 7 indices of fatigue on a 5-point scare; 1 = poor; 5 = excellent)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:33:43 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruciani-2009">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:34:03 +0000" MODIFIED_BY="[Empty name]">
<P>N = 149 eligible pts with carnitine deficiency, cancer and fatigue (n = 27 were excluded due to screen failure)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:34:16 +0000" MODIFIED_BY="[Empty name]">
<P>L-carnitine (initial dose 0.5 g/day for 2 days, followed by 1 g/day for 2 days, then 2 g/day for 10 days or placebo), followed by an open-label phase, during which all pts received L-carnitine for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>FACT-An, LASA, MMSE, KPS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:34:42 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruciani-2012">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:14 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT phase III trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-13 16:25:18 +0100" MODIFIED_BY="[Empty name]">
<P>376 pts with cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:35:19 +0000" MODIFIED_BY="[Empty name]">
<P>Pts were randomly assigned to either 2 g/day of L-carnitine oral supplementation or matching placebo for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:16 +0100" MODIFIED_BY="[Empty name]">
<P>BFI, FACIT-F</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Della-Cuna-1989">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:20 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:36:34 +0000" MODIFIED_BY="[Empty name]">
<P>403 pts with cancer</P>
<P>Average age 62.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:36:39 +0000" MODIFIED_BY="[Empty name]">
<P>Methylprednisolone 125 mg/day IV 8 weeks</P>
<P>Matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:19 +0100" MODIFIED_BY="[Empty name]">
<P>NOSIE, LASA, the Physicians' Global</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:36:53 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Escalante-2014">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:23 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, DB, RCT - cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:37:21 +0000" MODIFIED_BY="[Empty name]">
<P>N = 42 pts were enrolled and were diagnosed with lymphoma, myeloma or breast, gastrointestinal or lung cancers, and either undergoing chemotherapy or hormonal treatment or completed treatment in the previous 12 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:37:37 +0000" MODIFIED_BY="[Empty name]">
<P>The study duration was 4 weeks. Patients were randomised into 1 of 2 arms:</P>
<P>Methylphenidate (18 mg/day) for 2 weeks followed by placebo for 2 weeks (arm A) or placebo for 2 weeks followed by methylphenidate (18 mg/day) for 2 weeks (arm B)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:24 +0100" MODIFIED_BY="[Empty name]">
<P>BFI at the end of each 2-week period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:37:51 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-21 13:45:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fisch-2003">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 10:17:44 +0100" MODIFIED_BY="[Empty name]">
<P>163 pts with cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-20 10:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluoxetine 20 mg/day 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-21 13:45:51 +0100" MODIFIED_BY="[Empty name]">
<P>FACT-G, BZSDS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:38:16 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jean_x002d_Pierre-2010">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, DB, RCT, phase III</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:39:10 +0000" MODIFIED_BY="[Empty name]">
<P>877 cancer patients enrolled in the study</P>
<P>N = 431 (modafinil) and n = 436 (placebo)</P>
<P>Majority of sample were Caucasian and reported diverse marital status and educational level. 67% of the participants were females at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:39:28 +0000" MODIFIED_BY="[Empty name]">
<P>100 mg of modafinil or placebo on day 10 of the chemotherapy cycle, then increase to the full dose of 200 mg of modafinil or placebo after 3 days and continue on this regimen until day 7 of study cycle 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:28 +0100" MODIFIED_BY="[Empty name]">
<P>BFI, ESS, POMS-DD</P>
<P>Fatigue and depression were assessed during cycles 2 to 4 using psychometrically valid measures</P>
<P>Group differences (treatment versus control) in the worst level of fatigue during the previous week at cycle 4 were examined using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (cycle 2)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:40:06 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kerr-2012">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:34 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 12:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>N = 30 pts with advanced disease in hospice hospital</P>
<P>2 weeks duration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:40:37 +0000" MODIFIED_BY="[Empty name]">
<P>Pts were randomly assigned to receive either 5 mg of methylphenidate or placebo at 8 am and 1 pm. Doses of methylphenidate were titrated every 3 days according to response and adverse effects. Home care patients were monitored daily by telephone and visited by a research nurse on study days 0 (baseline), 3, 7 and 14</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>PFS, VAS-F, ESAS, BDI-II, ESAS depression score, CESD</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:41:13 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knapp-2008">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:36 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-14 11:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>61 patients with HIV</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:41:48 +0000" MODIFIED_BY="[Empty name]">
<P>300 mg IM of testosterone enanthate or placebo for 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:37 +0100" MODIFIED_BY="[Empty name]">
<P>Body composition, muscle strength, physical function and MOS-30</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:42:15 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krupp-1995">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:40 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:42:55 +0000" MODIFIED_BY="[Empty name]">
<P>N = 119 pts with multiple sclerosis and severe fatigue were eligible (FSS score at least 4 of 7; 9 items, each with potential score of 1 to 7; scoring is done by calculating the average response)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:43:06 +0000" MODIFIED_BY="[Empty name]">
<P>Pts were randomised to treatment with pemoline (18.75 mg/day for 1 week, 37.5 mg/day for week 2, and 56.25 mg weeks 3 to 6) or placebo or amantadine (amantadine 100 mg twice a day) for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:39 +0100" MODIFIED_BY="[Empty name]">
<P>FSS, MS SFS, subjective response (verbal rating)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:44:38 +0000" MODIFIED_BY="[Empty name]">
<P>Authors conclude that "amantadine was significantly better than placebo in treating fatigue in MS patients", however, this applies only to ratings on the MS Specific Fatigue Scale, not on the FSS. Interestingly, the authors chose a FSS cut-off score as an inclusion criterion, which highlights this scale as a key instrument. Thus, a clear effect of amantadine on fatigue seems questionable</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lacasse-2004">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:44:56 +0000" MODIFIED_BY="[Empty name]">
<P>N = 23 of 342 pts with end-stage COPD were found eligible (n = 82 refusals)</P>
<P>12-week duration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:45:02 +0000" MODIFIED_BY="[Empty name]">
<P>Paroxetine was started at a dose of 5 mg/day, with weekly 5 mg increments up to a maximum of 20 mg/day "or the highest dose not associated with any side effect"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:43 +0100" MODIFIED_BY="[Empty name]">
<P>SF-36, "chronic respiratory questionnaire (CRQ)": 1 of 4 domains was fatigue (each domain includes 4 to 7 items and each item is scored on a 7-point-scale.); geriatric depression scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 17:15:08 +0000" MODIFIED_BY="[Empty name]">
<P>342 pts were assessed for eligibility; 319 pts were excluded to ineligibility (237 pts) and refusal (82 pts)</P>
<P>Primary outcome was quality of life</P>
<P>Very low number of participants. Power analysis was conducted: 80% was reached at sample size of 9 to detect large treatment effects (type I error 0.05). This number has not been reached</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lange-2009">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:47 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:47:19 +0000" MODIFIED_BY="[Empty name]">
<P>N = 21 pts with multiple sclerosis and fatigue</P>
<P>8-week duration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:47:34 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo or modafinil was started at a dose of 100 mg/day for the first week and 200 mg/day for the subsequent 7 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>FSS, FSS sum score was used (potential scores 4 to63), alertness test, NHPT, TMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:47:53 +0000" MODIFIED_BY="[Empty name]">
<P>The authors state that "the TMS subgroup consisted of 21 consecutive multiple sclerosis pts from a larger, randomised, double-blind trial"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lou-2009">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:51 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT pilot study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 13:48:18 +0000" MODIFIED_BY="[Empty name]">
<P>19 pts with Parkinson's disease</P>
<P>Duration 8 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 13:48:42 +0000" MODIFIED_BY="[Empty name]">
<P>Participants took their regular medications and were randomly assigned to the treatment group (9 participants, modafinil 100 mg capsule twice a day PO) or placebo group (10 participants) twice a day for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:50 +0100" MODIFIED_BY="[Empty name]">
<P>MFI, ESS, CESD</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 13:49:26 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moraska-2010">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:52 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT phase III study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:23:39 +0000" MODIFIED_BY="[Empty name]">
<P>148 pts with cancer were enrolled for this study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:23:57 +0000" MODIFIED_BY="[Empty name]">
<P>Pts were randomly assigned to receive 1 tablet of methylphenidate or placebo on days 1 through 7, 2 tablets on days 8 through 14, and 3 tablets on days 15 through 28. Each methylphenidate tablet was 18 mg, resulting in the goal dose of 54 mg/day for the final 2 weeks of the study. Tablets were to be taken in the morning</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>BFI, SED, SF-36 Vitality Subscale, LASA, PSQI, SGIC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:24:32 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:23:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morrow-2003">
<CHAR_METHODS MODIFIED="2015-04-20 15:23:55 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:25:23 +0000" MODIFIED_BY="[Empty name]">
<P>N = 549 of 704 cancer patients with fatigue (recruited on days 1 to 3 undergoing chemotherapy)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-04-13 13:27:08 +0100" MODIFIED_BY="mochamat ">
<P>Paroxetine 20 mg/day oral or placebo for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>FSC, MAF (total score was substituted by score of question no. 1; potential score 1 to 10), MPMM, CESD. Assessments were performed at cycles 3 and 4 of chemotherapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:25:43 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murray-1985">
<CHAR_METHODS MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, CT, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:26:12 +0000" MODIFIED_BY="[Empty name]">
<P>N = 40 pts with multiple sclerosis and persistent fatigue of at least 3 months' duration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:26:14 +0000" MODIFIED_BY="[Empty name]">
<P>Amantadine 100 mg or placebo twice a day</P>
<P>6 weeks "with one week wash-out period between active drug and placebo"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>KDSS; improvement of fatigue measured by percentage of participants who felt improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:26:41 +0000" MODIFIED_BY="[Empty name]">
<P>The authors reported that "In only a few instances the same patients were used in more than one study". Date of study investigation was 1985 and methods may have been different</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabkin-2000">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:27:17 +0000" MODIFIED_BY="[Empty name]">
<P>N = 74 HIV-positive men with hypogonadal symptoms (diminished libido, depressed mood, low energy, depleted muscle mass) and symptomatic HIV illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:27:30 +0000" MODIFIED_BY="[Empty name]">
<P>Testosterone cypionate IM injections (initial dose 200 mg, increased to 400 mg) bi-weekly for 6 weeks, followed by 12-week open-label maintenance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:03 +0100" MODIFIED_BY="[Empty name]">
<P>CGI scale ratings for libido, mood, energy and erectile function; CFS (7-item scale measured by response options from 1 = never to 5 = always)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:28:11 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabkin-2004">
<CHAR_METHODS MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:28:54 +0000" MODIFIED_BY="[Empty name]">
<P>HIV-positive men</P>
<P>N = 123 men were found eligible</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:29:16 +0000" MODIFIED_BY="[Empty name]">
<P>Testosterone cypionate IM injections (initial dose 200 mg, increased to 400 mg bi-weekly, or fluoxetine up to 60 mg/day (starting dose not mentioned; final mean dose 34 mg, range 20 mg to 40 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>CGI scale rating "was expanded to include ratings of energy, as well as mood and a global rating (CGI), significant improvement was defined as score of 1 or 2 on CGI"; HDRS; CFS scores (7-item scale measured by response options from 1 = never to 5 = always)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:29:43 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, the authors did not recommend testosterone as first-line treatment for depressive disorders in HIV-positive men, but suggested further investigation in pts experiencing fatigue as well as depression</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabkin-2009">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:07 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 13:05:10 +0100" MODIFIED_BY="[Empty name]">
<P>32 patients with amyotrophic lateral sclerosis (ALS)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-09 11:28:43 +0100" MODIFIED_BY="mochamat ">
<P>Modafinil 300 mg/day</P>
<P>Duration 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:08 +0100" MODIFIED_BY="[Empty name]">
<P>CGI improvement scale, FSS, ESS, BDI, RFS and VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:32:17 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-21 13:49:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabkin-2010">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 14:02:00 +0100" MODIFIED_BY="[Empty name]">
<P>115 pts with HIV/AIDS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-13 16:58:01 +0100" MODIFIED_BY="[Empty name]">
<P>Modafinil with maximum dose 200 mg/day for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-21 13:49:35 +0100" MODIFIED_BY="[Empty name]">
<P>CGI improvement, FSS, HDRS, BDI. Safety assessment used assays of CD4 cell count and HIV RNA viral load</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:33:09 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabkin-2011">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:13 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 14:02:06 +0100" MODIFIED_BY="[Empty name]">
<P>70 pts with HIV</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:34:01 +0000" MODIFIED_BY="[Empty name]">
<P>Maximum trial dose of armodafinil was 250 mg/day for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>CGI, FSS, HDRS and BDI. Safety was assessed with assays of CD4 cell count and HIV RNA viral load and the SAFTEE side effects rating scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:34:59 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenberg-1988">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:16 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-04 16:09:26 +0000" MODIFIED_BY="[Empty name]">
<P>N = 10 pts with multiple sclerosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 16:58:58 +0000" MODIFIED_BY="[Empty name]">
<P>Amantadine 200 mg/day or placebo for 1 week, followed by a 1-week wash-out, followed by a cross-over to another drug for 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>KEDSS (potential range 0 to 10; 0 = normal neurological examination, 10 = death), patient preference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:35:50 +0000" MODIFIED_BY="[Empty name]">
<P>Baseline values of KEDSS were not provided; very small participant number. No information concerning a power analysis given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roth-2010">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:18 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:35:59 +0000" MODIFIED_BY="[Empty name]">
<P>N = 32 pts ambulatory with prostate cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 17:00:01 +0000" MODIFIED_BY="[Empty name]">
<P>The patients were randomly allocated to receive either methylphenidate or placebo for a period of 6 weeks. Methylphenidate was administered in capsules containing 5 mg each, with a starting dose of 1 capsule in the morning</P>
<P>The dose was increased by 1 capsule (5 mg) on day 3, added as a midday dose, if fatigue was not substantially reduced, there was no toxicity from the study treatment and if the patient was willing to increase the dose. Dosage was titrated upwards (or down) every 2 to 3 days to a maximum of 6 capsules daily, divided into morning and midday doses (equivalent to a total maximum daily dose of 30 mg of methylphenidate)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>BFI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:37:25 +0000" MODIFIED_BY="[Empty name]">
<P>The authors suggest the need to monitor pulse and blood pressure during the treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Semiglazov-2006">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 14:20:13 +0100" MODIFIED_BY="[Empty name]">
<P>Pts with breast cancer N = 352</P>
<P>Average age 46.2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>Standardised mistletoe (PS76A) extract for 6 cycles of chemotherapy; matched placebo up to 18 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:24 +0100" MODIFIED_BY="[Empty name]">
<P>FACT-G</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:38:09 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaygannejad-2012">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:38:48 +0000" MODIFIED_BY="[Empty name]">
<P>N = 52 pts with multiple sclerosis</P>
<P>Age range 21 to 53 years old</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 16:59:01 +0000" MODIFIED_BY="[Empty name]">
<P>The first group received amantadine (100 mg twice a day) for a total of 4 weeks. The second group received 500 mg/day acetylsalicylic acid (ASA) for 4 weeks. After a 2-week wash-out period, they crossed over to the alternative treatment for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>FSS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:39:24 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simons-1996">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:39:55 +0000" MODIFIED_BY="[Empty name]">
<P>N = 206</P>
<P>Male 153, female 53</P>
<P>Average age 64</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-23 13:55:55 +0100" MODIFIED_BY="[Empty name]">
<P>Medroxyprogesterone acetate (MPA) 500 mg twice a day for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:30 +0100" MODIFIED_BY="[Empty name]">
<P>EORTC-QLQ-C30 fatigue subscale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:40:12 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spathis-2014">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:31 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 14:55:58 +0100" MODIFIED_BY="[Empty name]">
<P>N = 208 pts with non-small cell lung cancer (NSCLC) </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:40:40 +0000" MODIFIED_BY="[Empty name]">
<P>Modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>FACIT-F, ESS, HADS, QOL-LAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:41:13 +0000" MODIFIED_BY="[Empty name]">
<P>Future trials need to have sufficient power to evaluate the effect in those patients with severe fatigue and could incorporate a placebo wash-in period to minimise the influence of the placebo effect</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stankoff-2005">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:35 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>N = 115 pts with multiple sclerosis and "stable disability", minimal baseline score on MFIS of 45</P>
<P>N = 56 modafinil, N = 59 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-23 14:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>Modafinil initial dose 200 mg for 1 week, increased by 100 mg weekly up to 400 mg/day max., then continued for 2 weeks or placebo</P>
<P>5-week duration</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>MFIS; score range 0 to 84; lower score indicating less fatigue, VAS-F, ESS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:42:50 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1995">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:39 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:43:14 +0000" MODIFIED_BY="[Empty name]">
<P>N = 25 pts with post-polio syndrome and fatigue were eligible</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:43:18 +0000" MODIFIED_BY="[Empty name]">
<P>Amantadine 100 mg twice a day or placebo for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:39 +0100" MODIFIED_BY="[Empty name]">
<P>FSS; improvement of fatigue as noted by participants given in percentage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:43:36 +0000" MODIFIED_BY="[Empty name]">
<P>Very small participant numbers. Power analysis was calculated to detect 50% reduction in fatigue with 80% power and probability of type I error 0.05</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomassini-2004">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:45 +0100" MODIFIED_BY="[Empty name]">
<P>DB, RCT, cross-over pilot trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:43:53 +0000" MODIFIED_BY="[Empty name]">
<P>N = 36 pts with multiple sclerosis and fatigue</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 17:15:34 +0000" MODIFIED_BY="[Empty name]">
<P>Amantadine 100 mg twice a day or acetyl-L-carnitine (ALCAR) 1 g twice a day for 3 months, followed by a 3-month wash-out period, then followed by a cross-over to alternative treatment for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:44 +0100" MODIFIED_BY="[Empty name]">
<P>FSS, FIS, BDI, SEC; reduction of FSS scores observed in participants given in percentage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:45:21 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion of relapsing-remitting and secondary progressive multiple sclerosis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vasconcelos-2007">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:47 +0100" MODIFIED_BY="[Empty name]">
<P>DB, RCT, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:45:45 +0000" MODIFIED_BY="[Empty name]">
<P>N = 36 pts with post-polio syndrome</P>
<P>N = 18 (modafinil) and n = 18 (placebo)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:46:16 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment with modafinil or equivalent placebo lasted for 6-week periods, being separated by a 14-day wash-out interval. First 3 weeks of treatment, patients received half of the targeted dose (i.e. 200 mg/day supplied as 2 x 100 mg capsules, 1 at breakfast and lunch). At the end of the 3rd week patients doubled their intake (i.e. 400 mg/day, 200 mg at breakfast and lunch)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:48 +0100" MODIFIED_BY="[Empty name]">
<P>FSS, VAS-F, FIS, SF-36 QOL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:46:32 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wagner-2000">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-20 15:32:43 +0100" MODIFIED_BY="[Empty name]">
<P>N = 23 pts with HIV, depression and debilitating fatigue</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:47:17 +0000" MODIFIED_BY="[Empty name]">
<P>Dextroamphetamine initial dose 2.5 mg twice a day, titrated up to maximum of 40 mg/day. Mean dose was 26 +/- 12 mg daily, range 10 to 40 mg/day or placebo for 2 weeks, followed by 24 weeks of open-label trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:51 +0100" MODIFIED_BY="[Empty name]">
<P>SCID; HDRS, BFI, BHS, VAS for mood, CFS (possible range 0 to 28), VAS for energy level</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:47:36 +0000" MODIFIED_BY="[Empty name]">
<P>Groups were heterogenous concerning major depression, which was diagnosed in 12 of the 23 participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinshenker-1992">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:53 +0100" MODIFIED_BY="[Empty name]">
<P>DB, RCT, cross-over; 2-centre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:48:04 +0000" MODIFIED_BY="[Empty name]">
<P>N = 46 pts with multiple sclerosis and fatigue (patients with multiple sclerosis exacerbation during study period were excluded)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:48:19 +0000" MODIFIED_BY="[Empty name]">
<P>Pemoline titration in 1 week (18.75 mg to 75 mg/day), continued for 3 weeks or placebo, followed by a cross-over to the other treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>VAS-F, KEDSS, mBDI; tolerance of adverse effects and checklist to identify their nature</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>Interestingly, the authors noted increasing benefit from pemoline over the 2-week study period and supposed that there may have been a larger treatment effect if the study period was longer. Of 13 patients who chose to continue taking the drug, 7 were still taking it after 1 year and reported benefit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:24:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Westman-1999">
<CHAR_METHODS MODIFIED="2015-04-20 15:24:56 +0100" MODIFIED_BY="[Empty name]">
<P>DB, RCT, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:49:13 +0000" MODIFIED_BY="[Empty name]">
<P>N = 255 pts with cancer</P>
<P>Male 134, female 121</P>
<P>Average age 70 (not on treatment)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-23 14:02:54 +0100" MODIFIED_BY="[Empty name]">
<P>Megestrol acetate (MA) 320 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>EORTC-QLQ-C30</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:49:30 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:25:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wingerchuk-2005">
<CHAR_METHODS MODIFIED="2015-04-20 15:25:00 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT, cross-over</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-19 15:50:49 +0000" MODIFIED_BY="[Empty name]">
<P>N = 30 pts with multiple sclerosis and fatigue</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-19 15:51:00 +0000" MODIFIED_BY="[Empty name]">
<P>Acetylsalicylic acid (ASA) 1300 mg/day or placebo for 6 weeks, followed by 2-week wash-out period, followed by cross-over to alternative treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:24:59 +0100" MODIFIED_BY="[Empty name]">
<P>MFIS (possible score 0 to 84), KEDSS, CESD, Global Fatigue Change self assessment, VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:51:33 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-04-20 15:25:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yennurajalingam-2013">
<CHAR_METHODS MODIFIED="2015-04-20 15:25:02 +0100" MODIFIED_BY="[Empty name]">
<P>PC, DB, RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-23 14:03:56 +0100" MODIFIED_BY="[Empty name]">
<P>N = 84 pts with advanced cancer (dexamethasone = 43, placebo = 41)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-14 08:00:21 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to either dexamethasone 4 mg or placebo orally twice per day for 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-20 15:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>ESAS, FACIT-F, HADS, FAACT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-19 15:52:48 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BDI = Beck Depression Inventory; BFI = Brief Fatigue Inventory; BHS = Beck Hopelessness Scale; BZSDS = Brief Zung Self-Rating Depression Scale; CESD = Center for Epidemiologic Studies Depression; CFS = Chalder Fatigue Scale; CRQ = Chronic Respiratory Questionnaire; DB = double-blind; ECOG = performance status according to the Eastern Cooperative Oncology Group Scale; EORTC-QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; ESAS = Edmonton Symptom Assessment System; ESS = Epworth Sleepiness Scale; FAACT = Functional Assessment of Cancer Therapy&#8211;Anorexia-Cachexia; FACIT-F = Functional Assessment for Chronic Illness Therapy - Fatigue; FACT-An = Functional Assessment of Cancer Therapy - Anaemia; FIS = Fatigue Impact Scale; FSC = Fatigue Symptom Checklist; FSS = Fatigue Severity Scale; HADS = Hospital Anxiety and Depression Scale; HDRS = Hamilton Depression Rating Scale; IM = intramuscular; ITT = intention-to-treat; IV = intravenous; KDQ = Kidney Disease Questionnaire; KEDSS = Kurtzke Expanded Disability Status Scale; KPS = Karnofsky Performance Status; LASA = Linear Analogue Scale Assessments; MAF = Multidimensional Assessment of Fatigue; mBDI = Modified Beck Depression Inventory; MFI = Multidimensional Fatigue Inventory; MMSE = Mini Mental State Examination; MOS-30 = Medical Outcomes Study-Short Form 30; MPMM = Monopolar Profile of Mood States; MS = multiple sclerosis; MS SFS = Multiple Sclerosis Specific Fatigue Scale; NHPT = Nine Hole Peg Test; NOSIE = Nurses' Observational Scale for Inpatient Evaluation; NRS = numeric rating scale; PC = placebo-controlled; PFS = Piper Fatigue Scale; PO = per oral; POMS-DD = Depression-Dejection subscale of the Profile of Mood States; prn = as needed; PSQI = Pittsburgh Sleep Quality Index; pts = participants; QOL = RAYS quality of life; QOL-LAS = quality of life linear analogue scale; RCT = randomised controlled trial; RFS = Role Function Scale; RT = radiation therapy; SAFTEE = Systematic Assessment for Treatment Emergent Events; sc = subcutaneous; SCID = depression according to Structured Clinical Interview for DSM-IV; SD = standard deviation; SE = standard error; SEC = Social Experience Checklist; SED = Symptom Experience Diary; SF-36 = Short Form-36; SGIC = Subject Global Impression of Change; TMS = transcranial magnetic Social Experience Checklist; VAS = visual analogue scale; VAS-F = visual analogue scale - fatigue</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;AH: see note in Geisler 1996&lt;/p&gt;&lt;p&gt;Author: We have moved it into second reference under &lt;a link_type=&quot;STUDY&quot; href=&quot;Krupp 1995&quot; protected=&quot;true&quot;&gt;Krupp 1995&lt;/a&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-04-20 15:21:15 +0100" NOTES_MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-03-19 15:56:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agteresch-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 15:56:21 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:08 +0000" MODIFIED_BY="[Empty name]">
<P>Focus of this study was sedation related to narcotics, not fatigue</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:09 +0000" MODIFIED_BY="[Empty name]">
<P>Focus of study was cancer cachexia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bruera-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:10 +0000" MODIFIED_BY="[Empty name]">
<P>Focus of this study was sedation related to narcotics, not fatigue</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capuron-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:10 +0000" MODIFIED_BY="[Empty name]">
<P>Main focus of this study was not fatigue</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 09:45:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 09:45:20 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label study, case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 15:56:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cerchietti-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 15:56:51 +0000" MODIFIED_BY="[Empty name]">
<P>Not blinded, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 09:45:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruciani-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 09:45:16 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 09:46:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruciani-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 09:46:01 +0100" MODIFIED_BY="[Empty name]">
<P>Phase I/II study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 09:46:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cueva-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 09:46:42 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 01:28:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cullum-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 01:28:26 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label study, case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Conno-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:23 +0000" MODIFIED_BY="[Empty name]">
<P>Main focus of this study was depression and appetite</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 15:57:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diel-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 15:57:35 +0000" MODIFIED_BY="[Empty name]">
<P>Part of the study was open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 09:51:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Downer-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 09:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>Main focus of this study was cachexia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunlop-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:28 +0000" MODIFIED_BY="[Empty name]">
<P>Focus of this study was depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 09:53:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gehring-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 09:53:54 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 15:58:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graziano-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 15:58:02 +0000" MODIFIED_BY="[Empty name]">
<P>The drug was intended to treat fatigue, which was induced by a treatment not a disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 15:59:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hannestad-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 15:59:34 +0000" MODIFIED_BY="[Empty name]">
<P>The participants were not at an advanced stage of illness or in a palliative situation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 15:59:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hovey-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 15:59:40 +0000" MODIFIED_BY="[Empty name]">
<P>The drug was intended to treat fatigue, which was induced by a treatment not a disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 15:59:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inoue-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 15:59:43 +0000" MODIFIED_BY="[Empty name]">
<P>The drug was intended to treat fatigue, which was induced by a treatment not a disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lauretti--2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:37 +0000" MODIFIED_BY="[Empty name]">
<P>Focus of this study was pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:00:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laval-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:00:06 +0000" MODIFIED_BY="[Empty name]">
<P>This article was published only as a protocol; no original results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:00:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lower-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:00:13 +0000" MODIFIED_BY="[Empty name]">
<P>The drug was intended to treat fatigue, which was induced by a treatment not a disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:00:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mar-Fan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:00:14 +0000" MODIFIED_BY="[Empty name]">
<P>The drug was intended to treat fatigue, which was induced by a treatment not a disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:00:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McElhiney-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:00:31 +0000" MODIFIED_BY="[Empty name]">
<P>Primary focus of this study was not fatigue</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:08:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McElhiney-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:08:12 +0100" MODIFIED_BY="[Empty name]">
<P>Main focus of this study was cognitive function</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:10:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercadante-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:10:16 +0100" MODIFIED_BY="[Empty name]">
<P>Consecutive study, not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-23 14:05:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Metz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-23 14:05:00 +0100" MODIFIED_BY="[Empty name]">
<P>No randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:00:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moertel-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:00:39 +0000" MODIFIED_BY="[Empty name]">
<P>Single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-30 01:22:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohr-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-30 01:22:28 +0000" MODIFIED_BY="[Empty name]">
<P>Fatigue was not the primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:14:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monk-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:14:42 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:14:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moss-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:14:54 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label study, case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:00:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Popiela-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:00:46 +0000" MODIFIED_BY="[Empty name]">
<P>Single-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:02:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabkin-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:02:48 +0000" MODIFIED_BY="[Empty name]">
<P>Investigators used pre-selection ("mood responders were maintained" after an open-label trial)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:00:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabkin-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:00:59 +0000" MODIFIED_BY="[Empty name]">
<P>This study was a subset of another study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 01:28:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rammohan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 01:28:48 +0000" MODIFIED_BY="[Empty name]">
<P>Phase II study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-30 01:30:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Romani-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-30 01:30:28 +0000" MODIFIED_BY="[Empty name]">
<P>Authors state that "Due to the design of the study, [the similarly decreased fatigue scores in both groups] cannot be disjoined from a placebo effect."</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-11 01:28:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roscoe-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-11 01:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>Patients cannot be considered to be in a palliative care situation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-30 01:37:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sailer-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-30 01:37:44 +0000" MODIFIED_BY="[Empty name]">
<P>24 patients were assigned to 4 groups and patients were very heterogenous concerning disease duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:20:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaw-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:21:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaw-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:21:22 +0100" MODIFIED_BY="[Empty name]">
<P>Phase II study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-06 15:34:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spathis-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-06 15:34:09 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label trial; aim of study was to determine feasibility of conducting a RCT for fatigue in lung cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-30 01:38:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stockler-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-30 01:38:14 +0000" MODIFIED_BY="[Empty name]">
<P>Fatigue was studied as secondary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:23:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Torta-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:23:29 +0100" MODIFIED_BY="[Empty name]">
<P>Main focus was depression. Fatigue was secondary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-30 01:38:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wade-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-30 01:38:37 +0000" MODIFIED_BY="[Empty name]">
<P>Investigators focus on disability, not fatigue</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-19 16:01:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wagner-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-19 16:01:36 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label study, case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:24:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weitzner-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>Fatigue was not the primary outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:25:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilwerding-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:25:14 +0100" MODIFIED_BY="[Empty name]">
<P>Focus was not fatigue, but narcotic-induced sedation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-14 10:25:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zifko-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-14 10:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>Open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-05-14 09:53:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-05-21 13:46:47 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Ashtari-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Auret-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Barak-2014">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Brass-2001">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:52 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Breitbart-2001">
<DESCRIPTION>
<P>Used block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:29:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2006">
<DESCRIPTION>
<P>Restricted random assignment with random balance points from 1 to 5 blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:30:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2007">
<DESCRIPTION>
<P>Restricted random assignment with random balance points from 1 to 5 blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:52 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Butler-2007">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Canadian-MSRG-1987">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1989">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:56 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Cruciani-2009">
<DESCRIPTION>
<P>Computer program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:56 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Cruciani-2012">
<DESCRIPTION>
<P>Computerised randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:58 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Della-Cuna-1989">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Escalante-2014">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Fisch-2003">
<DESCRIPTION>
<P>Preprinted randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:01 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Jean_x002d_Pierre-2010">
<DESCRIPTION>
<P>Random number generator program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Kerr-2012">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Knapp-2008">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Krupp-1995">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Lacasse-2004">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Lange-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Lou-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:06 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Moraska-2010">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:25:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morrow-2003">
<DESCRIPTION>
<P>Computer-generated random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Murray-1985">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2000">
<DESCRIPTION>
<P>Computer-generated list of numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2004">
<DESCRIPTION>
<P>Computer-generated list of numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:11 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2009">
<DESCRIPTION>
<P>Block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2010">
<DESCRIPTION>
<P>Computer-generated list of numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2011">
<DESCRIPTION>
<P>Computer-generated list of numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Rosenberg-1988">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Roth-2010">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Semiglazov-2006">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:16 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Shaygannejad-2012">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:40:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simons-1996">
<DESCRIPTION>
<P>Block randomisation in permutation blocks of 4</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:41:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spathis-2014">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:42:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stankoff-2005">
<DESCRIPTION>
<P>Blocks of 4 randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Stein-1995">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Tomassini-2004">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:46:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vasconcelos-2007">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:22 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2000">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:24 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Weinshenker-1992">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Westman-1999">
<DESCRIPTION>
<P>Block randomisation in permutation<BR/>blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:51:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wingerchuk-2005">
<DESCRIPTION>
<P>Generated random number list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:27 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Yennurajalingam-2013">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-05-21 13:46:47 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Ashtari-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Auret-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Barak-2014">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:49 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Brass-2001">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:52 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Breitbart-2001">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:29:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2006">
<DESCRIPTION>
<P>A list of random assignments was prepared and the next eligible patient was entered on the next available assignment line</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:30:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2007">
<DESCRIPTION>
<P>A list of random assignments was prepared and the next eligible patient was entered on the next available assignment line</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-09 11:29:31 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Butler-2007">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Canadian-MSRG-1987">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1989">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:56 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Cruciani-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:56 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Cruciani-2012">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Della-Cuna-1989">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Escalante-2014">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Fisch-2003">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:01 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Jean_x002d_Pierre-2010">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Kerr-2012">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-21 13:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Knapp-2008">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Krupp-1995">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Lacasse-2004">
<DESCRIPTION>
<P>Random numbers table was used to allocate participants to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Lange-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Lou-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:24:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moraska-2010">
<DESCRIPTION>
<P>Centrally allocated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:08 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Morrow-2003">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Murray-1985">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Rabkin-2000">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Rabkin-2004">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:32:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rabkin-2009">
<DESCRIPTION>
<P>Centrally allocated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Rabkin-2010">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Rabkin-2011">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Rosenberg-1988">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Roth-2010">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:38:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Semiglazov-2006">
<DESCRIPTION>
<P>Centrally allocated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:39:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaygannejad-2012">
<DESCRIPTION>
<P>Group assignments were concealed in an opaque, sealed envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:18 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Simons-1996">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:18 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Spathis-2014">
<DESCRIPTION>
<P>Central telephone system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:19 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Stankoff-2005">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Stein-1995">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Tomassini-2004">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:46:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vasconcelos-2007">
<DESCRIPTION>
<P>Concealed allocations from investigators by securing treatment codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:22 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2000">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:24 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Weinshenker-1992">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:25 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Westman-1999">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:51:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wingerchuk-2005">
<DESCRIPTION>
<P>Allocation concealment from investigators by securing the results in the pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:27 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Yennurajalingam-2013">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-10-09 11:35:35 +0100" MODIFIED_BY="mochamat " NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-03-19 16:58:19 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:14:32 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Ashtari-2009">
<DESCRIPTION>
<P>Identical preprinted medication code labels</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-19 13:28:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Auret-2009">
<DESCRIPTION>
<P>The active drug and the placebo were pre-packed in identical generic capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:15:15 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Barak-2014">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:15:25 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Brass-2001">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:15:38 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Breitbart-2001">
<DESCRIPTION>
<P>All medications were prepared in identical capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:15:50 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Bruera-2006">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:16:03 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Bruera-2007">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-19 13:30:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Butler-2007">
<DESCRIPTION>
<P>Participants received a bottle of pills containing either the study drug or a matched placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:16:56 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Canadian-MSRG-1987">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:29:52 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1989">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:17:26 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Cruciani-2009">
<DESCRIPTION>
<P>The liquid carnitine and placebo were prepared by a research pharmacist and were identical in appearance and taste</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:17:45 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Cruciani-2012">
<DESCRIPTION>
<P>Drug and placebo matched in appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:18:11 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Della-Cuna-1989">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:18:21 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Escalante-2014">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:18:31 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Fisch-2003">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:18:41 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Jean_x002d_Pierre-2010">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:18:50 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Kerr-2012">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:18:59 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Knapp-2008">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:19:40 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Krupp-1995">
<DESCRIPTION>
<P>Drugs including the matching placebo were delivered by the pharmaceutical industry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:20:26 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Lacasse-2004">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:20:37 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Lange-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-19 16:58:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lou-2009">
<DESCRIPTION>
<P>Placebo group and treatment had the same appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:21:03 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Moraska-2010">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:21:17 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Morrow-2003">
<DESCRIPTION>
<P>Medication and placebo were identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:21:38 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Murray-1985">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:21:49 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Rabkin-2000">
<DESCRIPTION>
<P>Matching coded vials containing medication or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:25:20 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Rabkin-2004">
<DESCRIPTION>
<P>Matching coded vials containing medication or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:25:35 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Rabkin-2009">
<DESCRIPTION>
<P>Medication and placebo were identical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:25:48 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Rabkin-2010">
<DESCRIPTION>
<P>Medication and placebo were identical in appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:25:58 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Rabkin-2011">
<DESCRIPTION>
<P>Medication and placebo were identical in appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:26:07 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Rosenberg-1988">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:26:18 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Roth-2010">
<DESCRIPTION>
<P>Medication and placebo were identically appearing capsules</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-18 15:02:12 +0000" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Semiglazov-2006">
<DESCRIPTION>
<P>Medication and placebo were identical in terms of appearance, colour and packaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:26:44 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Shaygannejad-2012">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:26:54 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Simons-1996">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-19 15:41:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spathis-2014">
<DESCRIPTION>
<P>The over-encapsulated active drugs and placebo capsules were matched</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:27:17 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Stankoff-2005">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:27:26 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Stein-1995">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:27:35 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Tomassini-2004">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-19 16:58:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vasconcelos-2007">
<DESCRIPTION>
<P>Active drug and placebo had the same appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:27:56 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2000">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:28:04 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Weinshenker-1992">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-19 15:50:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Westman-1999">
<DESCRIPTION>
<P>Active drugs and placebo had the same shape, size, appearance, colour and taste</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-19 15:52:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wingerchuk-2005">
<DESCRIPTION>
<P>Active drug and placebo had the same appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-09 11:28:43 +0100" MODIFIED_BY="mochamat " RESULT="UNKNOWN" STUDY_ID="STD-Yennurajalingam-2013">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-03-19 15:47:40 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Ashtari-2009">
<DESCRIPTION>
<P>Withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Auret-2009">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Barak-2014">
<DESCRIPTION>
<P>Baseline observation carried forward</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-24 12:05:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brass-2001">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:52 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Breitbart-2001">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-19 13:17:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruera-2006">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:52 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Bruera-2007">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Butler-2007">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Canadian-MSRG-1987">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Cohen-1989">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:56 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Cruciani-2009">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:58 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Cruciani-2012">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Della-Cuna-1989">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Escalante-2014">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Fisch-2003">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Jean_x002d_Pierre-2010">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Kerr-2012">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Knapp-2008">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Krupp-1995">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Lacasse-2004">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Lange-2009">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-09 06:50:10 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Lou-2009">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:06 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Moraska-2010">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:08 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Morrow-2003">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Murray-1985">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-09 06:51:16 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2000">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-09 06:51:30 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2004">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2009">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2010">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-09 06:52:01 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rabkin-2011">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Rosenberg-1988">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Roth-2010">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Semiglazov-2006">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:45:42 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Shaygannejad-2012">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:18 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Simons-1996">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:18 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Spathis-2014">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:19 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Stankoff-2005">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Stein-1995">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Tomassini-2004">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Vasconcelos-2007">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-19 15:47:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2000">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:25 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Weinshenker-1992">
<DESCRIPTION>
<P>Used 'last observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-09 12:00:43 +0100" MODIFIED_BY="mochamat " RESULT="YES" STUDY_ID="STD-Westman-1999">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis; withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:27 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Wingerchuk-2005">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-08 13:33:27 +0100" MODIFIED_BY="Martin Mücke" RESULT="UNKNOWN" STUDY_ID="STD-Yennurajalingam-2013">
<DESCRIPTION>
<P>Used 'baseline observation carried forward' analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-10-27 15:24:22 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-10-27 15:24:22 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-03-19 15:50:26 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Size of study</NAME>
<DESCRIPTION>
<P>checking for possible biases confounded by small size</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Ashtari-2009">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:48 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Auret-2009">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:28:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barak-2014">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:51 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Brass-2001">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:52 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Breitbart-2001">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:29:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bruera-2006">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:30:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bruera-2007">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Butler-2007">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:32:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canadian-MSRG-1987">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:55 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Cohen-1989">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:56 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Cruciani-2009">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:36:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cruciani-2012">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:36:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Della-Cuna-1989">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:32:59 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Escalante-2014">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 13:38:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fisch-2003">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Jean_x002d_Pierre-2010">
<DESCRIPTION>
<P>&gt; 200 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Kerr-2012">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Knapp-2008">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:02 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Krupp-1995">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Lacasse-2004">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:05 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Lange-2009">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:06 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Lou-2009">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:24:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moraska-2010">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="YES" STUDY_ID="STD-Morrow-2003">
<DESCRIPTION>
<P>&gt; 200 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Murray-1985">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:09 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Rabkin-2000">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:11 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Rabkin-2004">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Rabkin-2009">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:33:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rabkin-2010">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:12 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Rabkin-2011">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Rosenberg-1988">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:15 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Roth-2010">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:38:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Semiglazov-2006">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:18 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Shaygannejad-2012">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:40:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simons-1996">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:41:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spathis-2014">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:43:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stankoff-2005">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Stein-1995">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:21 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Tomassini-2004">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:22 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Vasconcelos-2007">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:24 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Wagner-2000">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:25 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Weinshenker-1992">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-19 15:50:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Westman-1999">
<DESCRIPTION>
<P>Participants 50 to 199 per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:27 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Wingerchuk-2005">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 13:33:27 +0100" MODIFIED_BY="Martin Mücke" RESULT="NO" STUDY_ID="STD-Yennurajalingam-2013">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-11-01 09:51:47 +0000" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2015-03-20 10:08:48 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-03-20 10:08:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-10-06 15:35:04 +0100" MODIFIED_BY="[Empty name]">Drug treatment of fatigue: Populations, substances and outcome measures</TITLE>
<TABLE COLS="4" ROWS="51">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Patient population</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Substance</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Outcome measures</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fatigue in advanced cancer</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amphetamine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BFI, McGill Quality of Life Questionnaire, ECOG</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Auret-2009" TYPE="STUDY">Auret 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-carnitine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACT-An, LASA, MMSE, KPS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Cruciani-2009" TYPE="STUDY">Cruciani 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-carnitine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BFI, FACIT-F, depression and pain instrument</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Cruciani-2012" TYPE="STUDY">Cruciani 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Paroxetine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSC, MFI, Monopolar Profile of Mood States</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACIT-F, ESAS, daily diary</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bruera-2006" TYPE="STUDY">Bruera 2006</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cognitive function, FACIT-F, CESD, MMSE, KPS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Butler-2007" TYPE="STUDY">Butler 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BFI, SED, SF-36 vitality subscale, LASA, PSQI, SGIC</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Moraska-2010" TYPE="STUDY">Moraska 2010</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BFI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Roth-2010" TYPE="STUDY">Roth 2010</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BFI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Escalante-2014" TYPE="STUDY">Escalante 2014</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Donepezil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACIT-F, ESAS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bruera-2007" TYPE="STUDY">Bruera 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylprednisolone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NOSIE, LASA, Physician's Global</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Della-Cuna-1989" TYPE="STUDY">Della Cuna 1989</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BFI, ESS, POMS-DD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Jean_x002d_Pierre-2010" TYPE="STUDY">Jean-Pierre 2010</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACIT, ESS, HADS, QOL-LAS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluoxetine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACT-G</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Fisch-2003" TYPE="STUDY">Fisch 2003</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Standardised Mistletoe extract</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACT-G</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Semiglazov-2006" TYPE="STUDY">Semiglazov 2006</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Medroxyprogesterone acetate (MPA)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FACT-G</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Simons-1996" TYPE="STUDY">Simons 1996</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Megestrol acetate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EORTC-QLQ-C30 instrument</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Westman-1999" TYPE="STUDY">Westman 1999</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fatigue in amyotrophic lateral sclerosis (ALS)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGI-E, FSS, ESS, BDI, RFS, VAS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2009" TYPE="STUDY">Rabkin 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fatigue in HIV/AIDS</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pemoline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Armodafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGI-I, FSS, HDRS, BDI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2011" TYPE="STUDY">Rabkin 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGI-I, FSS, HDRS, BDI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amphetamine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SCID; HDRS, BFI, BHS, VAS for mood, CFS, VAS for energy level</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Testosterone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGIS "was expanded to include ratings of energy, as well as mood and a global rating. Significant improvement was defined as score of 1 or 2 on CGIS"; HDRS, CFS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Testosterone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGIS ratings for libido, mood, energy and erectile function; CFS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2000" TYPE="STUDY">Rabkin 2000</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Testosterone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Body composition, muscle strength and physical function, MOS-30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Knapp-2008" TYPE="STUDY">Knapp 2008</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluoxetine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Body composition, muscle strength and physical function, MOS-30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fatigue in multiple sclerosis</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pemoline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>VAS-F, KEDSS, mBDI; tolerance of adverse effects and checklist to identify their nature</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Weinshenker-1992" TYPE="STUDY">Weinshenker 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pemoline</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS, MS Specific Fatigue Scale, subjective response (verbal rating)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-carnitine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS, Fatigue Impact Scale, Beck Depression Inventory, Social Experience Checklist</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS, Fatigue Impact Scale, Beck Depression Inventory, Social Experience Checklist</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>KEDSS; mBDI, "Stroop Interference Test" (attentional measure of freedom from distracting information)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>KEDSS; mBDI, "Stroop Interference Test" (attentional measure of freedom from distracting information)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>KEDSS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Murray-1985" TYPE="STUDY">Murray 1985</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>KEDSS, patient preference</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rosenberg-1988" TYPE="STUDY">Rosenberg 1988</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>KEDSS; BDI; VAS-F</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Canadian-MSRG-1987" TYPE="STUDY">Canadian MSRG 1987</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ashtari-2009" TYPE="STUDY">Ashtari 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acetylsalicylic acid</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MFIS, KEDSS, CESD, SGIC, FSS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wingerchuk-2005" TYPE="STUDY">Wingerchuk 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acetylsalicylic acid</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS, alertness test, NHPT, TMS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lange-2009" TYPE="STUDY">Lange 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MFIS, VAS-F, ESS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Stankoff-2005" TYPE="STUDY">Stankoff 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS, VAS-F, FIS, SF-36 QOL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Vasconcelos-2007" TYPE="STUDY">Vasconcelos 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dexamethasone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FIS, QOL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Alfacalcidol (Vit. D)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FIS, QOL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Barak-2014" TYPE="STUDY">Barak 2014</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>End-stage renal</B>
</P>
<P>
<B>disease (ESRD)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-carnitine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>KDQ</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Brass-2001" TYPE="STUDY">Brass 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Parkinson's disease</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MFI, ESS, CESD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lou-2009" TYPE="STUDY">Lou 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Multi-type advanced</B>
</P>
<P>
<B>disease (hospice</B>
</P>
<P>
<B>patients)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFS, VAS-F, ESAS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kerr-2012" TYPE="STUDY">Kerr 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>End-stage COPD</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Paroxetine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SF-36, chronic respiratory questionnaire: 1 of 4 domains was fatigue, geriatric depression scale</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lacasse-2004" TYPE="STUDY">Lacasse 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Postpolio syndrome</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>FSS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Stein-1995" TYPE="STUDY">Stein 1995</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BDI = Beck Depression Inventory; BFI = Brief Fatigue Inventory; BHS = Beck Hopelessness Scale; CESD = Center for Epidemiologic Studies Depression; CFS = Chalder Fatigue Scale; DB = double-blind; ECOG = performance status according to the Eastern Cooperative Oncology Group Scale; EORTC-QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; ESAS = Edmonton Symptom Assessment System; ESS = Epworth Sleepiness Scale; FACIT-F = Functional Assessment for Chronic Illness Therapy - Fatigue; FACT-An = Functional Assessment of Cancer Therapy - Anaemia; FIS = Fatigue Impact Scale; FSC = Fatigue Symptom Checklist; FSS = Fatigue Severity Scale; HADS = Hospital Anxiety and Depression Scale; HDRS = Hamilton Depression Rating Scale; IM = intramuscular; ITT = intention-to-treat; IV = intravenous; KDQ = Kidney Disease Questionnaire; KEDSS = Kurtzke Expanded Disability Status Scale; KPS = Karnofsky Performance Status; LASA = Linear Analogue Scale Assessments; MAF = Multidimensional Assessment of Fatigue; mBDI = Modified Beck Depression Inventory; MFI = Multidimensional Fatigue Inventory; MMSE = Mini Mental State Examination; MOS-30 = Medical Outcomes Study-Short Form 30; MPMM = Monopolar Profile of Mood States; MS = multiple sclerosis; MS SFS = Multiple Sclerosis Specific Fatigue Scale; NHPT = Nine Hole Peg Test; NOSIE = Nurses' Observational Scale for Inpatient Evaluation; NRS = numeric rating scale; PC = placebo-controlled; PFS = Piper Fatigue Scale; PO = per oral; POMS-DD = Depression-Dejection subscale of the Profile of Mood States; prn = as needed; PSQI = Pittsburgh Sleep Quality Index; pts = participants; QOL = RAYS quality of life; QOL-LAS = quality of life linear analogue scale; RCT = randomised controlled trial; RFS = Role Function Scale; RT = radiation therapy; sc = subcutaneous; SCID = depression according to Structured Clinical Interview for DSM-IV; SD = standard deviation; SE = standard error; SEC = Social Experience Checklist; SED = Symptom Experience Diary; SF-36 = Short Form-36; SGIC = Subject Global Impression of Change; TMS = transcranial magnetic Social Experience Checklist; VAS = visual analogue scale; VAS-F = visual analogue scale - fatigue</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-03-19 17:00:06 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-11-03 05:50:06 +0000" MODIFIED_BY="[Empty name]">Overview of adverse reactions associated with fatigue treatment</TITLE>
<TABLE COLS="4" ROWS="28">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Drug and indication</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Impact of adverse reaction</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Symptoms </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acetyl-L-carnitine and amantadine in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (carnitine) and 5 (amantadine) of 36 patients withdrew</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Carnitine: insomnia, nervousness<BR/>Amantadine: nausea, dizziness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tomassini-2004" TYPE="STUDY">Tomassini 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 of 32 reported adverse reactions (versus 6 of 32 on placebo)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hallucinations, nausea, gastric irritation, early morning wakening, hyperactivity, flu-like illness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Murray-1985" TYPE="STUDY">Murray 1985</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212; </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Constipation, nausea, anxiety, influenza-like illness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Cohen-1989" TYPE="STUDY">Cohen 1989</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine, pemoline in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No severe adverse reaction (did not lead to withdrawal)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pemoline: palpitations, nausea, mood change, sleep disturbance, Amantadine: sleep disturbance, palpitations</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Krupp-1995" TYPE="STUDY">Krupp 1995</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dextroamphetamine</P>
<P>in HIV-positive men with fatigue</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None of 23 patients discontinued during the 2 weeks of DB, PC RCT</P>
<P> </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Overstimulation, heart palpitation, sleep deprivation, loss of appetite and/or weight, headache. The authors reported that adverse reactions generally were "transient, reversible, and well managed with dose reduction; no serious medical side effects were reported"</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wagner-2000" TYPE="STUDY">Wagner 2000</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dexamphetamine in advanced cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Drop-out rate in verum group compared to placebo group was statistically not significant</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Significant increase in pulse rate. Transient increase of dry mouth, insomnia, tremor, anorexia on days 6 and 8 (of 8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Auret-2009" TYPE="STUDY">Auret 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pemoline in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 of 46 dropped out because of adverse reaction; 25% of patients did not tolerate pemoline well according to the authors</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Most common side effects were anorexia, irritability, "jitteriness" and insomnia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Weinshenker-1992" TYPE="STUDY">Weinshenker 1992</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acetylsalicylic acid in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No serious adverse reaction</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nausea, transient epigastric pain (nausea, headache and diarrhoea occurred with placebo)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wingerchuk-2005" TYPE="STUDY">Wingerchuk 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate and pemoline in HIV</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Severe side effects relatively uncommon; 5 withdrew (2 on methylphenidate, 2 on pemoline, 1 on placebo)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Hyperactivity, jitteriness, dry mouth, rapid heart beat, difficulty sleeping, constipation, neuropathic pain (1 patient)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Breitbart-2001" TYPE="STUDY">Breitbart 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate in advanced cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No severe adverse effects</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Most pts reported insomnia, anorexia, restlessness, behavioural change and vertigo. Numbers in placebo groups were similar</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bruera-2006" TYPE="STUDY">Bruera 2006</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Donepezil in advanced cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No severe adverse effects</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Most pts reported anorexia, nausea, restlessness, dizziness, behaviour change, vertigo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bruera-2007" TYPE="STUDY">Bruera 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No statistically significant difference in prevalence of adverse events reporting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Most pts reported headache, insomnia, nausea, anxiety, dizziness, ataxia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Canadian-MSRG-1987" TYPE="STUDY">Canadian MSRG 1987</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Paroxetine in end-stage COPD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Only 1 of 12 pts dropped out because of adverse effects related to the drug</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Somnolence was reported by 5 pts, constipation, nausea, headache tremor were rated by 2 pts each</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Lacasse-2004" TYPE="STUDY">Lacasse 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Testosterone for HIV-positive pts</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 of 46 pts discontinued because of adverse reactions</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acne, irritability, insomnia, headache, nasal congestion</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2000" TYPE="STUDY">Rabkin 2000</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Testosterone and fluoxetine in HIV</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> &#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluoxetine: diarrhoea, nausea, nonspecific discomfort<BR/>Testosterone: sleepiness; all treatments: dry mouth, sleepiness, loose bowels</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2004" TYPE="STUDY">Rabkin 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil for HIV</P>
<P>patients</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Treatment-emergent side effects were relatively uncommon</P>
<P>CD4 cell count did not show either statistically or clinically significant changes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2010" TYPE="STUDY">Rabkin 2010</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Armodafinil in HIV</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Armodafinil was well tolerated, with few and transient adverse events</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The most common was headache</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rabkin-2011" TYPE="STUDY">Rabkin 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Amantadine in post-polio syndrome</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> &#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Insomnia was the commonest reported adverse reaction; dry mouth was noted by 1 patient</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Stein-1995" TYPE="STUDY">Stein 1995</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>L-carnitine in</P>
<P>end-stage renal</P>
<P>disease (ESRD)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No serious adverse event was believed by the investigators to be certainly or probably drug-related</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Flu syndrome, injection-site reaction, pain, pharyngitis,</P>
<P>headache and hypertension showed no difference in frequency between L-carnitine and placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Brass-2001" TYPE="STUDY">Brass 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate in cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No serious adverse effect</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Some pts experienced nausea, vomiting, facial rash</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Escalante-2014" TYPE="STUDY">Escalante 2014</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fluoxetine in cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>A total of 16 adverse events were judged to be possibly due to the treatment and 6 to taking the placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allergic reaction, cardiac arrhythmia, dyspnoea, headaches, dizziness, mood change, myalgia, fever, diarrhoea, abdominal pain</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Jean_x002d_Pierre-2010" TYPE="STUDY">Jean-Pierre 2010</LINK>
</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate in</P>
<P>cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>There was a significant difference in self reported toxicities (SED)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Increased levels of nervousness and appetite loss in the methylphenidate group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Moraska-2010" TYPE="STUDY">Moraska 2010</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Methylphenidate in</P>
<P>cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No severe adverse reaction</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (31%) men who started receiving methylphenidate had to be discontinued from the study due to increased blood pressure</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Roth-2010" TYPE="STUDY">Roth 2010</LINK>
</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Medroxyprogesterone acetate (MPA) in cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nausea and vomiting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Simons-1996" TYPE="STUDY">Simons 1996</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acetylsalicylic acid and amantadine in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acetylsalicylic acid and amantadine are both well tolerated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The most common side effects of acetylsalicylic acid were nausea (n = 53) and transient epigastric pain (n = 51). The most common side effect of amantadine was also nausea (n = 51)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Shaygannejad-2012" TYPE="STUDY">Shaygannejad 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil in cancer</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modafinil seemed to be well tolerated</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Most symptoms are nausea, vomiting, anxiety and headache</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Spathis-2014" TYPE="STUDY">Spathis 2014</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dexamethasone in multiple sclerosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 adverse events were probably related to study treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain grade 3 and vomiting grade 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yennurajalingam-2013" TYPE="STUDY">Yennurajalingam 2013</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>COPD = chronic obstructive pulmonary disease; DB = double-blind; PC = placebo-controlled; pts = participants RCT = randomised controlled trial</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-05-23 14:52:03 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-05-23 14:51:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Methylphenidate versus placebo in cancer</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="74" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FACIT-F score change</NAME>
<GROUP_LABEL_1>Methylphenidate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methylphenidate</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5804921855154155" CI_START="-0.18655907772473418" EFFECT_SIZE="0.19696655389534062" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="7.5" MODIFIED="2014-05-15 14:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="9.8" SD_2="11.3" SE="0.19567993832808972" STUDY_ID="STD-Bruera-2006" TOTAL_1="52" TOTAL_2="53" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.1587474884026303" CI_START="0.7648370433063245" EFFECT_SIZE="1.4617922658544773" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="2.8" MODIFIED="2014-05-15 14:58:27 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="2.28" SD_2="2.66" SE="0.3555959334179845" STUDY_ID="STD-Butler-2007" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-05-23 14:51:48 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Modafinil versus placebo in multiple sclerosis</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="67" TOTAL_2="69" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fatigue score change</NAME>
<GROUP_LABEL_1>Modafinil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours modafinil</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5993648027502383" CI_START="0.5813231240303616" EFFECT_SIZE="1.5903439633903" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="-0.4" MODIFIED="2010-03-19 00:44:02 +0000" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="7.7" SD_2="8.5" SE="0.5148160105588501" STUDY_ID="STD-Lange-2009" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.002625191568381091" CI_START="-0.735009096956136" EFFECT_SIZE="-0.36619195269387744" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="13.7" MODIFIED="2010-03-19 00:53:34 +0000" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="13.64" SD_2="13.49" SE="0.1881754701471257" STUDY_ID="STD-Stankoff-2005" TOTAL_1="56" TOTAL_2="59" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-05-23 14:52:03 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Pemoline versus placebo in multiple sclerosis</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2015-04-20 15:21:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="50" TOTAL_2="53" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fatigue score change</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Pemoline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.08040562114221443" CI_START="-0.12040562114221444" EFFECT_SIZE="-0.02" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.04" MODIFIED="2015-04-08 11:05:12 +0100" MODIFIED_BY="mochamat " ORDER="16" SD_1="0.2" SD_2="0.2" SE="0.051228299057636345" STUDY_ID="STD-Krupp-1995" TOTAL_1="27" TOTAL_2="35" WEIGHT="0.0"/>
<CONT_DATA CI_END="18.428257016040455" CI_START="-2.4282570160404564" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="-1.0" MODIFIED="2015-04-08 11:05:48 +0100" MODIFIED_BY="mochamat " ORDER="15" SD_1="18.0" SD_2="16.0" SE="5.320637061852778" STUDY_ID="STD-Weinshenker-1992" TOTAL_1="23" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-05-21 13:46:48 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-04-20 15:26:04 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVQAAAKmCAYAAAASIGY6AAA+cElEQVR42u2df4RU7f//b5IkyZKs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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-05-21 13:46:48 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjAAAADOCAMAAAAXKMgdAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-05-21 13:46:48 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about risk of bias items for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASwAAAZtCAIAAAD3vP5lAABPgElEQVR42u3dvW4lx/X1YQIGDAcM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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-05-21 13:46:48 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Methylphenidate vs Placebo in cancer, outcome: 1.1 FACIT-F score change.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzkAAABwCAMAAAAKc04SAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-05-21 13:46:48 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Modafinil in multiple sclerosis, outcome: 4.1 Modafinil.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxUAAABwCAMAAABfEq1MAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-05-21 13:46:48 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Pemoline in multiple sclerosis, outcome: 3.1 Fatigue score change.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuQAAABwCAMAAABhEpUrAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-08-16 13:25:26 +0100" MODIFIED_BY="Anna Erskine">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2016-08-16 13:25:26 +0100" MODIFIED_BY="Anna Erskine" NO="1">
<TITLE MODIFIED="2016-06-20 09:31:47 +0100" MODIFIED_BY="Anna Erskine">Feedback submitted to Cochrane.org</TITLE>
<DATE_SUBMITTED>
<DATE DAY="6" MONTH="6" YEAR="2016"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2016-08-16 13:24:03 +0100" MODIFIED_BY="Anna Erskine">
<P>
<B>Comments submitted via the Cochrane.org online contact form, and forwarded to the PaPaS Review Group by Nancy Owens, Cochrane Communications &amp; External Affairs Department</B>
</P>
<P>Name: Vasiliy Vlassov</P>
<P>Which category applies to this message? Editorial</P>
<P>Subject: erroneous explanation</P>
<P>Message:</P>
<P>Here</P>
<P>
<A HREF="http://www.cochrane.org/news/featured-review-pharmacological-treatments-fatigue-associated-palliative-care">http://www.cochrane.org/news/featured-review-pharmacological-treatments-fatigue-associated-palliative-care</A>
</P>
<P>"drugs that improve anaemia (lack of iron)," damn shaming wrong</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2016-08-16 13:25:26 +0100" MODIFIED_BY="Anna Erskine">
<P>
<B>Editorial response</B>
</P>
<P>The contributor highlights the definition of anaemia used by the authors in the Plain Language Summary and the summary version of the review on Cochrane.org. We attempted to contact Vasiliy Vlassov on more than one occasion in order to clarify the intended meaning of the comment, but we did not receive a response. Our interpretation of the comment is that the definition of anaemia in the PLS is misleading, and so this has now been amended to 'anaemia (a shortage of red cells or haemoglobin in the blood)'.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2016-06-20 09:33:30 +0100" MODIFIED_BY="Anna Erskine">
<P>Mrs Anna Erskine, Managing Editor, and Professor Christopher Eccleston, Co-ordinating Editor, at the Pain, Palliative and Supportive Care Review Group; Martin Mücke, Contact Person.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-03-19 17:08:42 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-05-14 11:17:56 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-03-19 16:57:09 +0000" MODIFIED_BY="[Empty name]">
<P>Subject search was run on 28 April 2014</P>
<TABLE COLS="3" ROWS="62">
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>1.</P>
</TD>
<TD VALIGN="TOP">
<P>NEOPLASMS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>2.</P>
</TD>
<TD VALIGN="TOP">
<P>(neoplasm* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukeni* or lymphoma* or malignan*):ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>3.</P>
</TD>
<TD VALIGN="TOP">
<P>MULTIPLE SCLEROSIS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>4.</P>
</TD>
<TD VALIGN="TOP">
<P>"multiple sclerosis":ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>5.</P>
</TD>
<TD VALIGN="TOP">
<P>AMYOTROPHIC LATERAL SCLEROSIS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>6.</P>
</TD>
<TD VALIGN="TOP">
<P>"amyotrophic lateral sclerosis":ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>7.</P>
</TD>
<TD VALIGN="TOP">
<P>ACQUIRED IMMUNODEFICIENCY SYNDROME</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>8.</P>
</TD>
<TD VALIGN="TOP">
<P>AIDS-RELATED COMPLEX</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>9.</P>
</TD>
<TD VALIGN="TOP">
<P>HIV</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>10.</P>
</TD>
<TD VALIGN="TOP">
<P>HIV WASTING SYNDROME</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>11.</P>
</TD>
<TD VALIGN="TOP">
<P>"acquired immunodeficiency syndrome":ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>12.</P>
</TD>
<TD VALIGN="TOP">
<P>"AIDS related complex":ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>13.</P>
</TD>
<TD VALIGN="TOP">
<P>"HIV":ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>14.</P>
</TD>
<TD VALIGN="TOP">
<P>"human immunodeficiency virus":ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>15.</P>
</TD>
<TD VALIGN="TOP">
<P>LUNG DISEASES</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>16.</P>
</TD>
<TD VALIGN="TOP">
<P>PULMONARY DISEASE CHRONIC OBSTRUCTIVE</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>17.</P>
</TD>
<TD VALIGN="TOP">
<P>HEART DISEASES</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>18.</P>
</TD>
<TD VALIGN="TOP">
<P>"lung disease*" or "heart disease*" or "pulmonary disease*"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>19.</P>
</TD>
<TD VALIGN="TOP">
<P>HEART FAILURE</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>20.</P>
</TD>
<TD VALIGN="TOP">
<P>"cardiac failure" or "heart failure"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>21.</P>
</TD>
<TD VALIGN="TOP">
<P>"incurable disease*" or "incurable illness*"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>22.</P>
</TD>
<TD VALIGN="TOP">
<P>((terminal or advanced or progressive or "end stage" or end-stage) and (illness* or disease*))</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>23.</P>
</TD>
<TD VALIGN="TOP">
<P>BONE MARROW TRANSPLANTATION</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>24.</P>
</TD>
<TD VALIGN="TOP">
<P>(neutropeni* or neutropaeni*):ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>25.</P>
</TD>
<TD VALIGN="TOP">
<P>RADIOTHERAPY</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>26.</P>
</TD>
<TD VALIGN="TOP">
<P>(radioth* or radiat* or irradiat* or radiochemo* or chemotherapy*):ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>27.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8220;bone marrow&#8221; NEAR transplant*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>28.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8220;bone-marrow&#8221; NEAR transplant*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>29.</P>
</TD>
<TD VALIGN="TOP">
<P>(fatigue near/4 treatment) or (treated near/4 treated) or (fatigue near/4 therapy) or (fatigue near/4 intervention)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>30.</P>
</TD>
<TD VALIGN="TOP">
<P>(asthenia near/4 treatment) or (treated near/4 treated) or (fatigue near/4 therapy) or (fatigue near/4 intervention)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>31.</P>
</TD>
<TD VALIGN="TOP">
<P>((tired* near/4 treatment) or (tired* near/4 treated) or (tired* near/4 therapy) or (treatment near/4 exhausted) or (exhausted near/4 therapy) or (exhaustion near/4 therapy))</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>32.</P>
</TD>
<TD VALIGN="TOP">
<P>apathy or apathetic or lassitude or lethargy* or &#8220;feeling drained&#8221; or &#8220;feeling sleepy&#8221; or &#8220;feeling sluggish&#8221; or &#8220;feeling weak*&#8221;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>33.</P>
</TD>
<TD VALIGN="TOP">
<P>(FATIGUE or cancer-related fatigue or cancer related fatigue):ti,ab,kw</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>34.</P>
</TD>
<TD VALIGN="TOP">
<P>tired* or weary or weariness or exhaustion or exhausted or lackluster or astheni* or asthenia*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>35.</P>
</TD>
<TD VALIGN="TOP">
<P>lack* NEAR/2 energy</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>36.</P>
</TD>
<TD VALIGN="TOP">
<P>lack* NEAR/2 vigour</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>37.</P>
</TD>
<TD VALIGN="TOP">
<P>lack* NEAR/2 vigor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>38.</P>
</TD>
<TD VALIGN="TOP">
<P>loss NEAR/2 energy</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>39.</P>
</TD>
<TD VALIGN="TOP">
<P>loss NEAR/2 vigour</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>40.</P>
</TD>
<TD VALIGN="TOP">
<P>loss NEAR/2 vigor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>41.</P>
</TD>
<TD VALIGN="TOP">
<P>lost NEAR/2 energy</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>42.</P>
</TD>
<TD VALIGN="TOP">
<P>lost NEAR/2 vigour</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>43.</P>
</TD>
<TD VALIGN="TOP">
<P>lost NEAR/2 vigor</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>44.</P>
</TD>
<TD VALIGN="TOP">
<P>palliati* or hospice or &#8220;end of life&#8221;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>45.</P>
</TD>
<TD VALIGN="TOP">
<P>#1-#28/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>46.</P>
</TD>
<TD VALIGN="TOP">
<P>#29-#44</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>47.</P>
</TD>
<TD VALIGN="TOP">
<P>#45 AND #46</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>48.</P>
</TD>
<TD VALIGN="TOP">
<P>dexamphetamine or dextroamphetamine</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>49.</P>
</TD>
<TD VALIGN="TOP">
<P>ANTIDEPRESSIVE AGENTS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>50.</P>
</TD>
<TD VALIGN="TOP">
<P>ADRENERGIC UPTAKE INHIBITORS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>51.</P>
</TD>
<TD VALIGN="TOP">
<P>glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or corticosteroids</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>Carnitine or L-carntine</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>53.</P>
</TD>
<TD VALIGN="TOP">
<P>modafinil</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>54.</P>
</TD>
<TD VALIGN="TOP">
<P>amantadine or donepezil or pemoline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>55.</P>
</TD>
<TD VALIGN="TOP">
<P>Methylphenidate or d-threo-methylphenidate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>56.</P>
</TD>
<TD VALIGN="TOP">
<P>paroxetine</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>57.</P>
</TD>
<TD VALIGN="TOP">
<P>Aspirin or acetylsalicylic acid</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>58.</P>
</TD>
<TD VALIGN="TOP">
<P>citalopram</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>59.</P>
</TD>
<TD VALIGN="TOP">
<P>bupropion</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>60.</P>
</TD>
<TD VALIGN="TOP">
<P>testosteronecypionate</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>61.</P>
</TD>
<TD VALIGN="TOP">
<P>#48 - #60/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>62.</P>
</TD>
<TD VALIGN="TOP">
<P>#47 AND #61</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-08-13 10:56:26 +0100" MODIFIED_BY="Laila Tyrrell">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Subject search combined with the recommended study design filter was run on 28 April 2014 (using OVID)</P>
<TABLE COLS="3" ROWS="60">
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>1.</P>
</TD>
<TD VALIGN="TOP">
<P>exp Neoplasms/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>2.</P>
</TD>
<TD VALIGN="TOP">
<P>(cancer* or malignan*).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>3.</P>
</TD>
<TD VALIGN="TOP">
<P>multiple sclerosis.af.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>4.</P>
</TD>
<TD VALIGN="TOP">
<P>amyotrophic lateral sclerosis.af.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>5.</P>
</TD>
<TD VALIGN="TOP">
<P>(sclerosis adj4 (amyotroph* or multiple)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>6.</P>
</TD>
<TD VALIGN="TOP">
<P>exp acquired immune deficiency syndrome/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>7.</P>
</TD>
<TD VALIGN="TOP">
<P>aids related complex.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>8.</P>
</TD>
<TD VALIGN="TOP">
<P>exp Human immunodeficiency virus/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>9.</P>
</TD>
<TD VALIGN="TOP">
<P>(HIV or AIDS).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>10.</P>
</TD>
<TD VALIGN="TOP">
<P>bone marrow transplantation.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>11.</P>
</TD>
<TD VALIGN="TOP">
<P>radiotherapy.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>12.</P>
</TD>
<TD VALIGN="TOP">
<P>(carcinoma* or tumour* or adenocarcinoma* or leukeni* or leukaemi* or lymphoma* or tumor*).mp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>13.</P>
</TD>
<TD VALIGN="TOP">
<P>(neutropeni$ or neutropaeni$).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>14.</P>
</TD>
<TD VALIGN="TOP">
<P>(radioth* or radiat* or irradiat* or radiochemo* or chemotherap*).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>15.</P>
</TD>
<TD VALIGN="TOP">
<P>Lung Disorders.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>16.</P>
</TD>
<TD VALIGN="TOP">
<P>heart disorders.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>17.</P>
</TD>
<TD VALIGN="TOP">
<P>congestive heart failure.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>18.</P>
</TD>
<TD VALIGN="TOP">
<P>cor pulmonale.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>19.</P>
</TD>
<TD VALIGN="TOP">
<P>cancer fatigue.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>20.</P>
</TD>
<TD VALIGN="TOP">
<P>(cancer-related fatigue or cancer related fatigue).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>21.</P>
</TD>
<TD VALIGN="TOP">
<P>exp FATIGUE/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>22.</P>
</TD>
<TD VALIGN="TOP">
<P>(tired$ or weary or weariness or exhaustion or exhausted or lacklustred or ((astheni$ or asthenia$) and syndrome)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>23.</P>
</TD>
<TD VALIGN="TOP">
<P>((lack$ or loss or lost) adj2 (energy or vigour or vigor)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>24.</P>
</TD>
<TD VALIGN="TOP">
<P>(apathy or apathetic or lassitude or letharg$ or (feeling adj3 (drained or sleepy or sluggish or weak$))).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>25.</P>
</TD>
<TD VALIGN="TOP">
<P>((advanced or terminal* or progressi* or end-stage or endstage or "endstage") adj6 (disease or illness)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>26.</P>
</TD>
<TD VALIGN="TOP">
<P>palliati*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>27.</P>
</TD>
<TD VALIGN="TOP">
<P>(dexamphetamine or dextroamphetamine).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>28.</P>
</TD>
<TD VALIGN="TOP">
<P>(methylphenidate or threo$methylphenidate or d-threo-methylphenidate).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>29.</P>
</TD>
<TD VALIGN="TOP">
<P>donepezil.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>30.</P>
</TD>
<TD VALIGN="TOP">
<P>amantadine.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>31.</P>
</TD>
<TD VALIGN="TOP">
<P>(Carnitine or L-carntine).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>32.</P>
</TD>
<TD VALIGN="TOP">
<P>pemoline.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>33.</P>
</TD>
<TD VALIGN="TOP">
<P>modafinil.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>34.</P>
</TD>
<TD VALIGN="TOP">
<P>paroxetine.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>35.</P>
</TD>
<TD VALIGN="TOP">
<P>(testosteronecypionate or androgen).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>36.</P>
</TD>
<TD VALIGN="TOP">
<P>(acetylsalicylic acid or aspirin).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>37.</P>
</TD>
<TD VALIGN="TOP">
<P>fluoxetin.mp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>38.</P>
</TD>
<TD VALIGN="TOP">
<P>citalopram.mp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>39.</P>
</TD>
<TD VALIGN="TOP">
<P>(glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or corticosteroids).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>40.</P>
</TD>
<TD VALIGN="TOP">
<P>bupropion.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>41.</P>
</TD>
<TD VALIGN="TOP">
<P>(anti depressant agents or anti depressive agents or Selective serotonin reuptake inhibitors).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>42.</P>
</TD>
<TD VALIGN="TOP">
<P>random*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>43.</P>
</TD>
<TD VALIGN="TOP">
<P>factorial*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>44.</P>
</TD>
<TD VALIGN="TOP">
<P>(crossover* or cross over* or cross-over*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>45.</P>
</TD>
<TD VALIGN="TOP">
<P>placebo*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>46.</P>
</TD>
<TD VALIGN="TOP">
<P>(doubl* adj blind*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>47.</P>
</TD>
<TD VALIGN="TOP">
<P>(singl* adj blind*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>48.</P>
</TD>
<TD VALIGN="TOP">
<P>randomized controlled trial.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>49.</P>
</TD>
<TD VALIGN="TOP">
<P>assign*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>50.</P>
</TD>
<TD VALIGN="TOP">
<P>allocat*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>51.</P>
</TD>
<TD VALIGN="TOP">
<P>evaluation study*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>52.</P>
</TD>
<TD VALIGN="TOP">
<P>prospective study*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>53.</P>
</TD>
<TD VALIGN="TOP">
<P>comparative study*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>54.</P>
</TD>
<TD VALIGN="TOP">
<P>(animal* or nonhuman* or animal experiment*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>55.</P>
</TD>
<TD VALIGN="TOP">
<P>#1-#18/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>56.</P>
</TD>
<TD VALIGN="TOP">
<P>#19-26/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>57.</P>
</TD>
<TD VALIGN="TOP">
<P>#27-41/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>58.</P>
</TD>
<TD VALIGN="TOP">
<P>#42-53/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>59.</P>
</TD>
<TD VALIGN="TOP">
<P>#55 AND #56 AND #57 AND #58</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>60.</P>
</TD>
<TD VALIGN="TOP">
<P>#59 NOT #54</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-08-16 16:17:01 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-04-09 12:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>Subject search combined with the recommended study design filter was run on 28 April 2014</P>
<TABLE COLS="3" ROWS="68">
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>1.</P>
</TD>
<TD VALIGN="TOP">
<P>neoplasm/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>2.</P>
</TD>
<TD VALIGN="TOP">
<P>(cancer* or malignan*)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>3.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;multiple sclerosis'/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>4.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;amyothropic lateral sclerosis&#8217;/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>5.</P>
</TD>
<TD VALIGN="TOP">
<P>sclerosis (amyotroph*4 or multiple)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>6.</P>
</TD>
<TD VALIGN="TOP">
<P>((&#8216;acquired immune deficiency syndrome&#8217;/exp) OR (&#8216;aids related complex&#8217;/exp))</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>7.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;Human immunodeficiency virus&#8217;/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>8.</P>
</TD>
<TD VALIGN="TOP">
<P>(HIV or AIDS)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>9.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;lung disease&#8217;/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>10.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;heart disease&#8217;/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>11.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;cor pulmonale&#8217;/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>12.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;congestive heart failure&#8217;/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>13.</P>
</TD>
<TD VALIGN="TOP">
<P>(neoplasm* or cancer* or carcinoma* or tumour* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or tumor* or tumor* or malignan*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>14.</P>
</TD>
<TD VALIGN="TOP">
<P>(neoplasm* or cancer* or carcinoma* or tumour* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or tumor* or tumor* or malignan*)/mj</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>15.</P>
</TD>
<TD VALIGN="TOP">
<P>(neutropeni* or neutropaeni*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>16.</P>
</TD>
<TD VALIGN="TOP">
<P>(neutropeni* or neutropaeni*)/mj</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>17.</P>
</TD>
<TD VALIGN="TOP">
<P>RADIOTHERAPY/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>18.</P>
</TD>
<TD VALIGN="TOP">
<P>(radioth* or radiat* or irradiat* or radiochemo* or chemotherapy*):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>19.</P>
</TD>
<TD VALIGN="TOP">
<P>(radioth* or radiat* or irradiat* or radiochemo* or chemotherapy*)/mj</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>20.</P>
</TD>
<TD VALIGN="TOP">
<P>((&#8216;bone marrow&#8217; transplant*4) or (&#8216;bone-marrow&#8217; NEAR transplant*))</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>21.</P>
</TD>
<TD VALIGN="TOP">
<P>advanced or terminal*6 or progressi*6 or end-stage or endstage or 'end stage' (disease or illness)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>22.</P>
</TD>
<TD VALIGN="TOP">
<P>FATIGUE/exp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>23.</P>
</TD>
<TD VALIGN="TOP">
<P>(Fatigue or &#8216;cancer-related fatigue&#8217; or &#8216;cancer related fatigue&#8217;):ab,py</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>24.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;FATIGUE&#8217;:de</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>25.</P>
</TD>
<TD VALIGN="TOP">
<P>tired* or weary or weariness or exhaustion or exhausted or lackluster or (asteni* or asthenia*) and syndrome</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>26.</P>
</TD>
<TD VALIGN="TOP">
<P>loss OR lost OR lack*2 AND (energy OR vigour OR vigor)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>27.</P>
</TD>
<TD VALIGN="TOP">
<P>apathy or apathetic or lassitude or lethargy* or (feeling (drained or sleepy or sluggish or weak*3))</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>28.</P>
</TD>
<TD VALIGN="TOP">
<P>palliati* or hospice or &#8216;end of life&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>29.</P>
</TD>
<TD VALIGN="TOP">
<P>#1 - #12/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>30.</P>
</TD>
<TD VALIGN="TOP">
<P>#13 - #21 /OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>31.</P>
</TD>
<TD VALIGN="TOP">
<P>#22- #28 /OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>32.</P>
</TD>
<TD VALIGN="TOP">
<P>#29 and #30 and #31</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>33.</P>
</TD>
<TD VALIGN="TOP">
<P>(dexamphetamine or dextroamphetamine):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>34.</P>
</TD>
<TD VALIGN="TOP">
<P>(methylphenidate or threomethylphenidate or d-threo-methylphenidate):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>35.</P>
</TD>
<TD VALIGN="TOP">
<P>Donepezil:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>36.</P>
</TD>
<TD VALIGN="TOP">
<P>amantadine:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>37.</P>
</TD>
<TD VALIGN="TOP">
<P>Carnitine or l-carnitine:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>38.</P>
</TD>
<TD VALIGN="TOP">
<P>Pemoline:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>39.</P>
</TD>
<TD VALIGN="TOP">
<P>Modafinil:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>40.</P>
</TD>
<TD VALIGN="TOP">
<P>Paroxetine:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>41.</P>
</TD>
<TD VALIGN="TOP">
<P>(testosteronecypionate or androgen):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>42.</P>
</TD>
<TD VALIGN="TOP">
<P>(acetylsalicylic acid or aspirin):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>43.</P>
</TD>
<TD VALIGN="TOP">
<P>fluoxetin:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>44.</P>
</TD>
<TD VALIGN="TOP">
<P>Citalopram:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>45.</P>
</TD>
<TD VALIGN="TOP">
<P>(glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or corticosteroids):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>46.</P>
</TD>
<TD VALIGN="TOP">
<P>Bupropion:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>47.</P>
</TD>
<TD VALIGN="TOP">
<P>(&#8216;anti depressant agents&#8217; or &#8216;anti depressive agents&#8217; or &#8216;Selective serotonin reuptake inhibitors&#8217;):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>48.</P>
</TD>
<TD VALIGN="TOP">
<P>#33 - #47 / OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>49.</P>
</TD>
<TD VALIGN="TOP">
<P>#32 and #48</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>50.</P>
</TD>
<TD VALIGN="TOP">
<P>controll*:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>51.</P>
</TD>
<TD VALIGN="TOP">
<P>factorial:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>52.</P>
</TD>
<TD VALIGN="TOP">
<P>(crossover or &#8216;cross over&#8217; or &#8216;cross-over&#8217;):ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>53.</P>
</TD>
<TD VALIGN="TOP">
<P>placebo:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>54.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;double blind&#8217;:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>55.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8217;single blind&#8217;:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>56.</P>
</TD>
<TD VALIGN="TOP">
<P>assign*:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>57.</P>
</TD>
<TD VALIGN="TOP">
<P>allocate*:ti,ab</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>58.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;crossover procedure&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>59.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;DOUBLE-BLIND PROCEDURE&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>60.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;RANDOMIZED CONTROLLED TRIAL&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>61.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;SINGLE BLIND PROCEDURE&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>62.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;evaluation study&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>63.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;prospective study&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>64.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;comparative study&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>65.</P>
</TD>
<TD VALIGN="TOP">
<P>&#8216;animal experiment&#8217; OR &#8216;nonhuman experiment&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>66.</P>
</TD>
<TD VALIGN="TOP">
<P>#50-#64/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>67.</P>
</TD>
<TD VALIGN="TOP">
<P>#49 AND #66 AND ([adult]/lim OR [aged]/lim) AND [humans]/lim AND [embase]/lim</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>68.</P>
</TD>
<TD VALIGN="TOP">
<P>#67 NOT #65</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2015-03-20 10:10:31 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-08-16 16:18:13 +0100" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-03-20 10:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>Subject search combined with the recommended study design filter was run on 28 April 2014 (using OVID).</P>
<TABLE COLS="3" ROWS="60">
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>1.</P>
</TD>
<TD VALIGN="TOP">
<P>exp Neoplasms/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>2.</P>
</TD>
<TD VALIGN="TOP">
<P>(cancer* or malignan*).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>3.</P>
</TD>
<TD VALIGN="TOP">
<P>multiple sclerosis.af.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>4.</P>
</TD>
<TD VALIGN="TOP">
<P>amyotrophic lateral sclerosis.af.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>5.</P>
</TD>
<TD VALIGN="TOP">
<P>(sclerosis adj4 (amyotroph* or multiple)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>6.</P>
</TD>
<TD VALIGN="TOP">
<P>exp acquired immune deficiency syndrome/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>7.</P>
</TD>
<TD VALIGN="TOP">
<P>aids related complex.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>8.</P>
</TD>
<TD VALIGN="TOP">
<P>exp Human immunodeficiency virus/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>9.</P>
</TD>
<TD VALIGN="TOP">
<P>(HIV or AIDS).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>10.</P>
</TD>
<TD VALIGN="TOP">
<P>bone marrow transplantation.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>11.</P>
</TD>
<TD VALIGN="TOP">
<P>radiotherapy.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>12.</P>
</TD>
<TD VALIGN="TOP">
<P>(cancinoma* or tumour* or adenocarcinoma* or leukeni* or leukaemi* or lymphoma* or tumor*).mp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>13.</P>
</TD>
<TD VALIGN="TOP">
<P>(neutropeni$ or neutropaeni$).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>14.</P>
</TD>
<TD VALIGN="TOP">
<P>(radioth* or radiat* or irradiat* or radiochemo* or chemotherap*).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>15.</P>
</TD>
<TD VALIGN="TOP">
<P>Lung Disorders.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>16.</P>
</TD>
<TD VALIGN="TOP">
<P>heart disorders.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>17.</P>
</TD>
<TD VALIGN="TOP">
<P>congestive heart failure.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>18.</P>
</TD>
<TD VALIGN="TOP">
<P>cor pulmonale.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>19.</P>
</TD>
<TD VALIGN="TOP">
<P>cancer fatigue.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>20.</P>
</TD>
<TD VALIGN="TOP">
<P>(cancer-related fatigue or cancer related fatigue).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>21.</P>
</TD>
<TD VALIGN="TOP">
<P>exp FATIGUE/</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>22.</P>
</TD>
<TD VALIGN="TOP">
<P>(tired$ or weary or weariness or exhaustion or exhausted or lacklustred or ((astheni$ or asthenia$) and syndrome)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>23.</P>
</TD>
<TD VALIGN="TOP">
<P>((lack$ or loss or lost) adj2 (energy or vigour or vigor)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>24.</P>
</TD>
<TD VALIGN="TOP">
<P>(apathy or apathetic or lassitude or letharg$ or (feeling adj3 (drained or sleepy or sluggish or weak$))).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>25.</P>
</TD>
<TD VALIGN="TOP">
<P>((advanced or terminal* or progressi* or end-stage or endstage or "endstage") adj6 (disease or illness)).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>26.</P>
</TD>
<TD VALIGN="TOP">
<P>palliati*.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>27.</P>
</TD>
<TD VALIGN="TOP">
<P>(dexamphetamine or dextroamphetamine).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>28.</P>
</TD>
<TD VALIGN="TOP">
<P>(methylphenidate or threo$methylphenidate or d-threo-methylphenidate).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>29.</P>
</TD>
<TD VALIGN="TOP">
<P>donepezil.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>30.</P>
</TD>
<TD VALIGN="TOP">
<P>amantadine.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>31.</P>
</TD>
<TD VALIGN="TOP">
<P>(Carnitine or L-carntine).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>32.</P>
</TD>
<TD VALIGN="TOP">
<P>pemoline.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>33.</P>
</TD>
<TD VALIGN="TOP">
<P>modafinil.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>34.</P>
</TD>
<TD VALIGN="TOP">
<P>paroxetine.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>35.</P>
</TD>
<TD VALIGN="TOP">
<P>(testosteronecypionate or androgen).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>36.</P>
</TD>
<TD VALIGN="TOP">
<P>(acetylsalicylic acid or aspirin).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>37.</P>
</TD>
<TD VALIGN="TOP">
<P>fluoxetin.mp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>38.</P>
</TD>
<TD VALIGN="TOP">
<P>citalopram.mp</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>39.</P>
</TD>
<TD VALIGN="TOP">
<P>(glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or corticosteroids).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>40.</P>
</TD>
<TD VALIGN="TOP">
<P>bupropion.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>41.</P>
</TD>
<TD VALIGN="TOP">
<P>(anti depressant agents or anti depressive agents or Selective serotonin reuptake inhibitors).mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>42.</P>
</TD>
<TD VALIGN="TOP">
<P>random*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>43.</P>
</TD>
<TD VALIGN="TOP">
<P>factorial*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>44.</P>
</TD>
<TD VALIGN="TOP">
<P>(crossover* or cross over* or cross-over*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>45.</P>
</TD>
<TD VALIGN="TOP">
<P>placebo*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>46.</P>
</TD>
<TD VALIGN="TOP">
<P>(doubl* adj blind*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>47.</P>
</TD>
<TD VALIGN="TOP">
<P>(singl* adj blind*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>48.</P>
</TD>
<TD VALIGN="TOP">
<P>randomized controlled trial.mp.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>49.</P>
</TD>
<TD VALIGN="TOP">
<P>assign*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>50.</P>
</TD>
<TD VALIGN="TOP">
<P>allocat*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>51.</P>
</TD>
<TD VALIGN="TOP">
<P>evaluation study*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>52.</P>
</TD>
<TD VALIGN="TOP">
<P>prospective study*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>53.</P>
</TD>
<TD VALIGN="TOP">
<P>comparative study*.ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>54.</P>
</TD>
<TD VALIGN="TOP">
<P>(animal* or nonhuman* or animal experiment*).ti,ab.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>55.</P>
</TD>
<TD VALIGN="TOP">
<P>#1-#18/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>56.</P>
</TD>
<TD VALIGN="TOP">
<P>#19-26/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>57.</P>
</TD>
<TD VALIGN="TOP">
<P>#27-41/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>58.</P>
</TD>
<TD VALIGN="TOP">
<P>#42-53/OR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>59.</P>
</TD>
<TD VALIGN="TOP">
<P>#55 AND #56 AND #57 AND #58</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#</P>
</TD>
<TD VALIGN="TOP">
<P>60.</P>
</TD>
<TD VALIGN="TOP">
<P>#59 NOT #54</P>
</TD>
</TR>
</TABLE>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-08-09 13:24:20 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="AFF_z1311251608423525204649809803050_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1311251608423525204649809803050">
<ADDRESS>
<DEPARTMENT>Department of General Practice and Family Medicine</DEPARTMENT>
<ORGANISATION>University Hospital of Bonn</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bonn</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1405160957131110616118394243293_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1405160957131110616118394243293">
<ADDRESS>
<DEPARTMENT>Department of Anesthesiology and Intensive Care</DEPARTMENT>
<ORGANISATION>University of Diponegoro/Kariadi Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Semarang</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ID">Indonesia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full-text papers included in qualitative synthesis (n = 45) (46 reports)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full-text publications assessed for eligibility (n = 95)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Papers initially screened by two review authors (n = 1459)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Papers after duplicates removed (n = 1459)&lt;/p&gt;" WIDTH="123">
<FLOWCHARTBOX TEXT="&lt;p&gt;Papers identified from databases and handsearching (n = 1645)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Papers excluded (n = 1364)&lt;/p&gt;" WIDTH="134"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Full-text publications excluded, with reasons (n = 49)&lt;/p&gt;" WIDTH="139"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>